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ABSTRACT 
Sickle cell anaemia (SS) is a haernoglobinopathy involving production of 
sickle haernoglobin (HbS, p6 Glu-->Val), which is able to polymerise leading to 
vaso-occlusion. Hydroxyurea (HU) treatment increases foetal haernoglobin (HbF) 
levels but decreases vaso-occlusion and red cell adhesion molecule (AM) 
expression, and therefore improves clinical symptoms. In this thesis, the 
contribution of AMs, HbF and endothelial factors to the severity of sickle cell 
disease has been studied. 
Flow cytometry for measurement of HbF-containing red cells (F'cells), AM- 
expressing red cells (AM+cells) and reticulocytes (retics) was developed and 
validated using single-, double- and triple-colour staining procedures. The AMs 
examined were CD36, CD41 and CD49d. 
F+cells are increased in SS patients over normal control subjects. In the 
controls, the percentage of F+mature red cells (%F+MRCs) is equal to %F+retics 
leading to an enrichment ratio (ER = %F+MRCs / %F+retics) close to 1.0, 
indicating no survival advantage of F+cells. However in SS patients, the ER is 
about 1.5-2.5 indicating a survival advantage of F+cells. AM+cells in SS patients 
are also increased over the controls. In both the controls and SS patients, the 
AM+ceII depletion ratio (AMDR = %AM+MRCs / %AM+retics) is decreased to less 
than 0.05, indicating a rapid shedding of AMs from reticulocytes during 
maturation. This shedding is confirmed by a reduction of %AM+ceIIs to 
undetectable levels after 5 days of reticulocytes in culture. In HU-treated SS 
patients, F+cell increment and AM+cell reduction are found. The %AM+retics for 
pre- and post-HU treatment is not different, suggesting that AM+ceII reduction is 
dependent on the reduction of reticulocytes. In the controls, proportion of F+cells 
expressing AMs is higher than F'cells, indicating that F+cells are more primitive. 
In SS patients, these proportions are similar. However, in HU-treated SS 
patients, the proportion of F+cells expressing AMs is lower than F-cells, 
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confirming that F+cells survive longer so that they have more time to shed more 
AMs. This finding is similar in both reticulocyte and MRC populations. 
Vascular endothelial growth factor (VEGF) may be involved in vaso- 
occlusion. It is significantly increased in SS patients. VEGF is able to induce nitric 
oxide metabolite (NOx) release. However in this thesis, NOx levels were not 
increased in SS patients and no correlation was found between NOx and VEGF 
levels. No relationship was observed between VEGF and either erythropoietin or 
Hb levels, suggesting that VEGF increment may not be due to generalised 
anaernia. Increases in soluble endothelial selectin (sE-Selectin) and soluble 
vascular cell adhesion molecule 1 (sVCAM-1) found in SS patients indicate 
endothelial activation. Beta-thromboglobulin (BTG) and platelet factor 4 (PF4) 
were also increased in SS patients, due to local platelet activation in vivo. 
Platelets as well as endothelial cells contain VEGF, therefore the increased 
VEGF levels in SS could be a consequence of local ischaernia resulting from 
vaso-occlusion and local platelet and endothelial cell activation. 
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Chapter 1 
CHAPTER1 
GENERAL INTRODUCTION 
1.1. OBJECTIVES AND SCOPE OF THIS THESIS 
The broad objective of this thesis is to characterise factors that may 
influence the severity of sickle cell disease. Two factors, which are known to 
influence the sickling process, are the foetal haernoglobin (HbF) content and the 
expression of adhesion molecules on sickle red cells. In general, a high HbF 
content slows the rate of sickle haernoglobin (HbS) polymerisation within sickle 
red cells under hypoxic conditions, thus leading to a lower proportion of sickle or 
crescent red cells in the circulation and a milder disease process. On the other 
hand, any factor, which can increase the adhesion of red cells to endothelium, 
will slow blood flow and increase the risk of sickling. The latter mechanism has 
been increasingly recognised as important in recent years. It is not clear from 
current knowledge to what extent the beneficial effects of HbF or the deleterious 
effects of red cell-endothelial adhesion interact to determine the course of 
sickling process. In this thesis, a method to study HbF content and adhesion 
molecule expression on the same red cells has been developed and at the 
same time examines the age of the red cells by staining for RNA content. In this 
approach it is possible in principle to look at the influence of HbF content and 
adhesion molecule expression on survival of sickle red cells beyond the 
reticulocyte stage. This has not previously been investigated. 
A second approach to examining the influence of erythrocyte-endothelial 
interaction on sickle cell disease is to measure markers of endothelial activation, 
platelet activation and anaernia in various states of sickle cell disease e. g. in 
steady state, in crisis and on hydroxyurea (HU) treatment. In the final chapter, 
these markers in the plasma e. g. vascular endothelial growth factors (VEGF), 
nitric oxide metabolites (NOx), soluble vascular cell adhesion molecule 1 
(sVCAM1), soluble endothelial selectin (sE-selectin), beta-thromboglobulin 
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(BTG), platelet factor 4 (PF4), haemoglobin (Hb) and erythropoietin (Epo) which 
are believed to be influenced by erythrocyte-endothelial interaction were 
measured and compared. 
In this introductory chapter, a brief description of the pathophysiology of 
sickle cell disease is given. This is followed by a review on the influence of HbF 
to the sickling process. Finally the importance of erythrocyte-endothelial 
interaction to the sickling process is reviewed. 
1.2. SICKLE CELL DISORDERS 
Sickle cell disorders are inherited or genetic diseases resulting from a 
structural mutation of the P-chain of haernoglobin gene resulting in the 
production of sickle haernoglobin (HbS) instead of normal adult haernoglobin 
(HbA). HbS production is the result of a single point mutation at the 6 th codon (P). 
The normal GAG codon is substituted by GTG (Marotta et a/., 1977b; Mears et al., 
1981). This substitution results in the insertion of a non-polar valine residue 
instead of a highly polar glutamic acid (P6Glu->Val) in the P-globin chain that is 
recognised as Ps. Thus HbS has more positive charge than normal HbA. 
Therefore it migrates further than HbA in gel electrophoresis (Slightom et a/., 
1997). The substitution leads to its ability to polymerise in the deoxygenated state 
or hypoxia and its solubility is reduced (Noguchi et al., 1981). Low oxygen tension 
(such as in post-capillary venules where 02 tension is about 40 mmHg) can 
induce HbS polymerisation. Solubility of deoxy-HbS is only 1% of the oxy-form 
(Perutz & Mitchinson, 1950). HbS polymer (tactoid) builds up within the red cells 
after its conformational change in the deoxy state. The polymer formation can 
induce membrane damage, increase rigidity and change the red cell shapes 
from normal biconcave to crescent or sickle forms (Mohandas & Evans, 1989). 
The condition is autosomal recessive in clinical terms but co-dominant in 
productional terms. Thus although heterozygotes (AS) have both Hb A and HbS 
in each red cell ( <50% HbS and >50% HbA ), clinical complications are seldom 
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seen (Ogunye & Ejiogu, 1982). The pathophysiology and basic knowledge of 
sickle cell disease (SS) is reviewed as follows. 
1.3. SICKLE HAEMOGLOBIN 
In general, haemoglobin is composed of two pairs of polypeptide chains 
called globin chains, and each chain is folded around a haern molecule. The 
different globin chains are similar in their molecular structure and amino acid 
composition but are clearly divided into two groups: alpha-like chains (CC- and ý- 
chains) containing 141 amino. acids and beta-like chains (0-, Y-, 8- and - C-chains) 
containing 146 amino acids. Each chain binds a haern molecule, hence there 
are 4 haern molecules for each Hb molecule called tetramer. As mentioned 
earlier, sickle haernoglobin (HbS) is the result of a single point mutation of P- 
globin gene. The mutant gene produces ps-globin. Therefore HbS is composed 
of 2cc-chains and 2ps-chains. Diagram of HbS tetramer is shown in Figure 1.3.1. 
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Figure 1.3.1 Diagram of sickle haemoglobin tetramer 
(From Dean & Schechter, 1978) The helical outline of each chain and the (X- 
carbon polypeptide backbone of one a- and one l3-chain are shown. The ý6 
Glu->Val substitutions are indicated with a heavy arrow and a heavy line. Amino 
acid residues in the region of probable contacts within the polymer are denoted 
with a filled circle and their number in the amino acid sequence. Arrows indicate 
residues on the backside of the molecule. The diagram has been simplified in 
that the identification of all the mutants is shown in the C02 S tetramer whereas 
their exact location is still ambiguous. 
Sickle haemoglobin polymerisation leads to increase cell rigidity, 
membrane damage and a shape change to crescent or sickle forms (Figur 
1.3.2). This provokes many kinds of clinical manifestations, such as vaso- 
occlusive painful crisis, acute chest syndromes, priapism, stroke, haemolysis 
and anaemia (Rodgers, 1998). 
(-Ilu Val) 
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Figure 1.3.2 Scanning electron micrograph of sickle red cells 
(From Serjeant, 1994) Magnification x19,000 by Drs Klug, Lessin and Albert. 
1.4. GEOGRAPHICAL DISTRIBUTION OF SICKLE CELL DISORDERS 
Sickle cell disease is widely distributed among black people and also 
people in Southern Italy, Northern Greece, Southern Turkey, North-Eastern Saudi 
Arabia and India. In Africa, clear tribal variations occur between peoples living in 
similar environments in Uganda and Tanzania. Bantu-speaking tribes have 
higher and more consistent frequencies than Hermitic-speaking tribes 
(Lehmann, 1954). Examination of sickle haplotypes shows at least 5 different 
haplotypes, suggesting at least five separate occasions on which the HbS 
mutation has occurred independently and been selected for by environmental 
pressures (Ashley-Koch et al., 2000). 
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Contribution of malaria to the distribution of the sickle cell gene 
It is believed that haernoglobinopathies, including sickle cell disease, 
provide protection against malaria in many malarial regions of the world and that 
natural selection is responsible for elevating and maintaining their gene 
frequencies. The epidemiological and in vitro data demonstrate that this principle 
applies to sickle cell disease (Allison, 1964; Roth et al., 1978). Malarial endemic 
areas usually co-exist with high prevalence of sickle cell trait. The first 
observation on malaria and the sickle cell trait was in Northern Zimbabwe 
(former Rhodesia) where it was found that malarial parasites presented less 
frequently in blood films of sickle cell trait individuals (Beet, 1947). It was 
confirmed later that malaria was significantly less common in children with sickle 
cell trait, and that even those who had malaria usually had less severe 
complications (Raper, 1956), Plasmodium falciparum is the only type of malaria 
that sickle cell trait clearly protects against while protection in other types is 
inconclusive (Fleming et al., 1979). There is evidence that P. falciparum-infected 
red cells in sickle cell trait patients are sequestrated by the reticulo-endothelial 
system and exposed to low oxygen tension permitting potassium loss and 
lowering of pH, factors known to inhibit parasite growth in vitro (Ginsburg et al., 
1986). 
1.5. PATHOPHYSIOLOGY OF SICKLE CELL DISORDERS 
1.5.1. Sickle haemoglob. in polymerisation 
Sickle haemoglobin polymer structure 
Polymers of deoxy HbS form fibres termed tactoids. These fibres are 
composed of up to 14 strands of HbS molecules (Carragher et al., 1988) (Figure 
1.5.1.1). In the deoxy HbS crystal, the Pr3 valine interacts with the ý5 phenylalanine 
and the p88 leucine of an adjacent tetramer of HbS (Noguchi et al., 1985) (-F-: Ig-ure 
1.5.1.2). Other contacts between tetramers occur and are important for polymer 
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stability, but such contacts alone are not critical for initiation of polymerisation. 
Other mutations at some of these contact points can stabilise or destabilise the 
sickle polymer (Watowich et al., 1993). 
Critical 
nucleus 
16 k. 
Figure 1.5.1.1 Sickle haemoglobin polymerisation 
(From Ferrone et al., 1985) 
(A) In homogeneous nucleation of HbS tetramers, a critical nucleus of 
haernoglobin molecules forms with subsequent appearance of polymer. 
Polymer formation is not stable until a critical nucleus is achieved. 
(B) In heterogeneous nucleation, the additional polymers can grow on the 
surface of the original polymer causing them to become more stable. 
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Fiqure 1.5.1.2 Deoxygenated sickle haemoglobin polymers 
(From Ferrone et al., 1985) Contact points are shown. Figures A and B show a 
single lis-globin chain, ý6 valine interacting with 085 phenylalanine and p88 leucine 
of an adjacent tetramer. In figure C, normal 06 glutamic acid in HbA cannot make 
this contact as its charge and size does not fit. 
Factors affecting the rate of polymerisation 
Polymerisation of HbS in solution is dependent on temperature (Anderson 
& Biro, 1994), ionic strength (Bookchin & Balazs, 1986), level of 2,3- 
diphosphoglycerate (Cohen-Solal et al., 1998) and oxygen concentration (Alston 
et al., 1984). The HbS tetramer concentration defines the solubility of HbS and is 
in equilibrium with the HbS polymers. Fully oxygenated HbS cannot polymerise, 
but partially or fully deoxygenated HbS can. The rate of tactoid formation is 
inverted proportional to the 1 Oth power of the deoxy HbS concentration (Ferrone et 
al., 1985). Any factor, which increases this concentration, will sharply increase 
the rate of sickling. For example, dehydration of the red cell increases the 
haemoglobin concentration and hence that of deoxy HbS, thus increasing the 
rate of tactoid formation. Conversely factors diluting the concentration of HbS, 
such as the presence of other normal Hb (HbA or HbF) which interact less rapidly 
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with deoxy HbS, will slow this process. Thus either HbA or HbF can inhibit HbS 
polymerisation and improve the clinical conditions of sickle cell patients. The 
mechanism of inhibition is believed to be the inability of HbA and HbF to be 
incorporated into the HbS polymer. This results in slower growth of the HbS 
polymer. The protective effect of HbF is clearly shown when the sickle cell gene is 
co-inherited with the hereditary persistence of foetal haernoglobin (HPFH) gene. 
In such individuals, each red cell has approximately 20-30% of HbF in addition to 
HbS and the patient typically has very mild clinical symptoms (Danish et al., 
1989). When HbS co-exists with another haernoglobin, in the compound 
heterozygote, the different polymerisation tendencies are also consistent with the 
clinical severity of that compound genotype (Brittenham et al., 1985). 
In the case of a mixture of HbS and HbF, neither the HbF tetramer (a2y2) 
nor the HbS-HbF hybrid tetramer (a2p S y) can initiate polymerisation. In contrast, 
the HbS-HbA hybrid tetramer (a2psPA) has a greater chance of initiation. When a 
polymer free HbS solution is deoxygenated, a delay time occurs before any 
polymer is detected and then it rapidly accumulates. This observation is 
explained by the "double-nucleation" hypothesis in which it is believed that an 
initial homogeneous nucleation of polymer takes place first in the solution and 
then a subsequent explosive heterogeneous nucleation on the template of ready- 
formed polymers occurs later (Eaton & Hofrichter, 1990) (Figure 1.5.1.1). The 
delay time of HbS polymerisation is inversely correlated to 1010 times the 
concentration of deoxy HbS . This implies that a small reduction in HbS 
concentration might have a critical role in improving the clinical disease by 
prolonging the delay time which allows more time for sickle red cells to escape 
the sickling process at the post-capillary venules (Cao & Ferrone, 1996). The 
polymerisation inside sickle red cells appears to occur similarly to that of HbS in 
solution. However, a wide range of different densities and HbS concentrations 
exists in each patient. This results in a wide range of delay times from 
milliseconds to many seconds (Noguchi et al., 1983). The variability in delay 
times determines the different fates of sickle red cells (Mozzarelli et al., 1987) 
(Figure 1.5.1-3). 
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Figure 1.5.1.3 Vaso-occlusion in sickle cell disorders 
(From Mozzarelli et al., 1987) 
(A) A sickle red cell without polymer or no significant membrane damage, 
perhaps a HbF containing red cell, is passing through the capillary smoothly. 
(B) A sickle red cell with few polymers is trapped for a while, because of its 
longer delay time, so it escapes the capillary but deforms later in the venule. 
(C) A sickle red cell with some polymers is trapped longer, because of its shorter 
delay time, so it deforms within the capillary but escapes into the venule 
without any occlusion. 
(D) A sickle red cell with more polymers is trapped and obstructs the capillary 
microcirculation. 
(E) A sickle red cell, which is trapped in the capillary, may escape later but goes 
out with permanent membrane damage. 
(F) A sickle red cell with permanent membrane damage and high rigidity is 
trapped in the microcirculation and produces vaso-occlusion. 
These fates of red cells are dependent on the delay time of individual 
cells, polymer concentration, degree of membrane damage, vascular tone 
(vasoconstriction and vasodilatation) red cell and endothelial adhesion 
molecules and plasma factors. 
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Thus the interaction of any particular sickle red cell and its environment 
determines whether, when, and where vaso-occlusion will occur. The starting 
point of vaso-occlusion is likely to depend not only on features intrinsic to the 
sickle red cell, such as HbS concentration, delay time, polymer content and 
membrane impairment, but also on local factors extrinsic to the cell, such as the 
activations of vascular endothelial cells, leukocytes, platelets and coagulation 
factors, cytokine release and the balance of vasodilators and vasoconstrictors 
(Figure 1.5.1.4). 
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Fiqure 1.5.1.4 Pathophysiology of vaso-occlusion 
(From Embury, 1996) See text for details. 
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1.5.2. Mechanism of vaso-occlusion 
Vaso-occlusion is a multi-factorial process involving many cell types, 
cytokines, activation markers and microvascular environment (Hillery, 1998). 
Where ever vaso-occlusion takes place will depend on a balance between the 
rate of tactoid formation and the rate of blood flow in the microvasculature. Vaso- 
occlusion is thought to occur predominantly in the post-capillary venules. As the 
flow slows in post-capillary venules where the P02 is low, conditions favouring 
tactoid formation can arise. The flow rate can be affected by many factors such as 
the viscosity of the blood, the deformability of the red cells, the vessel diameter, 
and the tendency of red cells or other cells to adhere to the vascular endothelium. 
In the 'steady state' a dynamic equilibrium exists between the rate of formation of 
tactoids at low P02 and tactoid dissolution as the red cells flow back to more 
oxygenated environments,, This equilibrium can be disturbed by a number of 
external factors such as hypoxia (e. g. at high altitudes or intense exercise), 
vasoconstriction (such as. in cold weather or emotional excitements), dehydration 
and acidosis, which increases risk of vaso-occlusion (especially in inflammatory 
conditions where adhesion molecules on endothelium are upregulated). These 
mechanisms appear to be temporally different within the same patient, and 
between different patients. Genetic factors, acquired red cell characteristics, the 
internal environment of the patients and the behaviour of the different sickle cell 
genotypes modulate all plasma factors and vascular factors. All of these 
determine the vaso-occlusive type and severity of the disease (Stuart & Johnson, 
1987). Such disease complexity provides many potential targets for therapeutic 
interaction. (Figure 1.5.2). 
, 
30 
Chapter 1 
HbS HbS 
solution polymer 
00 to 6 0 - ee 
ft6 
s 
F) S 
610161 66joA so a 
0 
% 
Amino acid t 
replacement as 
GAG --*- P6 Glu Val 00 
Oxy Deoxy'ý" 
ltýe 
00 
00 it 
HbS cell 
Cell 
heterogeneity 
Figure 1.5. Pathogenesis of sickle cell disorders 
Vaso-occlusion 
(From Rodgers, 1998) The nucleotide (GAG-ýGTG) and amino acid (Glu-Nal) 
substitution of sickle haernoglobin (HbS), polymer formation on hypoxia or 
deoxygenation, cell sickling, cellular heterogeneity, sickle cell endothelial 
adhesion and vaso-occlusion is shown. 
1.5.3. Sickle red cell heterogeneity 
The circulating sickle red cells differ even in the same patient (Bertles & 
Milner, 1968). For example, some sickle reticulocytes are very dense with mean 
corpuscular haernoglobin concentrations (MCH) of up to 50 g/dl compared with 
the normal range of 27-38 g/dl. The sickle red cells present in various shapes 
such as oval, asterisk, crescent or sickle shapes because of the differences in 
HbS concentrations, rates of polymerisation and content of polymer forms. These 
include the crenate cells and discocytes, which can be either very dense or 
normal. Some sickle red cells are irreversibly fixed in their bizarre contour. Some 
are dense at the time of release from the bone marrow, while others become 
more dense later in circulation (Bookchin et al., 1991). The density of each sickle 
red cell is determined by its Hb content and its capacity to maintain normal 
hydration and ionic balance. The aged cells usually become more dense 
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because their membrane damage causes ionic imbalance and dehydration 
(Nash, 1991). They also tend to have more membrane bound IgG (Green et al., 
1985). The number of HbF containing red cells (F+cells) and dense cells can 
differ widely among patients, and this may be genetically controlled. The degree 
of haemolysis directly correlates with the number of irreversibly sickle and dense 
red cells. There is a paradox in the relationship between cell density and vaso- 
occlusion. The higher proportion of dense cells, the fewer vaso-occlusive painful 
crises are found (Lande et al., 1988). The proportion of dense cells falls as the 
crisis starts and rises again as the painful crisis resolves (Ballas & Castillo, 
1992). These findings probably suggest that the more deformed, more adherent 
but less dense sickle red cells may stick to the endothelium inside the vessel 
wall first, then the dense cells follow and are removed later. 
1.5.4. Membrane damage of sickle red cells 
Vaso-occlusion is rarely found in sickle cell trait (AS) since each red cell 
contains only about 40% HbS, the rest being HbA. However, the renal medulla is 
always acidic, hypoxic and hyper-osmotic. These conditions are suitable for HbS 
polymerisation. Even sickle cell trait red cells deform in this environment 
occasionally leading to haematuria. Renal concentrating ability is nearly normal 
in individuals with sickle cell trait and sickle cell co-inherited with a-thalassaemia 
(S/cc-thal), where the HbS content is about 30% and fewer polymers exist inside 
the cells. This indicates the importance of the HbS concentration (Gupta et al., 
1991). Deoxy-HbS polymer, and perhaps a high concentration of oxy-HbS, may 
cause secondary damage to the cell contents and membrane. This damage 
reduces the capacity of sickle red cells to maintain their normal K+ gradients, 
which are mediated by activation of the K: Cl co-transport channels, leading to cell 
swelling, deoxygenation, acidification, high intracellular Ca 2+ and sickling. 
Membrane phospholipids may lose their asymmetry by exposing the 
procoagulant aminophospholipid, phosphatidyl serine (PS), which normally 
presents inside the cell membrane (Helley et a/., 1996). This leads to an 
inappropriate initiation of coagulation process. Abnormal interactions among 
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membrane cytoskeletal proteins are also found. This may be due to iron- 
mediated oxidation, which promotes the clustering of ankyrin, band 3 and 
glycophorin together with oxidised HbS (Corbett & Golan, 1993). Micro- 
vesiculation may occur when the HbS polymer penetrates the cytoskeleton and 
protrudes outwards as a lipid-ensheathed bud, or even dissociates into the 
circulation as a micro fragment. A relatively rapid reduction of oxygen 
concentration (50% reduction Of 02 within 1 minute) over sickle red cells causes 
a sharp increase in individual viscosity and a granular appearance characterized 
by an irregular surface with small spicule-like projections (Kaul & Xue, 1991). 
(F igu re 1.5.4) 
Asymmetry maintained by 
transport of PS and PE 
Bilayer scrambling 
Inactive flipase impairs 
phospholipid asymmetry 
Fiqure 1.5. Membrane damage in sickle red cell 
(From Rodgers, 1998) Phosphatidyl serine (PS) and phosphatidyl ethanolamine 
(PE) are translocated to the outer leaflet of the membrane of sickle red cells, 
perhaps because of sickling-induced damage and because the enzyme 
responsible for maintaining normal phospholipid asymmetry is not functioning 
properly. Sickle haernoglobin polymer protrudes through the membrane 
skeleton, distorting the lipid bilayer and leading to loss of membrane lipid as 
micro-vesicles. 
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Membrane damaged sickle red cells are able to adhere to vascular 
endothelial cells (Hebbel et a/., 1980a). The mechanism of attachment may vary 
according to the type of endotheliurn encountered. The adhesion of sickle red 
cells onto vascular endothelial cells is thought to reduce blood flow so that 
polymerisation, sickling and vaso-occlusion occur before their transit through the 
microvasculature is completed. Sickle red cells adhere to vascular endothelial 
cells via membrane adhesion molecules such as CD36 (GPIV, GPIllb or 
thrombospondin receptor), CD41 (GPIlb or allb integrin) and CD49d (N integrin) 
on sickle red cell surface. Some plasma proteins such as von Willebrand factor 
(vWF), thrombospondin (TSP), fibrinogen (FB) and fibronectin (FN) are thought to 
bridge the interaction of sickle red cells with vascular endothelial cell surface 
molecules such as laminin (LM), glycoprotein lb (GPlb), integrins, vascular cell 
adhesion molecule (VCAM) and Fc receptor (Fc-R) (Hebbel, 1997; Moore et al., 
1996). Clinical severity is thought to be related to the degree of adhesion of sickle 
red cells to vascular endothelial cells (Hebbel et al., 1980b). 
1.6. CLINICAL CONSEQUENCES OF SICKLE CELL DISORDERS 
1.6.1. Life expectancy and causes of death in sickle cell disease 
Life expectancy varies depending on socio-economic conditions as well 
as the genotypes of sickle cell disorders. In homozygous sickle cell patients 
(SS), after the first 6 months of life where persistence of HbF protects against 
sickling, the highest mortality occurs within the first 5 years with the greatest risk 
between 6-12 months. In the Jamaican cohort study, there was about 6% 
mortality within the first year of life, with a continuing but lesser mortality rate 
thereafter and a 10-year survival of 84% (Thomas et al., 1982). In addition, 
another peak of mortality appears in women aged between 20-24 years, partly 
due to pregnancy related complications (Smith et al., 1996). In the USA and the 
Caribbean, survival of SS patients of Western African origin commonly exceeds 
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30-40 years. Survival is even greater in SS patients in India and Eastern Saudi 
Arabia where almost all patients survive into adult life (Gelpi, 1979). 
The common causes of death among sickle cell patients are acute chest 
syndromes, acute splenic sequestration, renal failure and meningitis (Thomas et 
al., 1982). In infancy, pneumococcol septicaernia predominated in the past, but 
penicillin prophylaxis has reduced this cause of death (Day et al., 1992). 
However, penicillin-resistant pneumococcus increasingly threatens the success 
of this drug (Woods et al., 1997). Renal failure as a cause of death predominates 
in patients over the age of 40 years. In another study of 3764 American patients, 
the median age at death was 42 years for male SS and 48 years for female SS 
patients. Among those with sickle cell co-inherited with HbC (SC) patients, the 
median age was 60 years for males and 68 years for females. The factors 
associated with high risk of early death were acute chest syndromes, renal 
failure, seizures, a base line white-cell count higher than 15,000 cel I/MM3 and a 
low HbF level. However, over 50% of followed patients survived beyond 50 years 
(Platt et al., 1994). 
1.6.2. Acute complications of sickle cell disorders 
Vaso-occlusive painful crisis 
Acute vaso-occlusive painful crisis is the most common complaint of 
patients with SS. The pathogenesis of vaso-occlusion has been described in 
terms of chaos theory (Embury, 1996). Where the crisis begins is still not clearly 
known. It is likely to be somewhere in the microvasculature through mechanisms 
described above, but the larger arteries, especially in the brain and lung, can 
also be included. Typically painful crises involve the long bones in adult life 
causing severe limb pain. The ribs may also be involved causing chest pain. In 
infancy the hands and feet are often involved causing 'hand-foot' syndrome often 
associated with swelling of these extremities. Experimental evidence suggests 
that many different elements inside and on the membrane of the sickle red cells, 
on endothelial cells and in the plasma, provoke and mediate vaso-occlusion. 
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The frequency and severity vary among patients and also within the same patient 
from time to time. Any type of stress may precipitate a painful episode. The 
frequency of painful crises varies directly with the haernatocrit but inversely with 
HbF levels. 
Acute chest syndromes 
Acute chest syndromes (ACS) are characterised by chest pain, fever, 
hypoxia, dyspnoea and new infiltrates on chest radiography. ACS is the most 
common cause of death in adults and the second most common cause of 
hospitalisation (Vichinsky, 1991). The incidence of ACS is age and genotype 
dependent. It is 3 times more common in young children than in adults and is 
most common in SS followed by S/00thal, SC and S/p+thal in decreasing order of 
frequency. The incidence of ACS is inversely related to HbF levels and the degree 
of anaernia, but is directly related to WBC count during the steady state (Castro et 
al., 1994). ACS is closely associated with vaso-occlusive painful crises 
especially in adults (Styles et al., 1996). Thirty % of ACS is associated with 
painful crises. Adhesion of sickle red cells to endotheliurn of small or even 
medium pulmonary vessels may be the primary cause of ACS (Haynes & 
Kirkpatrick, 1993; Sugihara et al., 1992). Pulmonary thrombo-embolism is 
uncommon as a cause of ACS despite the presence of hypercoag u lability in 
sickle cell patients (Haupt et al., 1982). However after occlusion has occurred, 
platelet activation, endothelial activation and hype rcoag u lability are the causes of 
inflammatory activation. Management of ACS including antibiotics, oxygen 
inhalation, and transfusion in mild cases and exchange transfusion in severe 
cases are recommended. 
Infection (Pneumococcal septicaemia) 
Pneumococcal infection is a high risk in children with sickle cell anaernia 
(Samuels-Reid, 1984), the greatest risk being in SS children with splenornegaly 
(Topley et al., 1982) and age under 6 years (John et al., 1984). Pneumococcal 
pneumonia, septicaemia and meningitis are common and have a high mortality 
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rate among SS children. Prophylactic penicillin is recommended to start from 4-6 
months for entire life. Pneumococcal vaccine should be given at 2 years and a 
booster dose at 4 or 5 years (Salamah et aL, 1987). Other infections are also 
increased, such as Haemophilus influenza type B, salmonella osteomyelitis and 
Escherichia coli septicaernia. 
Folate deficiency 
Megaloblastic anaernia due to folate deficiency may be found in sickle cell 
disease associated with severe diarrhoea and low folate levels (Sinow et al., 
1987). Most patients respond to folate supplements (1 mg daily) quite well, but 
the megaloblastic picture may still remain until folate levels are normalised 
(Rabb et al., 1983). Factors affecting folate deficiency are a low folate diet, 
diarrhoea, and folic acid antagonists such as pyrimethamine and anticonvulsant 
drugs. In sickle cell disorders, the haernolytic process makes increased folate 
demands. Folate supplements (1-5 mg daily) is recommended for children with 
sickle cell disease. 
Aplastic crisis 
Aplastic crisis is characterised by acute severe anaernia (reduction of Hb 
from 8.6 to 3.5 g/dl within a few days) with a low reticulocyte count (0.2%) and a 
marked decrease in red cell precursors in the bone marrow. This can be rapidly 
fatal if not recognised rapidly. The bone marrow typically recovers within 10 days 
with intense erythroid hyperplasia, increased reticulocytes and Hb increasing to 
the previous levels (Morley et al., 1973). The aetiology of the crisis is human 
parvovirus (1319) infection (Kelleher et al., 1984). This infection occurs in about 
two thirds of children in the UK but only causes problems if red cell survival is 
short, such as in SS or other haemolytic disorders. Supportive treatment and 
blood transfusion are required and prognosis is usually good if the condition is 
recognised early (Goldstein et al., 1987). 
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Acute splenic sequestration 
Acute splenic sequestration is characterised by a large number of red 
cells sequestrated within the spleen, leading to a sudden fall in Hb level, usually 
life-threatening and with high prevalence in young children aged less than 5 
years (Topley et a/., 1981). Splenic enlargement, a sharp drop in Hb to lower than 
2 g/dl within a few days and sudden collapse are common features. Most 
. patients require emergency 
blood transfusion. Splenectomy for prophylaxis of 
further episodes is usually recommended after 2 attacks (Kar, 1999). 
Stroke 
Stroke follows occlusion of cerebral vessels and affects about 10% of 
patients with SS (French et al., 1997). This occurs most commonly in young 
children, median age at 6 years, and has a 50-70% chance of recurring within 3 
years after the first attack. Chronic transfusion can reduce the risk of a second 
attack. Trans-cranial Doppler to detect velocity of blood flow or MRI to detect 
infraction in the cerebral may predict stroke risk (Adams, 2000). 
Priapism 
Priapism is characterised by congestion of the corpora due to the 
occlusion preventing drainage of blood out of the penis. Acute priapism is 
characterised by prolonged painful erection for several hours. Exchange 
transfusion is required but surgical drainage is often needed. Stuttering priapism 
is characterised by repetitive, reversible, painful erection usually lasting less than 
3 hours and may have a severe attack lasting more than 3-4 hours. Such an 
episode may cause permanent scarring and/or impotence (Monga et al., 1996). 
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1.6.3. Chronic complications of sickle cell disorders 
Chronic haemolytic anaemia 
All sickle red cells do not survive equally because of their cellular 
heterogeneity. The HbF content of the sickle red cell is the most prominent factor 
that effects survival, possibly by reducing the tendency towards membrane 
damage as HbF can delay or prevent HbS polymerisation (Bertles & Milner, 
1968). Quite a few sickle red cells are destroyed intravascularly. Most of them 
have serious membrane damage due to mechanical forces and they are very 
sensitive to complement-mediated lysis. However, the majority of sickle red cells 
are destroyed extravascularly. They contain more immunoglobulin G (IgG) on 
their surface than normal red blood cells. This may be due to the membrane 
damage caused by both HbS polymerisation and oxidative free radicals. 
Macrophages, with IgG-Fc receptors, bind these cells and clear them from the 
circulation. The densest cells appear to have more surface bound IgG, and to be 
more rapidly sequestered. The degree of haernolysis is directly related to the 
proportion of IgG bound sickle red cells and/or dense sickle red cells (Green et 
al., 1985). Sickle red cells entrapped in the microvasculature may be 
sequestrated rapidly, typically in the spleen. Linking haemolysis to the vaso- 
occlusive process is the fall in dense cell numbers during the first stage of the 
painful crisis, which is followed by reticulocytosis, a response to the anaemia 
resulting from increased haemolysis. Sickle reticulocytes seem to contain more 
membrane adhesion molecules than normal reticulocytes. Such cells may either 
initiate or prolong the painful crisis. Once the crisis is resolved, the dense sickle 
red cells rebound to the level shown before the crisis, probably because there is 
no more entrapment or sequestration. This explanation may not fit in all crisis 
patients since the mechanism underlying vaso-occlusive painful crises is very 
complicated and many points remain to be explored. Increased haernolysis 
alone is not enough to be the major cause of clinically significant worsening of 
the anaernia in sickle cell disease (Mohandas & Evans, 1989). 
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The lifespan of sickle red cells is decreased from a normal 120 days to 
just 10-20 days in most patients. Haemoglobin levels are typically about 6-9 g/dI 
and the reticulocyte count is about 5-15%. In the steady state, tissue oxygen 
delivery is nearly normal because of the hyperdynamic circulation and much 
lower oxygen affinity of HbS. Persistent anaernia is due to the higher turnover rate 
of red cells and haemolysis. Extravascular haemolysis causes increases in 
bilirubin levels which may be associated with jaundice and gall stones especially 
in adult patients over the age of 20 years (Ballas et al., 1980). 
Avascular necrosis 
Avascular necrosis or osteonecrosis may occur in sickle cell patients, 
especially in the femoral head (Hernigou et al., 1993). This complication is more 
common in SC than SS possibly because of the higher blood viscosity in SC 
(Ballas et al., 1989). 
Chronic renal failure 
Chronic renal failure (CRF) is often found in sickle cell patients over age of 
40 years and is a serious condition (Wong et al., 1996). Patients at this age 
should have their renal function monitored regularly. Falling of Hb levels and 
worsening anaemia with impaired renal function are the signs of CRF. Blood 
transfusion may be necessary to improve oxygen delivery. In case of end stage 
renal failure, haemodialysis is required (Powars et al., 1991). Renal 
transplantation can be considered if the organ is available (Ojo et al., 1999). 
Retinopathy 
Proliferative sickle retinopathy (PSR) is described as arterio-venous 
communication lesions at the border of the vascular and avascular retina (Mason 
& Scherrer, 1991). Complications include retinal haemorrhage and retinal 
detachment (Siegel, 1988). PSR is more common in SC disease and S/P+ 
thalassaernia type III than in SS (Talbot et al., 1988). Males are more affected 
than females. Peak PSR prevalence in SS is 30 years but in SC is 25-29 years in 
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males and over 40 years in females. Vitrectomy and retinal reattachment surgery 
are necessary in severe cases (Penman & Serjeant, 1992). 
Chronic leg ulcers 
Chronic leg ulceration is a major cause of morbidity and commonly found 
in adolescence and early adult life (Baum et a/., 1987). Osteomyelitis may 
complicate deep ulcers. Supportive treatments are required along with improved 
personal hygiene (Sher & Olivieri, 1994). Blood transfusion, exchange 
transfusion and hydroxyurea treatment may benefit. 
1.6.4. Management of sickle cell disorders 
Prevention of infections 
Sickle cell patients (SS) has an unusual relationship with certain 
infections. Individuals with sickle cell trait (AS) are less likely to die following a 
first infection with Plasmodium falciparum than normal (AA) subjects, but in SS 
such an infection may precipitate a fatal crisis. Several acquired abnormalities 
render SS more susceptible to a number of infections (Fleming, 1989; John et 
al., 1984). The increased susceptibility to infection with polysaccharide- 
encapsulated bacteria (S. pneumonia and H. influenzae) is secondary to the 
absence or impairment of splenic function. Thus, all SS patients should receive 
the polyvalent anti-pneurnococcal vaccine every 3-5 years and Haemophilus 
influenza type B vaccine at 2,4 and 6 months after birth. Other recommended 
vaccinations, in addition to routine childhood vaccines, include influenza vaccine 
annually and hepatitis B vaccine at birth or first visit of children and adults who 
have no serological evidence of previous exposure to hepatitis B virus. 
Prophylactic oral penicillin should be given to infants and children with SS on a 
daily basis for a minimum of 5 years or for life (Gaston et al., 1986). Cellular 
immunity may be compromised by transfusion-related iron overload and 
abnormalities in B-cell immunity may explain antigen-processing defects. 
Escherichia coli infection is usually associated with urinary tract infections in 
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adult females. Patients with SS are also susceptible to osteomyelitis secondary 
to Salmonella typhimurium in addition to the usual causes of bacterial 
osteomyelitis, such as S. aureus. 
Role of blood transfusion 
Most SS patients tolerate chronic anaernia well, because HbS has 
decreased oxygen affinity and is thus more efficient in delivering oxygen to 
tissues. Moreover there is a direct relation between haernatocrit value and painful 
episodes. Painful episodes occur more frequently in mild rather than severely 
anaernic patients. A higher blood viscosity may worsen the severity and increase 
the frequency of vaso-occlusive painful crises. 
Transfusion should be considered carefully because an increase in blood 
viscosity can precipitate a crisis. There are two independent objectives of blood 
transfusion in SS patients. One is the improvement of oxygen-carrying capacity in 
severely anaernic patients. The second is a dilution in the proportion of 
circulating sickle red cells in order to improve microvascular perfusion, such as 
in acute chest syndromes or in the prevention of recurrent stroke (Styles & 
Vichinsky, 1997). Specific indications for blood transfusion are listed in Table 
1.6.4.1. 
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Table 1.6.4.1 Indications for blood transfusion in sickle cell disease 
(From Rodgers, 1998) 
Accepted indications 
Simple transfusion 
Hb <5.0 g/dl with significant signs and symptoms of severe 
anaernia 
Angina or high cardiac output 
Acute haemorrhage 
Acute splenic or liver sequestration 
Pre-operative preparation with general anaesthesia 
Exchange transfusion 
Acute cerebral infarction 
Acute chest syndrome 
Multi-organ failure syndromes including fat embolism 
Acute priapism unresponsive to therapy 
Surgery 
Prevention of recurrent stroke in children 
Possible indications 
Leg ulcers 
Complicated pregnancy 
Chronic organ failure 
Before injection of hypertonic contrast media 
Adults with cerebrovascular accident history 
Frequent painful episodes 
The aim of exchange transfusion is to increase or to maintain a Hb level at over 
10 g/dI and to decrease HbS level at lower than 30%. 
All SS patients older than 6 months should have complete red cell antigen 
phenotyping prior to the first transfusion and the records kept available at all 
times in the blood bank. Phenotype determination should include at least ABO, 
43 
Chapter 1 
Rh, Kidd, Kell and Duffy blood groups. Leukocyte-reduced red cell concentrate is 
recommended especially in children because it reduces febrile non-haernolytic 
transfusion reaction, alloirnmunisation and cytornegalovirus (CMV) infection and 
minimises reactions to white blood cells. (Rodgers, 1998) 
Role of hydroxyurea 
It has been recognised for many years that HbF prevents HbS 
polymerisation and thus reduces the severity of sickle cell disease. Hydroxyurea 
(HU) has been shown both to increase HbF levels and decrease the severity of 
the disease (Charache, 1993). At first the clinical benefit of HU was thought to be 
its action of increasing HbF levels alone, but it appears that clinical benefit is 
observed before maximal HbF levels are achieved (Styles et al., 1997). Later 
studies showed that the reduction in neutrophils, monocytes, platelets and 
reticulocytes due to bone marrow suppression may play a more important role in 
contributing to the clinical benefit (Charache et al., 1996). 
A double-blind placebo-controlled trial of HU in 299 adult SS patients who 
had had at least 3 painful episodes per year, showed that HU significantly 
reduced the frequency of painful crises, ACS, hospitalisation and the need for 
blood transfusion (Charache et al., 1996). The HbS-containing red cells became 
less dense, and haemolysis was reduced. These changes and the reduction in 
painful episodes are achieved before the increases in the HbF levels (Styles et 
al., 1997). In other studies, HU reduced the adherence of sickle cells to 
endotheliurn in vitro and increased the length of time for HbS polymerisation or 
delay time (Adragna et a/., 1994; Bridges et al., 1996). Reticulocytes expressing 
adhesion molecules on their surface are reduced in HU treated SS and SC 
patients (Browne & Hebbel, 1996). These reductions correlated with the 
reduction in the frequency of painful episodes (Steinberg et al., 1997). 
Mechanisms of action of hydroxyurea in sickle cell disease are summarised in 
Fiaure 1.6.4. 
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Figure 1.6.4 Mechanisms of action of Hydroxyurea in sickle cell disease 
(From Steinberg, 1999) In the marrow, hydroxyurea increases the proportion of 
erythrocytes containing HbF by its antiproliferative and possibly apoptotic effects 
on progenitor cells. The proportion of HbF containing cells may be increased 
because hydroxyurea results in a reduction in the number of cell divisions prior to 
the release of red cells from the bone marrow. Hydroxyurea has no known direct 
effect on gene expression. In the bloodstream, higher concentrations of HbF 
reduce the polymerisation of HbS and the numbers of deformed, dense and 
damaged red cells. Red cells with a high HbF content survive longer, attenuating 
haemolysis and leading to reduction in reticulocyte count. The numbers of 
circulating reticulocytes, granulocytes, monocytes and platelets are also reduced. 
The likelihood of vaso-occlusion is reduced by the reduction in the number of 
dense, poorly deformable red cells and adhesion molecule expressing 
reticulocytes. 
There are still many unknowns in HU action. It is unclear whether the 
clinical benefit results directly from increase in HbF levels or other factors such 
as decrease in white blood cells, platelets, reticulocytes and red cells expressing 
adhesion molecules (Steinberg, 1999). Other unknowns include, the optimal 
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dosing schedules, prediction of toxicity, prediction of responders and non- 
responders, proper assessment of the long-term risk/benefit. Although painful 
crisis and acute chest syndrome are reduced following HU treatment, however 
the impact on survival is not yet known. Monitoring toxicity and compliance of SS 
patients on HU treatment must be vigorous. Initial doses should begin with 15- 
20 mg/kg/day. No more than 2 weeks supply of drug should be given at a time. 
Before the maximal tolerated dose can be achieved, the patients should be 
monitored for myelotoxicity every 2 weeks and doses should be escalated only 
every 8 weeks. The signs of toxicity can be monitored by weekly full blood count 
(FBC). If the WBC is <2,000/ld, platelet <80,000/gI, a fall in Hb by <2 g/dI/day 
and/or absolute reticulocyte count <80,000/gi, then the drug should be stopped. 
Weekly FBC should be continued to monitor the return of blood cells. Patients 
and parents should be informed that the benefit of HU treatment might not be 
achieved before 3 months of therapy. Adult male and female patients should be 
advised to use an appropriated form of birth control, because of unknown 
teratogenesis of HU (Steinberg, 1999). 
Bone marrow transplantation 
Children age under 16 years with severe complications (stroke, recurrent 
ACS, refractory pain) and with an HLA-matched sibling donor available, are the 
best candidates for bone marrow transplantation (BMT). Only a very small 
number of sickle cell patients have undergone BMT so far. More than 90% of SS 
patients who have undergone BMT survive, 70-85% had disease-free survival 
and 15% had graft rejection. Neurological complications (seizures or intracranial 
bleeding) were common in the first BMT recipients (Walters et al., 1996). Careful 
control of blood count, blood pressure and anticonvulsant prophylaxis may 
prevent complications. Follow-up is still short and the full extent of adverse 
reaction is unknown. The ability of BMT to reverse organ damage is also 
unknown, but early reports suggest some improvement in lung, bone and CNS. It 
has been suggested that cord blood stem cells may provide more resources for 
BMT in a larger number of sickle cell patients (Brichard et al., 1996). As more 
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beneficial but potentially hazardous treatments as BMT become available, it 
would be of great value to be able to predict the severity of SS more accurately. 
Low HbF levels and the absence of (x-thalassaemia may predict a more severe 
clinical course (Thomas et al., 1997). However with modern supportive care, 
most patients can live longer than 50 years with an acceptable quality of life. BMT 
may be associated with a short-term mortality of about 10% and this factor 
should be carefully considered. Controlled trials comparing conventional 
treatments such as blood transfusion, hydroxyurea therapy and transplantation 
have not been conducted and therefore the relative values of these treatments 
are still unclear. 
Table 1.6.4. Limitations and risks of three main treatments for sickle cell 
disease (from Vichinsky, 1991) 
Blood transfusion Hydroxyurea Therapy Bone Marrow Transplantation 
Alloirnmunisation Dose variability Graft rejection 
Iron overload Chronic myelotoxicity Limitation of donors 
Infection Variable response Late malignancy 
Venous stenosis Late malignancy Graft versus host 
Teratogenesis Central nervous system 
Not proven in children Sterility/growth impairment 
Short term high cost 
Prevention 
Prevention of sickle cell disease has been mainly limited to couples living 
in the developed countries with a high level of education and easy to access 
genetic services. A couple where both partners have sickle trait have a1 in 4 
chance of having a child with SS in each pregnancy. The foetus can be tested by 
chorionic villus biopsy at 10 weeks of gestation and a termination offered to the 
couple if this is culturally acceptable to them. As with other genetic diseases, the 
prevention programme is based on mass education, screening and genetic 
counselling. It should be pointed out to a couple that sickle cell disease has a 
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very variable (and presently unpredictable) clinical course because of genetic 
and environmental modifying factors. The genetic modifying factors are only 
partially understood. 
Prenatal diagnosis of sickle cell disease 
The substitution from glutamate to valine at 0' position in HbS molecule 
results from a point mutation in the DNA at that codon from GAG to GTG. This 
mutation can be detected by cleaving the DNA with a restriction enzyme that 
recognises the sequence in this region. The Mst-11 restriction endonuclease 
targets the sequence of CCTXAGG (where X is any base) which is present on pA 
gene but absent on Ps gene. The digesting on product contains 1.3 kb fragments, 
because of the missing of a target on Ps gene, corresponding to 1.1 kb fragments 
in the PA gene digesting on product. The fragments are then separated by gel 
electrophoresis and visualised by Southern blotting using 32 P-labelled DNA 
probe, which is complementary to both fragments, because the 1.3 kb fragment 
also contains the 1.1 kb sequence. An autoradiograph reveals whether the pA 
gene, the Ps gene, or both are present in the DNA sample, which was obtained 
from a chorionic villus biopsy or amniocentesis. 
1.7. FOETAL HAEMOGLOBIN AND SICKLE CELL DISORDERS 
1.7.1. Foetal haernoglobin levels and distribution 
Genetic control of HbF levels 
Globin gene switching and sequential gene activation and silencing 
during development involve complex interactions of erythroid-specific and 
ubiquitous trans-acting sequences that act positively or negatively to regulate 
transcription (Grosveld et al., 1993a). Located in a region of DNA that lies 6-18 kb 
Vto the e-globin gene, and composed of a series of DNase hypersensitive sites 
(HSs), the locus control region (LCR) plays a critical role in gene expression by 
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interacting with the promoters of the P-like genes (Grosveld et al., 1993b). Each 
HS contains genetically conserved binding domains for erythroid-specific and 
ubiquitous DNA-binding proteins (Figure 1.7.1). The LCR may act as a 
holocomplex, interacting with only a single promoter at any instant in time 
(Slightom et al., 1997). An arrangement where the gamma gene was proximal 
and the beta gene distal to the LCR resulted in predominant gamma-gene 
expression in the embryo. When the order was reversed and the gamma gene 
was placed distally to the LCR, gamma-gene expression in the embryo was still 
up to threefold higher than expression of the LCR-proximal beta gene. These 
findings suggest that the embryonic trans-acting environment interacts 
preferentially with the gamma genes irrespective of their order or proximity to the 
LCR (Peterson & Starnatoyannopoulos, 1993). Erythroid-specific transcription 
factors have been identified. GATA-1, related zinc-finger binding proteins and 
Friend of GATA play important roles in erythroid cell development and the 
transcription of both globin and non-globin erythroid-specific proteins. NF-E2, a 
B-zip transcription factor, consists of two subunits, one widely expressed and the 
other restricted to haernopoietic tissues. Erythroid Kruppel-like factor (EKLF) may 
be the most specific of the known erythroid transcription factors. Interacting with 
the O-globin gene promoter, EKLF may influence the y-O switch (Miller & Bieker, 
1993) (Perkins et al., 1995). 
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Figure 1.7.1 DNase hypersensitive sites of the P-globin gene cluster 
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(From Lu & Steinberg, 1996) DNase hypersensitive sites (HSs) of the P-globin 
gene cluster local control region (LCR) and cis-acting elements that play a role in 
the modulation of y-globin gene expression in sickle cell disorders. Within the 
large arrows are the regions examined in sickle cell patients who had high or low 
foetal haernoglobin (HbF) levels. 
Levels of HbF afterbirth 
After birth the proportion HbF continues to fall during childhood to the adult 
levels of less than 2% and still declines throughout adult life at a very slow rate. 
The GY: AY ratio varies in adults (Enoki et al., 1990) but GY is predominant in new- 
born babies (3: 1). Thus, the cc-globin like genes undergo just a single switch in 
expression (embryonic--)foetal/adult), whereas the P-like genes undergo 
switches twice (embryonic-4oetal->adult). In a small proportion of healthy 
individuals, HbF levels persist above 1-2% in adult life. The reasons for this are 
many and complex and are discussed below. 
Cellular distribution of HbF 
Analysis of the cellular distribution of HbF in normal adults using a 
sensitive immunofluorescent staining (Wood et al., 1975) shows that only a 
small subpopulation (1-7%) of red cells contain detectable amounts of HbF 
(F+cells). However, F+cells in adults are not similar to foetal red cells in new-born 
babies, neither in the amount of HbF per cell nor in the other characteristics (e. g. 
surface antigen, red cell enzymes, etc. ) (Weatherall, et al. 1981). In healthy 
adults, the amount of HbF per F+cell ranges up to 25% of total Hb in the cell 
(Boyer, 1975) and it is now clear that different F+cells have unequal amounts of 
HbF. In neonates, the proportion of HbF in foetal red cells may range from 50- 
90% (Weatherall, et al. 1981). The fall in HbF in the first year of life is associated 
with a fall in both the proportion of F+cells and the HbF content in the F+cells 
themselves (Henri et al., 1980). 
It seems that all red cell precursors have the capability to express some 
HbF but only a small subpopulation do so in detectable amounts. This concept is 
supported by findings that in clonal disorders of haernopoiesis such as 
polycythaemia vera and chronic myeloid leukaemia, the cellular distribution of 
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HbF or the proportion of F+cells is still the same as that in normal individuals 
(Papayannopoulou et al., 1978). If F+cells represented a distinct cell population, 
then most of these patients would have no F+cells at all, while a few would have 
all F+cells. 
1.7.2. Factors modulating HbF levels in adult life 
Genetic factors (Gilman & Huisman, 1984), gender and age (Miyoshi, et 
aIJ 988; Maier-Redelsperger, et al., 1994) may effect HbF levels. High HbF levels 
in adult life are acquired or inherited factors. The acquired factors consist of 
pregnancy, acute blood loss, leukaemia,. bone marrow transplantation, aplastic 
anaernia, refractory normoblastic anaernia, paroxysmal nocturnal 
haemoglobinurea, infant having a diabetic mother and juvenile chronic myeloid 
leukaemia. The inherited factors can be divided into 2 sub-groups; primary and 
secondary. The primary sub-group consists of hereditary persistent foetal 
haernoglobin (HPFH) and 8p-thalassaemia that can be divided in to non-deletion 
and deletion forms. The non-deletion form is further divided into autosomal- 
linked and X-linked. The secondary sub-group consists of sickle cell anaernia 
and P-thalassaemia. 
Hereditary persistent foetal haemoglobin (HPFH) and 30-thalassaemia 
Hereditary persistent foetal haernoglobin (HPFH) and 8p-thalassaemia are 
heterogeneous disorders, which are characterised by increased levels of HbF in 
adult life, because of a decrease or absence of P-chain synthesis and a variable 
compensatory increase in y-chain synthesis. The distinction between them was 
originally made on clinical and haernatological grounds before their related 
molecular defects were recognised. 
HPFH is a group of heterogeneous disorders in which there is an 
increased y-chain production into adult life (Steinberg, 2001). HPFH can be 
divided into two types based on the genetic basis. The first type results from a 
deletion of a variable length in the p-gene cluster. The second type is non- 
deletional where increased expression of y-gene results from single point 
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mutations in the gamma promoter region. In deletional variants, both GY and AY 
are synthesised in increased quantities. Non-deletional HPFH is associated with 
mutations in the promoter region of the G y- and Ay-globin genes (Huisman, 1997) 
resulting in increased expression of gamma genes. In such non-deletion 
variants, typically only one of the two y-chains is over expressed. 
Distribution of HbF among red cells in HPFH is recognised as either 
pancellular or heterocellular forms. In the pancellular form, almost every cell 
contains HbF, whereas in the heterocellular form, only a sub-population of red 
cells contains HbF. Most HPFH individuals are pancellular forms. The Swiss type 
HPFH is a heterocellular form which elevates HbF levels to 3.5-6.3% and 
produces about 10% F'cells or more (Sournmer et al., 1981). 
Homozygous HPFH is typically asymptomatic, with no clinical finding and 
no abnormal growth pattern. Such individuals produce 100% HbF with both GY 
and Ay and a slight erythrocytosis (RBC about 6-7 x106 /gl) due to the higher 
oxygen affinity of HbF relative to HbA. Their red cells are microcytic with MCV 
about 75 fl and slightly hypochromic with MCH about 25 pg. Reticulocyte count 
and bilirubin levels are normal. 
Heterozygous HPFH is also asymptornatic with increases in HbF levels 
from 10-30% of the total Hb. HbA2 is decreased to 1-2% and the rest is HbA. 
There is no haernatological abnormality and usually found by family study. 
6P-thalassaemia is a form of thalassaernia in which 0- and 8-globin chain 
production is absent, due to deletions and nondeletions of the structural P- and & 
gene complex similar to deletional forms of HPFH. This thalassaemia produces 
nearly 100% F+cells in homozygous state. However, the homozygous state is very 
rare. In HPFH, the increased y-chain production fails to fully compensate for the 
loss of O-chain production. Thus most patients with 8p-thalassaemia have mild 
anaemia (Hb levels 10-12 g/dl), hypochromic microcytosis, slight 
hepatosplenomegaly and some bone change associated with chronic erythroid 
hyperplasia. Reticulocyte count and bilirubin levels are elevated suggesting 
some degree of haemolysis. In the heterozygous 5p-thalassaemia, there is no 
specific clinical finding, no anaemia, and no splenomegaly and such individuals 
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usually have lower levels of HbF at about 5-20% with usually less than 90% of 
HbA. The blood picture is similar to that of a heterozygous O-thalassaemia with 
microcytic, slight hypochromic red cells. HbA2 is normal or slightly decreased and 
HbA is usually less than 90% of total Hb. (McKenzie, 1996) 
Other factors affecting foetal haemoglobin levels 
Xmnl polymorphism. This results from a C-->T substitution at position -158 
of the G 7-gene promoter which creates an Xmnl restriction enzyme site 
associated with an increase in the G7/G7+A7 ratio and an increase in HbF levels in 
both P-thalassaemic and sickle cell patients who carry this mutation (el-Hazmi, 
1989; Ballas et al., 1991). Increased HbF levels have also been observed in 
healthy individuals lacking genes for sickle or thalassaernia disorders who are 
heterozygous or homozygous for the Xmnl site (Sampietro et al., 1992). 
A region of about 0.5 kb, 1.65-1.15 kb 5' to the G7 gene, has been 
proposed as another area that potentially has a regulatory role in y-globin gene 
expression (Pissard & Beuzard, 1994). Designated as the pre_Gy framework, this 
region has several transcription factor binding sites and four polymorphic 
variants linked to the P-gene cluster haplotype. Whether the pre_G y framework is 
an important haplotype-linked regulatory region awaits for further study. 
Trans-acting elements is another factor that play a major role in the 
modulation of y-globin gene expression. Among potential trans-acting elements 
suspected of influencing y-globin gene expression, an X-linked F cell production 
(FCP) locus between DXS143 and DXS16 within Xp22.3-22.2 has been identified 
by linkage analysis but no gene has yet been identified (Dover et al., 1992). This 
locus may account, in part, for the high HbF levels in females compared to males 
found in both normal individuals and sickle cell patients. The phenotype of the 
FCP locus does not influence the HbF response in patients treated with 
hydroxyurea (Steinberg et a/., 1997). HbF production may also be influenced by 
genetic loci localised on chromosome 6q and by other loci unlinked to the 
globin gene cluster (Craig et al., 1996). 
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1.7.3. Evidence for protective effect of HbF in sickle cell disorders 
New-born protection 
In new-born babies with sickle cell disease the sickle forms of red cells 
are seen less than in adult patients. In 226 pairs of black mothers with sickle cell 
disease and their affected infants, only about 11% of SS new-born babies 
showed sickle form of red cells compared to nearly 100% in their mothers blood, 
(Watson et al., 1948). This finding suggests that high HbF levels in new-born 
babies have a protective effect against sickling. This is consistent with the 
absence of clinical episodes of sickle cell disease during the first 4 months of 
life. Furthermore as the HbF levels decline close to adult levels at about 4 
months after birth, the sickle red cells increase gradually, because low levels of 
HbF no longer give any protection. 
Sickle cell disease and hereditary persistence of foetal haernoglobin (HPFH) 
Sickle cell patients who are also heterozygous for HPFH produce about 
25-30% HbF of the total Hb, and show reduce anaernia and clinical 
complications despite the presence of 70% HbS (Conley et al., 1963). These 
observations suggest a protective effect of HbF on the sickling process (Tuan et 
al., 1980). 
Sickle cell patients in eastern oases of Saudi Arabia have unusually high 
levels of HbF at about 10-26% which are associated with a relatively mild 
disease (Brown et a/., 1972; Perrine et al., 1972). Saudi patients do have painful 
crises, meningitis and osteomyelitis but less seriously and less frequently. 
Childhood mortality is lower and there is less anaernia than the other groups of 
patients. Similar features are also found in sickle cell patients in Southern India 
(Brittenham et al., 1979). 
In sickle cell anaernia, cis-acting elements play a role in the modulation of 
HbF production. Their nature and modes of action are not clearly understood. 
Trans-acting elements also play a role in controlling HbF production in sickle cell 
disease. The X-linked F cell production (FCP) locus at Xp22.3-22.2 may account, 
54 
Chapter 1 
in part, for the higher HbF levels in the female relative to the male patients. This 
observation is also found in normal population (Miyoshi, et al., 1988). 
Protective effect of HbF induced by hydroxyurea in sickle cell patients 
The higher HbF and F+cell production following hydroxyurea treatment can 
reduce severity of the disease clearly. This has been mentioned before in section 
1.6.4 about the role of HU in SS management. 
1.8. OTHER MARKERS IN SICKLE CELL DISORDERS 
1.8.1. P-Globin gene cluster haplotypes 
Restriction fragment length polymorphisms (RFLPs) can be used as 
genetic markers to characterise individual genetic differences. RFLPs linked to 
the P-globin gene cluster define haplotypes of the sickle cell genotypes, which 
have been named after the geographic locations with the highest prevalence 
(Nagel & Fabry, 1984) (Table 1.8.1). The P-globin gene haplotype among cis- 
acting determinants serves as one marker for the genetic background inherited 
with the HbS gene and for elements that may influence y-globin gene expression 
(Nagel & Fabry, 1984). There are five haplotypes or genetic backgrounds, Benin, 
Bantu, Senegal, Cameroon and Arab-Indian, which arose with sickle cell 
mutation (Pagnier et al., 1984). Diverse genetic determinants inherited along with 
the ps gene may indicate possible causes of phenotypic variation in sickle cell 
disease. The haplotype bearing the Ps gene is associated with a variety of 
haernatological and clinical features that are likely, at least in part, to be 
mediated through effects on HbF concentration (Nagel & Fleming, 1992). Most of 
the RFLP sites used to define a haplotype have no known role in the differential 
transcription and temporal regulation of globin genes. An exception is the XmnI 
site (-158 C-J) that is 5' to the Gy gene in the Senegal and Arab-Indian 
haplotypes which is strongly associated with high expression of the Gy gene 
compared with theAy gene (Nagel & Fabry, 1984). The Senegal haplotype may 
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provide the genetic environment necessary for high levels of y-globin gene 
expression in the presence of erythroid hyperplasia (Ballas et a/., 1991). 
Table 1.8.1 Haplotypes associated with the sickle cell mutation 
(from Rodgers, 1998) 
Haplotype Frequency' Clinical Features Hb (gIdl) HbF 
Beniný' 50-60 severe 8.0-8.5 6-7 
Bantu (CAR)3 25 most severe 8.0-8.5 6-7 
Senega14 15 mild 8.5-9.0 8-9 
Cameroon 55 mild-severe 8.0 5-6 
Arab-Indianr' 0 mildest 10.0 15-20 
Atypica17 18 variable 8.0 5-6 
'Percentage in Africa n-America n population 
2 Benin homozygote 
3 Bantu homozygote and Benin/Bantu combined heterozygote 
4 Senegal homozygote and Senegal/Benin combined heterozygote 
5Cameroon heterozygote with any typical haplotype 
r3Arab-Indian homozygote 
7Atypical haplotype heterozygote with any typical haplotype 
The Arab-Indian haplotype accounts for more than 90% of the ps-gene- 
associated haplotypes in India and is prevalent in the eastern oasis of Saudi 
Arabia. These patients have high HbF levels and less severe anaernia but have 
similar vaso-occlusive complications to their compatriots from the western area 
where the Ps-gene is present on the Benin haplotype (Padmos et a/., 1991). In 
the Saudi Arabian population, the -158 C-->T polymorphism is strongly, but 
imperfectly, associated with high levels of HbF and G y-chain in sickle cell 
anaernia (Labie et al., 1985). This mutation may play a permissive role, 
necessary, but insufficient, to promote increased transcription of the Gy gene. 
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1.8.2. Co-inheritance of (x-thalassaemia with sickle cell anaemia 
a-Thalassaemia in African origin people usually results from the deletion 
of one or two (x-globin genes on chromosome 16. Nearly a third of Black Africans 
examined carry at least one (x-thalassaemia mutation, so these mutations are 
frequently found to co-exist with sickle cell mutations (Steinberg, et al. 1986). 
Patients with sickle cell and (x-thalassaemia usually have a lower MCV, lower 
reticulocyte count, less haemolysis and higher haernoglobin concentration 
compared to with patients with (x-thalassaemia alone (Steinberg & Embury, 
1986) (Table 1.8.2). 
Table 1.8.2 Haematological features of patients with sickle cell and (x- 
thalassaernia (From Steinberg & Embury, 1986) 
cc-globin genotype Hb (g/dI) mcv (fi) Reticulocytes (%) HbA2 
cc(x/(X(x 8.0±1.1 92±7 11±6 2.8±0.4 
-(X/aa 8.6±1.1 83±7 9±6 3.3±0.6 
-(X/-(x 9.2±1.3 72±4 7±5 3.8±0.4 
(x-Globin genotype shows the number of cc-globin genes present in patients with 
sickle cell anaernia. These data are the averages of values reported in studies of 
African origin sickle cell patients with a-thalassaemia. 
a-Thalassaemia affects the phenotype of sickle cell patients by reducing 
the red cell haernoglobin concentration. Concurrent a-thalassaemia diminishes 
the polymerisation potential of HbS in sickle cell anaernia, reducing haemolysis 
and anaemia. Clinically, the outcome of coincident sickle cell associated with (x- 
thalassaemia is incongruous. Vaso-occlusive events appear undiminished. 
Fewer dense deformable red cells are found. The coincidence with (x- 
thalassaernia raises the haernatocrit. HbF levels are simultaneously increased 
which would be expected to reduce vaso-occlusion (Phillips et a/., 1991). 
Patients with sickle cell and (x-thalassaemia have less painful episodes and 
less bone complications than those with sickle cell anaernia alone. 
Nevertheless, more blood transfusions may also be needed to protect against 
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bone marrow, brain and other organ damages, skin ulcers of the legs and retinal 
vascular impairments, which are found less commonly in patients with either a- 
thalassaernia or sickle cell anaernia alone (Rodgers, 1998). 
1.8.3. Compound heterozygote characteristics 
Clearly the compound heterozygote such as SC and SP-thal, may lead to a 
different phenotype than classical SS. In addition to the classical SS genotype, 
several compound heterozygous states may also result in an alteration in sickle 
cell syndromes clinically. 
Sickle cell with P-thalassaemia (SIP-thal). Sickle cell with P-thalassaemia has 
two general genotypes; S/po-thalassaemia and S/P+-thalassaemia. In S/PO- 
thalassaernia, the normal P-globin is completely absent. The clinical features 
appear similar to sickle cell anaemia (SS). Vaso-occlusions are even more 
common than in SS, probably because these patients have a higher Hb 
concentration, which raises blood viscosity and slows the blood flow. In S/D+- 
thalassaernia, the normal P-globin is present but in reduced levels. The clinical 
features depend on the type of P+-thalassaemia mutation. The HbA production 
varies from very low to high, but HbS always predominates. Patients with a low 
production of HbA usually present with a similar phenotype to SS or S/PO- 
thalassaernia. The majority of S/p+-thalassaemic patients have about 20-30% 
HbA with milder clinical symptoms (Kulozik et al., 1991). 
Sickle cell with haemoglobin C (SC). Haemoglobin C also results from a single 
point mutation in the p6_codon. The codon changes from GAG to AAG which 
substitutes lysine instead of glutamic acid (06GIu-4Lys) (Marotta et al., 1977a; 
Marotta et al., 1977b). The pathophysiology of SC disease is determined by the 
specific interaction of HbS with HbC that are present in a near 1: 1 ratio in the red 
cells (Bunn et al., 1982). SC red cells have a decreased cation content but an 
increased density, which promotes HbS polymerisation. Osmotic swelling of SC 
red cells reduces their oxygen affinity, the rate of sickling and deoxygenation 
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induced K+efflux (Fabry et al., 1982). The SC disease is generally milder and 
prognosis better than with SS, although some complications are more common. 
Avascular necrosis of the hip is generally more common in SC than SS. The 
combined effect of increased haernoglobin level, cell density and blood viscosity 
may lead to a very high prevalence of retinopathy in SC patients, and is present in 
about 80% of adult SC patients but uncommon in adult SS patients (Kent et al., 
1994). 
HbD Punjab or HbD Los Angeles has a substitution of GAG by CAG, glutamic 
acid to glutamine, at p121 (0 121 Glu-)Gln). HbD Punjab is widely distributed among 
the Sikhs in the Punjab state of India at about 1% of population. It also occurs in 
the black population in the Caribbean, North America and in Britain especially 
among Anglo-Indian children. The combination of S and D (SID disease) is 
typically more severe than SC disease (Serjeant, 1994). 
1.8.4. P-Globin gene silencer 
A region of DNA of 530 bp 5' to the P-globin gene is an AT-rich region 
where polymorphic variants are linked to the P-globin gene cluster haplotype. 
This putative P-globin gene silencer may influence the expression of the P-globin 
gene by binding a repressor, BP1, whose differential binding may variably inhibit 
p-globin gene transcription. The evidence is still incomplete but this area could 
influence the clinical heterogeneity of sickle cell anaernia by suppressing Ps 
synthesis (Elion et al., 1992). 
1.8.5. Haemoglobin A2 (HbA2) 
HbA2 the tetramer of 2(x- and 28-globin chains, inhibits the polymerisation 
of HbS to the same extent as HbF (Poillon et a/., 1993). However it is unlikely that 
variations in the HbA2 level affect the phenotype of sickle cell anabmia. When Do- 
thalassaemia is caused by a deletion of the 5' portion of the P-globin gene, the 
HbA2 level far exceeds than expected. Individuals who inherit this type of mutation 
with HbS may benefit clinically. Preliminary studies in transgenic mice that over 
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express the 8-globin gene suggest that too much HbA2 may injure the red cell, 
perhaps analogously to HbC, by its strong interaction with the membrane (Nagel, 
et al. 1995). 
1.8.6. Other genetic factors 
The effect of genetic differences in vascular function, endothelial cell 
biology, leukocyte function, platelet function, adhesion molecules on both red 
cells and endothelial cells, coagulation factors and red cell membrane proteins 
and lipids on modulation of disease severity are not clearly understood. Glucose- 
6-phosphate dehydrogenase (G6PD) deficiency is common in sickle cell 
anaemia. The phenotype of G6PD deficiency with sickle cell anaernia is variable 
and no conclusion regarding the combination could be drawn (Steinberg et a/., 
1988). There are many other genetic markers in inherited blood diseases such 
as red cell membrane content, red cell enzymes, coagulation abnormalities, 
other haernoglobinopathies and other genetic diseases to be explored that may 
influence the sickle cell anaernia phenotype. 
1.9. ERYTHROCYTE-ENDOTHELIAL INTERACTION IN SICKLE CELL DISORDERS 
1.9.1. Adhesion molecules involved in cell-cell interaction 
The evidence that the clinical severity of sickle cell disorders may be 
affected by the degree of sickle red cell adherence to vascular endothelial cells 
was discussed in section 1.5.4. Sickle red cells adhere to vascular endothelial 
cells via membrane adhesion molecules (AMs). AMs are expressed on every cell 
in the body and act as cell to cell or cell to matrix bridges. They may also mediate 
signals for growth, differentiation, activation, movement and trafficking of cells. In 
general there are 4 superfamilies of AMs (Moore et al., 1996). 
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Selectin super-family 
Selectins are all transmembrane proteins. They have in common the 
presence of NI-12-terminal C-type (Ca 2+-dependent) lectin-like binding domain, an 
epidermal growth factor-like region, a variable number of consensus repeat 
sequences similar to those appearing in complement-regulatory proteins 
(CRPs), a membrane-spanning region and a short cytoplasmic region. The 
selectins are important in the early stages of leukocyte adhesion. Stimulation of 
the endotheliurn induces leukocytes to roll along the vessel wall. This rolling 
involves adherence and de-adherence to the endothelium. The weak adhesive 
force of the selectins is suited for this rolling phenomenon. Activation of the 
rolling leukocyte by chemokines, cytokines or chemoattractants leads to the 
shedding of L-selectin from the leukocyte surface. The low density of L-selectin 
after the shedding allows leukocytes to be localised at inflammatory sites. 
Selectins can be sub-classified into 3 groups according to the number of CRP 
domains or their cellular origin (Moore et al., 1996). 
L-selectin (leukocyte adhesion molecule 1, LAM-1, CD62L or Lue-8) has 2 
CRIP domains, a MW of 74-100 kDa, and presents on leukocyte membranes. Its 
ligands are MadCAM-1, GlyCAM-1 and CD34. Its main functions are bridging 
among lymphocytes inside lymph nodes and homing of lymphocytes or 
monocytes to endotheliurn during adhesion, movement, rolling, flattening and 
extravasation. The soluble form of L-selectin (sL-selectin) can be detected at 
increased levels in inflammation and infection, due to its shedding from activated 
leukocytes. 
P-selectin (granule membrane protein-140, GMP-140 or CID62P) has 9 
CRP domains, a MW of 140 kDa, and presents on platelets, megakaryocytes and 
Weibel-Palade body (vWF storage vacuole inside platelet) membranes. It also 
presents in small amounts on endothelial cells. Its ligand is PSGL-1. Its main 
functions are bridging between activated platelets and neutrophils or monocytes. 
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E-selectin (endothelial leukocyte adhesion molecule-1, ELAM-1 or 
CID62E) has 6 CRP domains, a MW of 95-115 kDa, and presents only on 
endothelial membranes. Its ligands are ESLA and PSGL-1. Its main function is 
bridging between activated endothelial cells and leukocytes. 
Integrin super-family 
Integrins are also transmembrane proteins with a C-terminus anchored to 
the cytoskeleton. They function to receive and transmit external signals into cells 
and to bridge between the cells and extracellular matrix (ECM). Integrins are non- 
covalent heterodimers consisting of an a- and a 0-chain. At least 14 types of a- 
chain and 8 types of p-chain have been identified. Integrins are classified into 8 
groups according to their P-chain type. There are at least 20 integrins identified 
so far. Integrins can be recognised by 3 different nomenclatures; their descriptive 
name, heterodimeric name and cluster designation numeric name (for example, 
lymphocyte function antigen 1 or LFA-1, (ILD2 and CID1 1 a/CD1 8 are all the same 
integrin). Integrins can adhere to many types of ECM such as fibronectin, 
vitronectin, laminin, collagen, vWF, factor X and fibrinogen. The counter-receptors 
or ligands of integrins in the ECIVI are oligopeptides, for example, RGD (arginine- 
glycine-aspartate) in fibronectin, DGEA (aspartate-glycine-glutamine-alanine) 
and EILDV (glutamine-isoleucine-leucine-aspartate-valine) in other ECMs. 
Integrins are calcium dependent proteins. (Moore et al., 1996) 
PI-Integrin family (very late antigen or VLA). This family all have a common 
pl-chain (VLAP, gplla or CD29) associated with various cc-chains. There are at 
least 9 types of VLA identified so far; VLA-1 (alp,, CD49a/CD29), VLA-2(cc2pl, 
CD49b/CD29), VLA-3 (OC301, CD49c/CD29), VLA-4 (a4pl, CD49d/CD29), VLA-5 
(cc5pl, CD49e/CD29), VLA-6 (cc6pl, CD49f/CD29), C(701, a8p, and avpl. 
P,, Integrin family (LeuCAM). This family all have a common P2-chain 
(CD18) associated with various cc-chains. There are at least 3 types of leuCAM 
identified so far; LFA-1 (lymphocyte function antigen 1, CCL02 or CD11a/CD18), 
Mac-1 (macrophage 1, (XM02 or CD11b/CD18) and LeuCAMc (complement 
receptor4, CR4, (XXP2, p15O/95orCD11c/CD18). 
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fl3-Integrin family (Cytoadhesin). These all have a common 03-chain 
(CD61) associated with various a-chains. There are at least 2 types of 
cytoadhesin identified so far; gpIlb/Illa ((XllbD3, or CD41/CD61) and VNR 
(Vitronectin receptor, OCV03 or CD51/CD61). 
Other fl-Integrin families. These have another type of 0-integrin 
associated with various types of (x-integrins such as (X604, CCVP59 (XVNv (X4071 (XEP79 
(XV08. 
Immunoglobulin-like super-family 
Members of the Ig-like super-family are also transmembrane proteins with 
a C-terminus anchored to the cytoskeleton and an extracellular N-terminus, 
which consists of several Ig-like domains. They vary in the number of Ig-like 
domains. The Ig-like superfamily can be classified into 2 types. Cl-types are 
involved in antigen recognition and include the major histocompatibility (MHC) 
antigens. C2-types are cellular adhesion proteins and complement ligands and 
are involved in antigen presentation. These two types are sometimes very difficult 
to classify due to overlapping functions. There are at least 17 Ig-like members 
identified so far; ICAM-1 (intracellular adhesion molecule 1 or CD54), ICAM-2 
(CD102), ICAM-3 (CD50), VCAM-1 (vascular cell adhesion molecule 1, INCAM-1 
or CD106), VCAM-1 alt (alternatively spliced VCAM-1), PECAM-1 (platelet 
endothelial cell adhesion molecule 1, EndoCAM or CD31), MadCAM-1 (mucosal 
addressing cell adhesion molecule 1), LFA-2 (lymphocyte function antigen 2 or 
CD2), LFA-3 (CD58), BL-CAM (B-lymphocyte cellular adhesion molecule or 
CD22), Cell-CAM-105 (cell-cell adhesion molecule 105), NCAM (natural killer cell 
adhesion molecule, D2-CAM, NKH-1 or CD56), CTLA-4 (cytotoxic T-lymphocyte 
adhesin 4), B7 (CD80), 137-2 (CD86), CD4, CD8 and CD48. (Moore et al., 1996) 
Miscellaneous 
There are many adhesion molecules which cannot be classified into 
either superfamily such as; sialyl Lewis )ý sialyl Lewis A, platelet glycoprotein IV 
(gpIllb, thrombospondin receptor, TspR or CD36), platelet glycoprotein lb/IX 
63 
Chapter 1 
(gplb/IX), H-CAM (CD44), thrombospondin, unusually large vWF, CLA, CRII 
(complement receptor 1 or CD35), Endoglin (CD105), Fce RII (low affinity IgE 
receptor or CD23), GlyCAM-1 (L-selectin ligand), L-VAP-2, PSGL-1 (P-selectin 
glycoprotein ligand 1), VAP-1 (vascular adhesion protein 1), CD9, CD34, CD39, 
CD40, CD40 ligand, CD59 and CD63. (Moore et al., 1996) 
1.9.2. Adhesion molecule expression on sickle red cells 
CD36 or platelet glycoprotein IV (PItGPIV) or thrombospondin receptor 
(Tsp. R. ) is a 78-88 kDa transmembrane glycoprotein. It is found on 
megakaryocytes, platelets, endothelial cells, monocytes, reticulocytes and some 
tumour cell lines. It also presents at increased levels in sickle cell reticulocytes 
and stress reticulocytes. (Moore et al., 1996) 
CD411CD61, CD41 or platelet glycoprotein Ilb (PItGPIlb) or allb integrin is a 
transmembrane glycoprotein composed of 2 chains, GPIlba (120 kDa) and 
GPIlbP (23 kDa) linked by a disulphide bond. CD41 is always non-covalently 
associated with CD61 to form GPIlb/Illa complex. CD41 is expressed by 
megakaryocytes, platelets and a small subset of CD34+cells (stem cells), 
suggesting that CD41/CD61 complex is a marker of megakaryocytic lineage. In 
the resting state the complex binds to immobilised fibrinogen but in the activated 
stage, it binds to soluble fibrinogen, fibronectin, VWF, vitronectin and 
thrombospondin. It plays an important role in platelet aggregation. CD61 or 
platelet glycoprotein Illa (PltGPIIIa) or P3 integrin is a 110 kDa transmembrane 
glycoprotein normally associated with CID41. CD61 can also associated with 
CD51 or ccv integrin to form vitronectin receptor (CD511CD61). CD41/CD61 is 
expressed only on megakaryocytes and platelets, whereas CD511CD61 is found 
on osteoclasts, endothelial cells, macrophages, fibroblasts, smooth muscle 
cells, synovial lining cells and renal glomerular cells. CD41/CD61 is also 
expressed on sickle reticulocytes. It is absent in persons with Glanzmann's 
thrombasthenia. (Moore et al., 1996) 
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CD49dlCD29, CD49d or N integrin is a transmembrane glycoprotein of 
145kDa without disulphide bonds. CD49d binds non-covalently to CD29 or P, 
integrin to form a4p, integrin or very late activation antigen 4 (VLA-4) or binds to P7 
integrin to form C07 integrin. CD49d in a complex with either p, or N integrin is 
not only involved in cell adhesion to fibronectin and vascular cell adhesion 
molecule 1 (VCAM-1) but also in intercellular leukocyte interactions. It is 
expressed on monocytes, lymphocytes, eosinophils, thymocytes and 
Langerhans cells. It is also expressed on sickle reticulocytes. CD29 or P, integrin 
or platelet glycoprotein Ila (PItGPIIa) is a transmembrane glycoprotein of 110 kDa 
that binds non-covalently to a, -a8 and av integrin. CD29 complexes are involved in 
cell-cell and cell-matrix adhesion, depending on the types of associated a 
subunits. They have broad cellular reactivities but are not expressed by 
erythrocytes. In normal peripheral blood they are found on a subset of CD4+ and 
CD8+ T lymphocytes and a minority of B-lymphocytes. The inducer subpopulation 
of CD4+ lymphocytes co-expresses CID4 and CID29. CD49d/CD29 are also 
expressed on sickle reticulocytes. (Moore et al., 1996) 
1.9.3. Interaction of AM expressing red cells with endotheliurn 
Adhesion molecules (AMs) are expressed on every cell in the body to act 
as a cell to cell or cell to matrix bridges. They also mediate signals for growth, 
differentiation, activation, movement and trafficking of cells. Some AMs such as 
CD36 (glycoprotein IV or GPIV or thrombospondin receptor; Tsp. R. ), 
CD41/CD61(GPIlb/illa or allb/03 integrin) and CD49d/CD29 (VLA4 or a401 
integrin) are expressed on sickle red cells especially in the reticulocyte 
population and are involved in red cell endothelium interactions. Recent work 
has demonstrated the importance of red cell membrane AM expression in sickle 
cell disorders (Moore et a/., 1996) by mediating the adhesion of red cells to 
endothelium. Several AMs which are absent on normal red cells have been found 
on sickle red cells. In particular, CD36 is known to be expressed on sickle 
reticulocytes (Hebbel, 1997). Thrombospondin from activated platelets acts as a 
bridge to adhere sickle red cells to the endothelium either via the vitronectin 
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receptor (VNR) or via CD36 on the endothelial cell surface. CD41/CD61 is also 
expressed on sickle reticulocytes and binds vWF multimers released from 
vascular endothelium, thereby acting as a bridge for VNR binding onto the 
vascular endothelium (Kumar et al., 1996). CD49d/CD29 has been shown to 
directly link sickle reticulocytes to endothelial VCAM-1 or fibronectin (Gee & Platt, 
1995). These mechanisms of adhesion are shown in Figure 1.9.3. Some blood 
group antigens, such as Lutheran (Le) and LW were also reported to be involved 
in mediated erythrocyte-endothelial interaction in sickle cell disorders (Parson et 
a/., 1999). Furthermore, ex vivo studies have shown that increased expression of 
AMs on sickle erythrocytes can induce obstruction of blood flow in the 
microvasculature (Brittain et al., 1993). Adhesion molecules are expressed in 
increased quantities in reticulocytes (Joneckis et al., 1993) and in a 
subpopulation of immature reticulocytes with a low density which have been 
called "stress reticulocytes" (Browne & Hebbel, 1996). Therefore stress 
reticulocytes carry some adhesion molecules which are normally expressed in 
the earlier erythroblastic stages in the bone marrow. 
Vascular endothelial cells (VECs) may be involved in the sickle vaso- 
occlusive process as innocent bystanders, since there are many circumstances 
that alter their native properties. Vascular endothelial cell damage, a trigger for 
abnormal blood flow, may be due to the damaged membrane of rigid sickle red 
cells scraping along the side of vasculature, so that oxidant radicals and other 
vascular endothelial cell activation markers are produced and released into the 
circulation, exacerbating the crisis (Hebbel et al., 1982). Increased expression of 
vascular cell adhesion molecules (VCAMs), intercellular adhesion molecules 
(ICAMs) on VECs and their soluble forms, and other tissue factors have been 
reported in sickle cell patients. These activated endothelial cells increase in 
numbers during the vaso-occlusive painful crises (Solovey et al., 1997). The 
balance of vasodilators and vasoconstrictors may be changed to favour 
vasoconstriction due to perturbation of the endothelium by the sickle red cell. The 
vasoconstrictor protein endothelin-1 is increased, while the action of the 
vasodilator nitric oxide (NO) may be impaired due to abnormal NO production by 
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the damaged endothelium. Another vasodilator, prostacyclin, may also be low in 
sickle cell disorders for a similar reason. However, prostacyclin release is 
subject to adherence of sickle red cells to the endothelial sub-stratum, which 
occurs only after serious endothelial damage (Sowemimo-Coker et al., 1992). 
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Fiqure--l-. 9.3 Erythrocyte-endothelial interactions in sickle cell disorders 
(From Moore, et al. 1996) 
(A) VLA-4 expressed on sickle reticulocytes adheres directly to VCAM-1 
expressed on vascular endothelial cells. VCAM-11 expression is induced by IL-11, 
TNF(Y. and IL-4. 
(B) GPIlb/Illa expressed on sickle reticulocytes binds to unusually large 
vWF multimers released from vascular endothelial cells. The reticulocyte- 
GPllb/llla-vWF complex is bound to vascular endothelial cells via the endothelial 
vitronectin receptor (VNR). 
(C) CD36 expressed on sickle reticulocytes binds to thrombospondin 
(Tsp). The reticulocyte-thrombospondin complex is then able to bind to vascular 
endothelial cells via two receptors (VNR or enclothelial CD36). 
Note- VLA-4 and GPIlb/Illa are also able to bind to thrombospondin. 
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1.9.4. Reticulocytes 
A reticulocyte is defined as a young red cell with residual RNA and 
mitochondria but without any nucleus. It stains a bluish colour in routine Wright's 
stain, the so called polychromatophilic red cell, and shows a bluish reticular 
appearance in supravital stain (new methylene blue or brilliant cresyl blue), the 
so called reticulocyte. Reticulocytes are released from the bone marrow into the 
circulation containing approximately 65% of their total haernoglobin content, the 
remaining 35% being synthesised within the circulation. Normal reticulocytes 
contain small amounts of iron in the form of haemosiderin and ferritin in their 
cytoplasm, which appear bluish in Prussian or iron stains, the so called 
siderocytes (Hoffbrand, 1993). 
Both normal (AA) and sickle cell (SS) infants are born with high reticulocyte 
levels, which decline gradually during the first 4 weeks. After that, sickle cell 
individuals have higher levels of reticulocytes than AA individuals, which is 
sustained throughout their life. This is a response to the severe anaernia in such 
patients, which is confirmed by elevated erythropoietin levels. Recent findings 
indicate that reticulocytes might have some significance in vaso-occlusive painful 
crises in sickle cell patients. They are likely to express more adhesion molecules 
than mature red cells, and they are also appear to be the first cell to adhere to the 
vascular wall, before the rigid irreversibly sickle cells are trapped. Reticulocyte 
levels in sickle cell patients are significantly higher than normal AA persons. 
(Moore et al., 1996) 
1.9.5. Contributions of other adhesive cells to the sickling process 
Mature sickle red cells sometimes circulate sticking to leukocytes, 
platelets or stress reticulocytes. Stress reticulocytes express increased levels of 
red cell membrane adhesion molecules (AMs) which can bridge to their specific 
ligands on endothelium to provoke an occlusive process (Sugihara et al., 1992); 
(Brittain et al., 1993); (Wick et al., 1993) & (Gee & Platt, 1995). Sickle cell patients 
have increased levels of stress reticulocytes along with other haemolytic 
anaernia patients, but why the other patients do not present with vaso-occlusion 
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has yet to be explored. In sickle cell and sickle cell with HbC diseases, 
hydroxyurea therapy has the capacity to decrease levels of reticulocytes and 
stress reticulocytes due to its suppression of haernopoiesis, and this reduction 
appears to correlate well with fewer pain crises (Charache et al., 1996). The 
influence of neutrophils and possibly eosinophils and basophils, in vaso- 
occlusion has been increasingly recognised. A high mortality rate correlates with 
a high granulocyte count in sickle cell disorders (Platt et al., 1994). The greatest 
reduction in granulocyte and monocyte counts appears to have greatest effect in 
reducing vaso-occlusive painful crisis episodes in sickle cell patients 
undergoing treatment with hydroxyurea (Charache et a/., 1996). The vascular 
endothelial cells in sickle cell patients interact with activated neutrophils, which 
are usually increased in sickle cell patients, then the activated or damaged 
endothelial cells release a large quantity of many different cytokines and their 
activation markers into the circulation which exacerbates the painful crisis 
(Hofstra et al., 1996). Increased platelet counts and increased numbers of 
activated platelets are found in sickle cell diseases, along with reversible and 
irreversible changes in the shape of the platelets. Thrombospondin (TSP) is 
released from activated platelets and can act as a bridge between stress sickle 
reticulocytes and the endothelium, initiating vaso-occlusion (Brittain et al., 1993). 
1.10. ENDOTHELIAL FACTORS AND PLATELET FACTORS 
1.10.1. Regulation of VEGF on endothelial cells 
Vascular endothelial growth factor (VEGF, also known as vascular 
permeability factor or vasculotropin) is a hypoxia inducible homodimeric 
glycoprotein of 35-45 kDa, with specific effects on vascular endothelial cells 
(VECs) including potent angiogenic, mitogenic and permeability-enhancing 
effects. VEGF was originally identified as a secreted product of tumour cells 
(Senger et a/., 1983; Senger et al., 1986) and is related to a family of cytokines 
including placental growth factor (PIGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E 
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(Maglione et al., 1991; Paavonen et al., 1996). Five isoforms of VEGF have been 
identified so far, comprising 121,145,165,189 and 206 amino acids, which are 
generated by alternative splicing from a single gene (Burchardt et al., 1999; 
Gluzman-Poltorak et al., 2000). VEGF121, VEGF145, and VEGF165 are secreted in 
soluble form, while VEGF189 and VEGF206 are cell membrane or extracellular- 
matrix bound unless proteolytically cleaved (Houck et al., 1992). VEGF mRNA is 
found in various cell types such as macro ph ag es/mo n ocytes, granulocytes, 
lymphocytes, megakaryocytes, platelets, mesangial cells, keratinocytes, 
hepatocytes and endothelial cells (Ferrara et a/., 1992). Two high affinity 
receptors for VEGF found on endothelial cells are the fts-like tyrosine kinase 
receptor 1 (Flt-1) and the tyrosine kinase insert domain-containing receptor 
(KDR/Fik-1) (Millauer et a/., 1993). These two receptors belong to the class III 
receptor-type tyrosine kinase family and have a high degree of amino acid 
sequence homology. However, VEGF receptors are now known to be located in 
uterine smooth muscle (Brown et al., 1997) and pancreatic ductal epithelium 
cells (Rooman et al., 1997) whereas only FIt-1 is found on monocytes (Clauss et 
al., 1996). This indicates that VEGF might have some effects on those cells apart 
from its known effect on VECs. 
VEGF is upregulated in response to hypoxia, which is the most specific 
signal that induces transcription of VEGF genes and stabilises their mRNA (Stein 
et al., 1995). Hypoxia not only upregulates synthesis and secretion of VEGF, but 
also modulates its effect via the paracrine induction of VEGF receptors in 
vascular endothelial cells (Flt-1 and KDR/Flk-1) (Viglietto et al., 1996). Whereas 
hypoxic exposure for 2 hours causes a demonstrable increase in VEGF mRNA in 
rat lung tissue ex vivo, but reaction to such treatment in vivo is slower, taking 
over 28 days for the mRNA to reach a detectable level (Tuder et al, 1995). Hypoxia 
is also known to increase the expression of a number of other genes encoding 
vascular cell mitogens produced by endothelial cells such as platelet-de rived 
growth factor B (PDGF-B) and endothelin-1 (ET-1). A 28-bp enhancer in the 5' 
upstream region of the VEGF gene mediates the expression of VEGF by 
endothelial cells under conditions of hypoxia (Kourembanas et al., 1997). The 
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response to hypoxia of the VEGF gene is controlled by two regulatory elements: 
the first one may be related to the erythropoietin enhancer and the second one 
appears to be a completely unrelated sequence (Minchenko et al., 1994). The 
hypoxia-inducible genes for erythropoietin (Epo), tyrosine hydroxylase (TH), and 
vascular endothelial growth factor (VEGF) are also regulated post- 
transcriptionally by proteins binding to specific regions located in the 3' 
untranslated region (UTR) of their mRNAs (Scandurro & Beckman, 1998). 
Several similarities between the oxygen-sensing mechanisms regulating the 
expression of VEGF and Epo have been reported, for example expression of both 
mRNAs is significantly upregulated by hypoxia and cobalt chloride (COC12) (Liu et 
al., 1999), the half-life of both mRNAs is markedly prolonged by cycloheximide 
(Steinbrech et al., 2000). Hypoxic induction of both Epo and VEGF is also 
inhibited by carbon monoxide (Goldberg & Schneider, 1994). 
Several effects follow VEGF interaction with its receptor on endothelial 
cells including increased intracellular calcium ion concentration [Ca 2+ ], release of 
von Willebrand factor (vWF), increased permeability to macromolecules, 
elongation of endothelial cells and stimulation of endothelial replication (Brock et 
al., 1991). The earliest effect is an increase of up to fourfold in cytoplasmic 
calcium concentration [Ca 2+] . This effect occurs on cultured endothelium cells 
(EC) within seconds after exposure to VEGF at low concentrations (Brock et al., 
1991). The effect of VEGF on releasing of vWF and other storage substances 
from EC is similar to that of other EC agonists such as thrombin and histamine. 
However VEGF appears to act through a different receptor from those agonists, 
since inhibitors of thrombin and histamine fail to inhibit this action of VEGF 
(Brock et al., 1991). VEGF was originally known as vascular permeability factor 
(VPF) according to its potent effect on increasing permeability of microvessels 
(Brock et al., 1991). Vesicular-vacuolar organelles (WO), grape-like clusters of 
uncoated vesicles and vacuoles found at intervals in the cytoplasm of ECs lining 
venules and small veins,. are activated by VEGF. After activation, WO open their 
fenestra to allow macromolecules across the cytoplasm from the vascular lumen 
into the abluminal basal lamina (Kohn et al., 1992). Thus WOs provide a 
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pathway whereby plasma proteins may exit the circulation and enter the tissues 
(Qu et al., 1995). In addition, VEGF is able to stimulate EC replication, elongation 
of their shapes and migration to perform angiogenesis (Dvorak et a/., 1995a). 
VEGF is also able to upregulate plasminogen activator, plasminogen activator 
inhibitor, collagenase, and tissue factors (Dvorak et al., 1995b). This indicates 
that VEGF is involved in almost all EC functions. 
VEGF levels were not documented in sickle cell anaernia (SS) at the time 
that work on this thesis began. In 1999 there was a report of elevated EDTA 
plasma VEGF levels in sickle cell patients (120+81 pg/ml) in comparison with 
healthy blood donors (38+35 pg/ml) (Solovey et al., 1999). That report suggested 
that the high VEGF levels had an anti-apoptotic effect on circulating endothelial 
cells (CECs) in sickle cell patients, since CECs in healthy donors showed higher 
levels of apoptosis than those in sickle cell patients and the apoptosis was 
related inversely to VEGF levels. However, the cause of increased VEGF levels in 
that report was not investigated. 
1.10.2. Regulation of nitric oxide on endothelial cells 
Nitric oxide (NO) is a small molecule consisting of 1 nitrogen and 1 oxygen 
atom and is a free radical with one unpaired electron. It can move freely 
throughout the vasculature because of the small size (Darley-Usmar et al., 1997; 
McAndrew et al., 1997). It is an endogenous vasodilator functioning as 
endothelium-derived relaxing factor (EDRF) (Palmer et al., 1987). NO is formed 
by conversion of L-arginine and molecular 02' to L-citrulline by hydroxylation of 
one of the L-arginine guanidino nitrogens (Ignarro, 1989). This reaction is 
catalysed by nitric oxide synthase (NOS) and its co-enzymes, which include 
reduced nicotinamide adenine dinucleotide (NADPH) and tetrahydrobiopterin 
(THB) (Moncada & Palmer, 1991; Nathan, 1992). 
NOS occurs in 2 forms, constitutive (cNOS) and inducible (iNOS) forms 
(Forstermann et al., 1994). Schemes for NO synthesis by cNOS and iNOS are 
shown in Figure 1.10.2-1. 
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(From Davies et a/., 1995) NO and L-citrulline are formed from L-arginine and 
molecular 02 by hydroxylation of one of the L-arginine guanidino nitrogens. There 
are two distinct NO synthase forms (NOS); constitutive (cNOS) (Figure A) and 
inducible (iNOS) (Figure B). cNOS and iNOS exist as dimeric and tetrameric 
complexes respectively. Each unit contains two identical subunits with four 
prosthetic groups; flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FIVIN), tetra hyd robiopte ri n (THB) and haem. The cNOS isoform is activated by 
humoral, chemical and mechanical signals acting on the cell and is calcium 
(Ca 2+ ) and calmodulin (CaM) dependent. cNOS associates with the cell 
membrane and when translocation into the cytosol occurs, its activity is inhibited. 
NO itself exhibits negative feed back inhibition on cNOS activity. The other 
isoform; NOS is induced by endotoxin (M), gamma-interferon (IFN-y), 
interleukin (IL) 1, IL-2 and tumour necrotic factor alpha (TNF-(x). However it is 
inhibited by glucocorticoids, P-transforming growth factor (TGF-P), IL-4 and IL10. 
It is calcium independent but its active form can bind tightly with CaM. NOS activity 
is regulated by the intracellular concentrations of various substances such as L- 
arginine, Ca 2+ , CaM, reduced nicotinamide adenine dinucleotide phosphate (NADPH) and THB and also some external factors, such as macrophage 
differentiation factor (MDF), lipopolysacharride (LIPS) and shear stress. 
NO production occurs in a large number of cell types such as neutrophils, 
macrophages, fibroblasts, hepatocytes, platelets, endothelial cells, vascular 
smooth muscle cells and neurones (Bredt, 1999). Constitutive cNOS is 
distributed in neurones and in endothelial cells. While inducible NOS is 
distributed in a wider variety of cell types such as macrophages, endothelial cells 
and smooth muscle cells. cNOS is now divided into two forms, nNOS or ncNOS 
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or NOS-1 (160kD) and eNOS or ecNOS or NOS-111 (133kD). Both are calcium 
dependent but synthesised from the independent genes and structurally distinct. 
Constitutive nNOS is mainly distributed in cytosol of neurones and functions as a 
neuronal messenger. While constitutive eNOS is found primarily in the 
membrane of endothelial cells and platelets and functions as smooth muscle 
relaxant. Inducible iNOS or NOS-11 (130kd) is cytosolic, calcium independent and 
can produce as high as nanomolar concentrations of NO. While nNOS and 
eNOS can produce only picomolar concentrations of NO. The function of iNOS is 
involved mainly in immunocytotoxicity. The mechanism of action of NO on 
vascular function is shown in Figure 1.10.2.2. 
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Figure 1.10.2.2 Mechanism of nitric oxide (NO) on vascular function 
(From Davies, et al. 1995) NO may be formed in the vascular wall by both 
constitutive nitric oxide synthase (cNOS or ecNOS and ncNOS) and inducible 
NOS (iNOS). The cNOS is activated by several pharmacological agonists such 
as acethylcholine (Ach), bradykinin (13K), serotonin (5-hydroxytryptamine, 5-HT) 
and adenosine, and by mechanical forces such as flow and shear stress. The 
pharmacological agonists act through G proteins and secondary effectors 
(indicated by round black dots) to increase intracellular calcium (Ca 2+) 
concentrations. Diffusion of NO from the endothelial cells inhibits the 
aggregation of red blood cells (RBCs) and platelets (Pits), and adhesion of 
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leukocytes. NO may be stored intracellularly as nitrosothiol (NO-THIOL) and 
dinitrosyl iron-cysteine (IDNIC). NO acts on soluble guanylate cyclase (sGC) in 
smooth muscle cells to form guanosine 3,5'-cyclic monophosphate (cGMP) 
which induces their relaxation. Systemic nitrodilators such as nitrosyl- 
haernoglobin (NO-Hb) in RBCs supply NO to endothelial and smooth muscle 
cells. Endothelial cells also produce oxygen free radicals, which can be 
scavenged or inactivated by NO. In sepsis and during a systemic inflammatory, 
both endothelial and smooth muscle cells can be induced to upregulate iNOS, 
which can produce approximately 1000 times more NO than cNOS and is active 
following induction for up to 20 hr. (CaM = calmodulin, THB = tetra hyd robio pteri n, 
GTP = guanosine 5'-triphosp hate) 
Increased NO and its metabolites (NOx) have been reported in response 
to a variety of homeostatic, inflammatory and mitogenic stimuli. In the 
vasculature, NO acts to resolve ischaernic damage and maintain blood flow 
(Cristol et al., 1993; Myers et a/., 1996). When intracellular Ca 2"* levels increase, 
Ca 2+ binds to calmodulin (CaM; a calcium binding protein) and to cNOS resulting 
in the stimulation of production and release of NO. iNOS is inducible by 
cytokines, endotoxin and mechanical injury (Moncada et al., 1991; Xie & Nathan, 
1994). 
NO is released from endothelial cells in response to growth factors, high 
intracellular calcium concentration and shear stress (Davies, 1995; Morbidelli et 
al., 1996). NO has a short half-life of less than 30 seconds in aqueous solution 
(Ignarro, 1990). This is because it has a high reactivity with adjacent molecules 
and/or is rapidly oxidised to its final metabolites (NOx), nitrate (NOO and nitrite 
(N02') (Ignarro, 1990). NOx are filtered in kidney and secreted in urine. NO also 
can react with 0210 form ONOO' (peroxynitrite) a highly cytotoxic species. NO can 
bind to haern-containing proteins such as haemoglobin (Hb) to form nitrosyl-Hb 
and circulate within red cells. A similar NO-haem interaction with soluble 
guanylate cyclase leads to increase intracellular cGMP levels. These stimulate 
endothelium dependent relaxation of vascular smooth muscle and inhibit platelet 
aggregation (Schmidt et al., 1993). 
Hypoxia inhibits expression of eNOS via transcriptional and 
postranscriptional mechanisms. Hypoxia decreases constitutive NOS (nNOS 
and eNOS) transcription and protein synthesis in cultured endothelial cells 
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(Phelan & Faller, 1996). Exposing cultured human umbilical vein endothelial 
cells (HUVECs) to low P02 results in a 40-60% reduction in steady-state eNOS 
mRNA levels (McQuillan et al., 1994). The lower levels of its mRNA result from a 
decreased transcription of the gene as well as a reduced mRNA stability. In co- 
culture experiments, hypoxic HLIVECs stimulated significantly less cGMP 
production in smooth muscle cells and hence presumably less NO synthesis, 
than the normoxic cells (McQuillan et al., 1994). This inhibitory effect of hypoxia on 
eNOS production by endothelial cells occurs after 24 h of hypoxia and persists for 
at least 48 h. (McQuillan et al., 1994). The effects of hypoxia on iNOS appear to be 
tissue specific. For example, hypoxia upregulates iNOS in a hypoxia inducing 
factor 1 (H I F-1 )-dependent manner in rat pulmonary microvascular but not in 
aortic smooth muscle cells (Palmer & Johns, 1998). So responses to hypoxia 
may be different in different tissues. Vaso-occlusion in sickle cell disorders 
induces local hypoxia and local hypoxia may then be involved in regulating NO 
production in endothelial cells. 
1.10.3. Relevance of NO in sickle cell disorders 
Increased plasma NOx levels were reported in sickle cell patients, using 
Cadmium as a reductant to reduce nitrate to nitrite and then measuring total NOx 
by the Griess reaction (Rees et al., 1995). This finding is possibly consistent with 
another report that microvascular endothelial cells in culture exposed to plasma 
from sickle cell patients with acute chest syndrome can increase NOx levels 
(Hammerman et al., 1999). Increases occurred within 2 hr of exposure in a 
concentration-dependent manner and were associated with increases in eNOS 
protein and its enzymatic activity, but no changes in NOS transcription, protein 
nor enzymatic activity were found (Hammerman et a/., 1999). The mechanism of 
this effect in unclear. Endotoxins can upregulate NOS and endotoxin is 
increased in some sickle patients in crisis. Since only plasma was used, this 
could not be a direct effect of hypoxia. 
Another report divided sickle cell patients into 3 groups of low, normal and 
high plasma levels of NOx (Lopez et a/., 1996). The high NOx levels were 
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associated with a low pain score, fewer vaso-occlusion episodes and vice versa. 
This implies that hypoxia-induced ischaemic pain is associated with low levels of 
NO. Later the same group reported that there was no significant correlation 
between changes in NOx levels and changes in pain scores in sequential 
samples taking from early admitted sickle cell patients in emergency department 
(Lopez et ah, 2000). These results suggest that low levels of NOx may be an 
indication of more severe tissue ischaemia. 
Other effects of NO in sickle cell disorders may be potentially beneficial or 
harmful. There is a report that NO inhibits both normal and sickle red cell 
adherence to endotheliurn suggesting that enhancement of NO production may 
have a benefit in sickle cell disease (Space et al., 2000). NO also inhibits 
leukocyte adhesion to the endotheliurn (Zachary et al., 2000). However, a 
disadvantage of increased NO is reported. NO and/or peroxynitrite, (ONOO-), a 
reactive oxygen species formed from superoxide radical (02) and NO, are 
responsible for initiating cell damage, which leads to apoptosis in kidney cells 
from transgenic sickle cell mice (Bank et a/., 2000). 
There are some advantages for inhalation of low concentration of NO gas 
(: 580 ppm) in sickle cell patients during ACS, because of its ability to ameliorate 
pulmonary hypertension and abnormal ventilation/perfusion. NO may confer 
some protection against polymerisation of sickle haemoglobin and exert an 
antiplatelet effect that may be beneficial in ACS (Sullivan et al., 1999). NO gas 
inhalation has been reported to increase the oxygen affinity of sickle cell 
erythrocytes. Also, a proposed allosteric alteration in haemoglobin, based on S- 
nitration of the beta-chain at cysteine 93, raise the possibility of altering the 
pathophysiology of sickle cell disease by inhibiting polymerisation or by 
increasing NO delivery to the tissues (Gladwin et al., 1999a). Augmentation of NO 
transport to the microvasculature seems a promising strategy for improving 
microvascular perfusion (Gladwin et a/., 1999b). There is also some evidence 
that NO acts as a mediator for hydroxyurea action in clinical improvements in 
sickle cell patients. Administration of hydroxyurea to rats at clinically relevant 
doses formed detectable levels of nitrosyl haemoglobin. The NOx detected in 
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rats resulted from the metabolism of hydroxyurea (Jiang et al., 1997). Nitrosyl 
haernoglobin has also been detected in hydroxyurea-treated sickle cell patients 
(Glover et al., 1999). Furthermore, NO is able to inhibit platelet adhesion to 
vascular endothelium (Radomski et al., 1987). Thus hyd roxyu rea-de rived NO may 
act as vasodilator and inhibit platelet adhesion to ease clinical symptoms of 
sickle cell patients. 
1.10.4. Relationship of VEGF and NO in the sickling process 
VEGF has been shown to have modulating effects on NO, by increasing 
eNOS. The proliferative effect evoked by VEGF on the cultured microvascular 
endothelial cells, isolated from coronary postcapillary venules, is reduced by 
pretreatment with NO synthase inhibitors (Morbidelli et a/., 1996). Exposure of the 
cells to VEGF induces a significant increment in cGIVIP levels and NO synthase 
inhibitors abolish this effect. Thus VEGF appears to stimulate the proliferation of 
postcapillary endothelial cells through the production of NO and cGIVIP 
accumulation (Morbidelli et al., 1996). In other experiments (Papapetropoulos et 
al., 1997), the short-term exposure of HUVECs to 20 ng/ml VEGF for 15 minutes 
(min) caused significant increments in cGMP levels. This increase was inhibited 
by NG -nitro-L-arginine methyl ester (L-NAME, a known inhibitor of NOS) at a 
concentration of 100 ýM This indicated that the increased cGMP was due to the 
release of biologically active NO (Papapetropoulos et a/., 1997). Thus the short- 
term exposure, of HUVECs to VEGF, promotes rapid NO release by increasing 
cytosolic Ca 2+ , known to 
be a trigger of eNOS activation. VEGF is also known to 
increase cytosolic Ca 2+ concentrations in human endothelial cells (Brock et al., 
1991). The longer-term exposure for 24 hours of HUVECs to VEGF has been 
shown to increase both eNOS protein levels and NO release possibly by the 
same mechanism (Papapetropoulos et al., 1997). Induction of NO by VEGF was 
also demonstrated using HUVECs treated with 10 ng/ml VEGF for 1 hr (Hood et 
al., 1998). In porcine aortic endothelial cells stimulated with VEGF (3,10,30 and 
100 ng/ml) for 24 hr, an increased expression of both eNOS and iNOS was found 
only via VEGF receptor-2 (KDR/Flk-1), not via VEGF receptor-1 (Fit-1) (Kroll & 
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Waltenberger, 1998). In bovine adrenal cortex epithelial cells (ACE), eNOS 
expression was induced by VEGF, reaching maximum levels after 2 days of 
constant VEGF exposure (500 pM), then declining to the base-line levels by day 5 
(Shen et al., 1999). 
Thus there is good evidence that VEGF induces NO synthesis through the 
induction of eNOS. How does hypoxia from vaso-occlusion in sickle cell 
disorders affect NO release in the microvasculature? Hypoxia induces VEGF 
synthesis taking 24-48 hours (Tuder et al, 1995). Following vaso-occlusion, there 
will be an induction in VEGF synthesis in endothelial cells of the 
microvasculature, which by analogy with lung endothelium, may take up to 28 
days to reach a maximum (Tuder et al, 1995). This increased VEGF will lead to 
secondary increased NO release and vasodilatation. However, hypoxia inhibits 
eNOS rapidly and the effect lasts up to 2 days. Thus vaso-occlusion might be 
predicted to have a biphasic effect on NO levels, the first being a decrease in NO 
resulting from eNOS inhibition and the subsequent being an increase in NO 
through VEGF induced eNOS. A scheme for the effect of hypoxia on VEGF and NO 
is shown in Figure 1.10-4. 
Therefore the work in this thesis examines both NO and VEGF in sickle 
cell patients in steady state, in crisis and on hydroxyurea treatment, to determine 
whether vaso-occlusion could result in detectable changes in these markers. 
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Figure-1.10.4 Effect of hypoxia on VEGF and NO 
* From (Papapetropoulos et al., 1997) and ** from (Tuder et al, 1995). 
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1.10.5. Platelet activation and its relevance in sickle disorders 
Normal platelet function 
Platelets play an essential role in the first phase of the haemostatic 
process. Platelets are activated by subendothelial collagen, microfibrils and von 
Willebrand factor (vWF) after blood vessel damage. This makes platelets adhere 
to exposed subendothelial matrix and aggregate to form a thrombus plug at the 
site to stop bleeding. Platelets can also be activated by several agonists such as 
adenosine diphosphate (ADP), thrombin, epinephrine, 5-hydroxytryptamine, 
thromboxane A2, prostaglandin H2, prostaglandin G2, plate let-activati ng factor 
and vasopressin. After activation, platelets change their shape from the normal 
discoid to develop dendritic extensions and release the contents of their storage 
granules. Dense-granules release ADP, calcium and serotonin which can 
activate nearby circulating platelets. Alpha-granules release BTG, PF4, VWF, 
fibrinogen, fibronectin, thrombospondin, platelet derived growth factor and 
plasminogen activator 1. All of these molecules can be used as platelet activation 
markers both in vivo and in vitro. 
Platelet activation in sickle disorders 
Evidence of platelet activation in vivo in sickle cell patients has been 
reported using various markers (Browne et al., 1996). However, there is one 
report of evidence against platelet activation in vivo of sickle cell patients 
(Buchanan & Holtkamp, 1983). Furthermore, VEGF is found to be synthesised in 
megakaryocytes and stored in platelets (Adams et al., 2000). 
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Prevention of platelet activation in vitro 
It is therefore important to determine whether serum or plasma is the 
most suitable for in vivo platelet activation study, and to take any necessary steps 
to minimise the contribution of platelet activation in vitro after blood collection. 
Therefore in order to avoid in vitro platelet activation, a special anticoagulant 
which can inhibit platelet activation in vitro was used instead of conventional 
anticoagulant. CTAD anticoagulant contains citrate, theophyline, adenosin and 
dipyridamol, designed for suppression of in vitro platelet activation. Theophyline 
enhances the action of prostaglandin El (PGE1) which blocks platelet activation 
(Hess et al., 1975) and dipyridamol stimulates biosynthesis of prostacyclin, 
another platelet activation inhibitor (Mentz et a/., 1981). Two platelet activation 
markers: BTG (a homotetrameric protein of 35.8 kDa, produced by platelets and 
stored in cc-granules) and PF4 (a homotetrameric plate let-specific protein of 
30kDa, produced by platelet and also stored in cc-granules) together with VEGF 
and NOx were examined in CTAD plasma from sickle cell patients as well as 
control subjects, looking for any evidence of platelet activation in vivo. Since 
activated platelets may release both VEGF (Banks et a/., 1998; Webb et al., 1998) 
and NOx (Ichiki et al., 1996; Marietta et al., 1997). 
1.10.6. Endothelial activation and its relevance to sickle cell disorders 
Vascular endothelial cells (VECs), which form the inner lining of blood 
vessels, play a pivotal role in regulating blood flow. They also actively control 
tissue homeostasis, vascular tone, blood-tissue exchange, coagulation, 
fibrinolysis and cellular trafficking. VECs produce and secrete many biological 
substances into the circulation and/or subendothelial extracellular matrix. These 
include von Willebrand factor and tissue factors that participate in platelet 
adhesion and coagulation, prostacyclin, thrombomodulin, and heparan sulphate, 
which contribute to antithrombotic properties of VECs, plasminogen activator and 
plasminogen inhibitors, and are essential for controlling fibrinolysis. VECs are 
the source of molecules regulating their growth and other cell growth. They 
produce angiotensin-converting enzyme, and act as target cells for lipoprotein 
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and hormone binding. Finally, they are the target for, and participate in, immune 
reactions. VECs contribute to the regulation of blood pressure and blood flow by 
releasing vasodilators such as nitric oxide (NO) and prostaglandin 12 (PG12), as 
well as vasoconstrictors including endothelin 1 (ET-1) and platelet activating 
factor (PAF). These compounds are not stored in intracellular granules but their 
synthesis and release are rapidly activated through specific receptors on VECs 
(Cines et al., 1998). Thus, endothelial cells constitute not only the first barrier 
between the blood and the extravascular space but also serve as a source of 
molecules influencing the structural and functional integrity of the circulation. 
VECs also express cell membrane adhesion molecules (CAMs) which act 
as binding sites for leukocytes and platelets during adhering, rolling and 
extravasation. E-Selectin (ELAM-1 or CD62E) is the specific CAM which is 
expressed predominately on post-capillary venules (Bevilacqua et al., 1989). 
VCAM-1 (INCAM-110 or CD106) is another CAM, which is also expressed on 
dendritic cells. ICAM-1 (CD54) is more broadly distributed, being expressed not 
only on VECs but also on monocytes, thymocytes, fibroblasts, chondrocytes and 
dendritic cells (Gearing et a/., 1992). These CAMs are normally expressed at a 
very low level. They are upregulated rapidly after activation by inflammatory 
cytokines such as IL-1 and TNF-alpha (Pigott et al., 1992). Alpha4betal (VLA4 or 
CD49d/CD29) (Walsh et al., 1991) and beta2 integrin (CD43) (Rosenstein et al., 
1991), are known to be specific ligands for VCAM-1 and ICAM-1 respectively. 
Sialyl Le (x) and sialyl Le (a) are believed to be E-Selectin ligands (Berg et al., 
1992). Soluble forms of CAMs are present in cell culture supernatants (Pigott et 
al., 1992) and in the serum or plasma of healthy individuals but are significantly 
increased in some types of malignancies (Harning et al., 1991). There is no 
evidence for alternatively spliced forms of CAMs, suggesting proteolytic cleavage 
from the cell surface as a mechanism of production of soluble forms. This 
mechanism is thought to be a negative feed back loop for limiting adhesion 
when the inflammatory site gets enough cells to combat the invaders or injuries. 
Soluble CAMs can also neutralise ligands on activated target cell surfaces thus 
reducing adhesion. Soluble E-Selectin can also be a chemo-attractant for 
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neutrophils and can stimulate the adhesive activity of leukocyte integrin CR3 
(CD11b/CD18, Mac-1, alpha m beta 2) on human neutrophils (Lo et al., 1991). 
This indicates that soluble CAMs not only neutralise their ligands but also have 
some more physiological and pathological significance. 
Endothelial cells may be activated directly by hypoxia, which is clearly of 
potential relevance to vaso-occlusion in sickle disorders. Hypoxia appears to 
regulate the synthesis and release of vasoactive substances involved in 
modulating vascular smooth muscle tone and remodelling the vasculature and 
surrounding tissue (Vane et al., 1990). The Oxygen tension (POA in arterial blood 
is approximately 150 mm. Hg., in tissues is 40 mm. Hg. whereas around 15-30 
mm. Hg. is defined as hypoxaemic conditions. However endothelial cells are able 
to sense and respond to P02 below 70 mm. Hg. (Faller, 1999). A variety of cells 
including VECs respond to hypoxia by increasing synthesis and release of the 
vasoconstrictors, ET-1 and PAF and also vasodilators, NO and PG12 to control 
vascular tone and blood flow (Cines et a/., 1998). VECs are found to decrease 
eNOS transcription and its protein levels under hypoxia (Phelan & Faller, 1996) 
but hypoxia has the opposite effect on iNOS. Hypoxia also induces synthesis and 
release of erythropoietin (Lacombe et a/., 1988) as well as VEGF (Tuder et a/., 
1995). 
In sickle cell patients in steady state (non-symptomatic patients), a high 
serum level of sVCAM-1 has been observed compared to the controls (Duits et 
al., 1996). In sickle cell patients in crisis, the levels of sVCAM-1 increase even 
more and seem to correlate with crisis development (Duits et a/., 1996; Stuart & 
Setty, 1999). Perfusion with sickle erythrocytes in cultured human endothelial 
cells, can upregulate ICAM-1 and VCAM-1 gene expression (Shiu et al., 2000), 
suggesting a direct stimulating effect of sickle erythrocytes. 
Numbers of circulating enclothelial cells (CECs) were significantly higher 
in the sickle cell patients than in the healthy subjects but the numbers in the 
crisis SS were not significantly different from steady state SS (Sowemimo-Coker 
et al., 1989). 
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Two endothelial cell activation markers: soluble endothelium selectin (sE- 
Selectin, a transmembrane protein of 115 kDa, specific marker for VEC activation 
or damage) and soluble vascular cell adhesion molecule 1 (sVCAM-1, another 
transmembrane protein of 100-110 kDa, a marker for VEC activation and 
damage but not restricted to VECs) were studied in order to compare the degree 
of endothelial activation in sickle cell patients and in control subjects. 
1.10.7. Other factors modulating red cell endothelial interaction in sickle cell 
disorders 
Inflammatory factors. Tissue necrotic factors, IL-1 and IL-4 are released 
in response to the inflammatory process associated firstly with vaso-occlusion 
and then with tissue hypoxia and cell damage. These factors are involved in 
increasing expression of VCAM-1 (the receptor of VLA-4) and E-selectin on 
endothelial cells which promote red cell adhesion to endothelial cells (Natarajan 
et al., 1996) 
Von Willebrand factors (unusually high molecular weight). This high 
molecular weight vWF is released from endothelial cells in response to 
endothelial activation due to vaso-occlusion. It then mediates the adhesion 
between gpllb/Illa (CD41/CD61) on the red cell membrane to vitronectin receptor 
(VNR) on endothelial cells. (Wick et a/., 1993) 
Erythropoletin (Epo). Production of Epo is regulated by changes in oxygen 
availability. Epo levels increase in response to hypoxia or anaernia. Increased 
levels of Epo in sickle cell disease are due to the anaernic state of the patient. 
Epo has no direct modulatory effect on vaso-occlusion but anaernia secondary to 
red cell damage as a consequence of vaso-occlusion and extravascular 
haemolysis may play a role as an indirect indicator for the vaso-occlusion. 
(Roger et al., 1991) 
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1.11. AIMS OF STUDY 
Development of flow cytometric methods for: 
Single-colour staining using either FITC or TC for F+cells assay. 
Simplify the procedure above and compare to the original procedure. 
Double-colour staining for simultaneous assay of F+cells, reticulocytes 
and F+reticulocytes. 
Three double-colour staining for co-distribution of HbF, RNA and AMs. 
Triple-colour staining for co-distribution of HbF, RNA and AMs. 
Contribution of foetal haemoglobin and red cell adhesion molecules to sickle 
red cell survival comparing to normal healthy controls 
F+cells, F+reticulocytes and enrichment ratios. 
Adhesion molecule expression on red cells, reticulocytes and F+cells. 
Co-distribution of adhesion molecule and foetal haemoglobin. 
Paired data analysis of red cell sub-population in the same patients. 
Follow up of a hydroxyurea treated sickle cell patient. 
Endothelial activation markers, platelet activation markers and anaemic 
markers in sickle cell disorders: 
Levels of VEGF and NOx in serum and plasma. 
Effect of in vitro platelet activation on release of VEGF, NOx and others. 
Relationship between plasma levels of VEGF and NOx. 
Relationship between plasma levels of VEGF, NOx and platelet count. 
Relationship between plasma levels of BTG, PF4 and platelet count. 
Relationship between plasma levels of VEGF, NOx and platelet activation 
markers (BTG and PF4). 
Relationship between plasma levels of VEGF, NOx and endothelial 
activation markers (sE-Selectin and sVCAM-1). 
Relationship between plasma levels of VEGF, NOx and anaernic markers 
(Hb and Epo). 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
2.1. BLOOD SAMPLES 
Normal control blood samples were taken from University College London 
postgraduate students and laboratory personnel. Sickle blood samples were 
obtained from sickle cell patients attending University College London Hospitals. 
Serum and plasma from EDTA, citrate, heparin and CTAD anticoagulated blood 
samples were stored at -700C for VEGF, NOx, Epo, sE-Selectin, sVCAM-1, BTG 
and PF4 assays. Red cell samples from either EDTA, citrate, heparin or CTAD 
anticoagulated blood were mixed with Alsever: PBS mixture (1: 1) to approximately 
45-50% haernatocrit and stored at 40C for flow cytometric assays. ' Haemoglobin 
typing and quantitation were done by HPLC. Full blood counts (FBC) and 
reticulocyte counts were run on a blood cell analyser. 
2.2. REAGENTS 
* Antibodies to mouse globulin conjugated to RPE and to biotin were purchased 
from Serotec, Oxford, UK. 
Bovine serum albumin (BSA) powder was purchased from Life Technologies, 
Paisley, UK. 
9 BTG and PF4 ELISA kits were purchased from Diagnostica Stago, Asnieres- 
Sur-Seine, France. 
* EDTA, citrate, heparin, CTAD anticoagulant and plain vacuum tubes for blood 
collection were purchased from Becton Dickinson, San Jose, CA, USA. 
9 Glutaraldehyde was purchased from Sigma, Poole, UK. 
9 HPLC reagent kits were purchased from BioRad, Hercules, CA, USA. 
* Isotype controls: mouse IgM, IgGl and IgGl conjugated to FITC and to TC 
were purchased from CalTag, Burlingame, CA, USA. 
* Monoclonal antibodies to human CD36, CD41 and CD49d were purchased 
from Serotec, Oxford, UK. 
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e Monoclonal antibody to human foetal haernoglobin conjugated to FITC and to 
TC was purchased from CalTag, Burlingame, CA, USA. 
9 Nitrate and Nitrite calorimetric assay kits were purchased from Cayman 
Chemicals, Ann Arbor, MI, USA. 
e Phosphate buffer saline (PBS) tablets were purchased from Oxoid, 
Basingstoke, UK. 
RPMI, FBS, P/S solutions were purchased from Life Technologies, Paisley, UK. 
Streptavidin conjugated to RPE was purchased from CalTag, Burlingame, CA, 
USA. 
9 Thiazole orange (TO) 100 ng/ml in PBS (Retic Count Reagent) was purchased 
from Becton Dickinson, San Jose, CA, USA. 
Thrombin activating protein (TRAP) was purchased from Sigma, Poole, UK. 
9 Triton X-100 was purchased from Sigma, Poole, UK. 
VEGF, Epo, sE-selectin and sVCAM-1 ELISA kits were purchased from R&D 
Systems, Abingdon, UK. 
2.3. SOLUTIONS AND MEDIA 
* 0.05% Glutaraldehyde in PBS (100 gl 25% glutaraldehyde in 50 ml PBS). It can 
be stored at 40C for up to 4 weeks. 
9 0.05% Triton X-100 in 0.1% BSA-PBS (25 Rl triton X-100 in 50 ml 0.1% BSA- 
PBS). It can be stored at 4C for up to 4 weeks. 
9 0.1% Triton X-100 in 0.1% BSA-PBS (50 [d triton X-100 in 50 ml 0.1% BSA- 
PBS). It can be stored at 4"C for up to 4 weeks. 
* 0.1% Bovine serum albumin in PBS (0.5 g BSA powder in 500 ml of PBS). It 
can be stored at 40C for up to 4 weeks. 
9 1% Formaldehyde in PBS (500 gl formaldehyde in 50 ml PBS). It can be stored 
at 40C for up to 2 months. 
4, Alsever's solution (0.33 g chloramphenicol, 0.50 g citric acid, 20.5 g dextrose, 
2.0 g inosine, 0.5 g neomycin sulphate, 4.2 g sodium chloride, and 8.0 g tri- 
sodium citrate dihydrate in 1 litre distilled water). It can be stored at 4'C for up 
to 2 months. 
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* Phosphate buffered saline (1 PBS tablet in 100 ml distilled water). It can be 
stored at RT for up to 4 months. 
o 1: 1 Alsevers solution: PBS (100 ml Alsever's solution plus 100 ml PBS). It can 
be stored at 40C for up to 2 months. 
9 Reticulocyte culture medium (500 ml RPMI-1640 supplemented with 63 ml 
citrate phosphate dextrose adenine formula 1; CPDA-1: 327 mg citric acid 
monohydrate, 251 mg sodium dihydrogen phosphate dihydrate, 2.63 g sodium 
chloride, 3.19 g dextrose monohydrate and 27.5 mg adenine in 63 ml distilled 
water; 10% FBS, and 1 IU/ml penicillin plus 1 ng/ml streptomycin (P/S). All 
ingredients were sterilised by passing through millipore filter before mixing. ) It 
can be stored at 4"C for up to 4 weeks. 
Thrombin activating protein (TRAP) solution (480 gM TRAP in PBS). It can be 
stored at 4"C for up to 4 weeks. 
2.4. EQUIPMENT 
9 Blood cell analyser model Sysmex SE-9500 (plus reticulocyte count) came from 
Sysmex, Kobe, Japan. 
ELISA reader model MR-700 came from Dynatech Laboratories, Guernsey, UK. 
Flow cytometer model Coulter Epic XL-MCL came from Coulter-Beckman, 
Luton, UK. 
HPLC analyser model BloRad VARIANT came from BioRad, Hercules, CA, 
USA. 
2.5. METHODS 
2.5.1. Flow cytometry 
Principles of flow cytometry 
Flow cytometry is the analysis of cellular or particle characteristics in a fluid 
suspension as they pass singly through a beam of light. The scattered light (both 
forward or low angle and side or 900 angle) and fluorescent intensity are measured 
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by a set of photodetectors (photomultiplier-diode tubes). The data collected by 
these detectors is transferred into a computer for further processing, analysis and 
display of the results. There are four basic compartments to a flow cytometer; the 
fluidic system, the optical system, the detecting system and the data processing 
system. 
The function of the fluid system is to create a stream of single particles or 
cells flowing through the flow cell or flow chamber from the sample tube through to 
the waste tank. This is achieved by hydrodynamic focusing, in which the sheath 
fluid is wrapped around the test sample and both are pumped together in the same 
direction along a tiny tube and then ejected directly through the flow chamber. The 
sheath fluid acts as a fluid ring singly escorting the sample particles through the 
flow cell (Figure 2.5.1.1). The flow rate can be adjusted to allow between less than 
a hundred to over a thousand particles passing through the flow cell per second. 
The function of the optical system is to create a light beam, usually a laser 
beam because of its monochromatic nature and high intensity, to project directly 
into the flow cell and hit the particles with high intensity. This causes the particles 
to show their specific characteristics of different forward (low angle) and side (90") 
light scatter and fluorescence (only in case that they are stained by fluorochromes). 
The function of the detector system is to detect all light and/or fluorescent 
signals emitted by the specific characteristics of the sample particles after they are 
hit by the laser beam (Figure 2.5.1.2). 
Finally, the function of the data processing system is to integrate the signals 
and display them in an understandable output such as single channel histogram 
(the signal from one detector plotted against the number of the detected particles), 
double-channel or dot-plot histogram (a single particle plotted as a dot in between 
two axes of signal from two different detectors) and triple-channel or prism 
histogram (the signal from the combination of three different detectors plotted 
against the number of the detected particles) (Figure 2.5.1.3). 
Flow cytometry is a more powerful analytical tool than light or fluorescent 
microscopy because of the larger number of cells analysed. The powerful 
computer allows the possibility of re-analysis using different ways of gating and 
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cut-off criteria. The limitation of flow cytometry is that the samples have to be free 
particles suspended in fluid. Therefore, solid tissues have to be digested into single 
cells before analysis. 
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Fiqure 2.5.1.1 Flow cell of Coulter Epics XL-MCL flow cytometer 
(From Coulter Epics XL-MCL instruction manual). The process begins with the flow 
of isotonic saline solution called the sheath fluid. The sheath fluid enters the flow 
cell from beneath and flows upward by positive pressure pump. The sample, which 
contains particles or cells in suspension also, flows upward, using the same pump. 
A single particle flows directly through the centre of the flow cell because of the 
pressure of the sheath fluid against it. This is called hydrodynamic focusing. The 
laser beam is projected through the centre of the flow cell. The sample particles hit 
by the laser are excited and emit a fluorescent signal that can be detected by the 
detector. 
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Figure 2.5.1.2 Optical system of Coulter Epics XL-MCL flow cytometer 
(From Coulter Epics XL-MCL instruction manual). The optical system includes 
forward scatter (FS), side scatter (SS), fluorescent channel 1 (FL1 for -525 nm), 
FL2 (for -575 nm), FL3 (for -620 nm) and FL4 (for -675 nm) respectively. Each 
channel has a photo-multiplier tube for signal acquisition. The signals are then 
transferred to a computer for further processing and display of results. 
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Fiqure 2.5.1.3 Three types of flow cytometric histograms 
(From left--->right) Single-channel histogram, Double-channel or dot-plot histogram 
and Triple-channel or prism histogram. See text for detail. 
Figure 2.5.1.4 Appearance of Coulter Epics XL-MCL flow cytometer 
(From Coulter, Epics XL-MCL, instruction manual). The Coulter Epics XL-MCL has 
4 major parts: a work station (a computer controlling all functions, processing and 
display of results both via the monitor and the print-out from a printer), Cytometer 
(flow cytometer), Multi-tube carousel loader (MCL) and Power supply (supplying 
both electric current and positive pressure). 
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Flow cytometer setting 
Gate setting 
In the flow cytometer model Coulter Epics XL-MCL (Figure 2.5.1.4) the gate 
for the red cell area is determined by using forward scatter (FSC) and logarithmic 
side scatter (logSSC). Firstly, a normal whole blood sample was put through the 
flow cytometer to get a whole picture of all the different types of blood cell cloud. 
The red cell cloud was the densest cloud of the picture, since it represents the 
biggest population in the blood. It could also be recognised as the fourth cloud of 
both granularity determined by logSS and size determined by FSC levels after 
granulocyte, monocyte and lymphocyte populations respectively. After the red cell 
cloud has been recognised, the other clouds were eliminated using the fast set 
programme of the computer to enhance the signals of both logSS and FSC until 
only the red cell cloud was present. However, a few lymphocytes may present, due 
to the similar size and granularity of these two populations. The red cell cloud was 
then assigned to be recognised as red cell gate. Every cell in this area was 
analysed further, while every cell outside this area was ignored. The red cell gate 
was put into histogram number 1 (Hist. 1). Then logarithmic fluorescent channel 1 
(IogFL1, green fluorescence at around 505-545 nm, designed for either RNA 
staining by Thiazole orange or HbF staining by FITC conjugate), IogFL2 (red 
fluorescence at around 555-595 nm, designed for adhesion molecule staining by 
RPE conjugate) and IogFL4 (deep-red fluorescence at around 655-695 nm, 
designed for HbF staining by TC conjugate) were set for signal acquisition and 
were put into the 3 separated single-channel histograms (Hist. 2,3 and 4 
respectively). Any cell in the red cell gate that emits any of these 3 fluorescent 
signals, will be recognised and counted as a positive cell in an appropriated 
histogram according to its fluorescence. After that the 3-pair combinations of 
double-colour signals (IogFL1 vs logFL2, IogFL1 vs IogFL4 and IogFL2 vs IogFL4) 
were put into the 3 separated double-channel histograms (Hist. 5,6 and 7 
respectively). The combination of all 3-colour signals was put into a triple-colour or 
prism histogram (Hist 8). This histogram showed the cell numbers in all 
combinations of the 3-colour signals (i. e. ---, +--, --+, +-+, -+-, ++-, -++ and ... for 
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logFL1 (green), logFL2 (red) and logFL4 (deep-red) respectively. A high flow rate 
and auto-stop at 50,000 events (particles or cells) within 360 seconds were used. 
(Refer to Coulter Epics XL-MCL instruction manual). 
Colour comDensation 
Interfering signals among these 3 colours were eliminated by using the fast 
colour compensation programme of the computer. Colour compensation can be set 
by putting one colour staining cells through the machine, which was then scaled up 
or down the fast compensation until no signal was present outside its channel. For 
example, with the FITC-staining cells the signals should present only in the green 
area not in the red or deep-red area adjacent to it. The compensation has to be set 
like this for all 3 colour used. (Refer to Coulter Epics XL-MCL instruction manual). 
Cut-off settin- 
The base line auto-fluorescence for non-specific binding was set at less 
than 0.3% (which is greater than mean plus 3 S. D. of negative control population) 
using samples which were either unstained or stained with irrelevant isotype 
control antibodies. This setting is recognised as a cut-off (point or line as 
appropriate) separating positive from negative populations. Any cell producing a 
fluorescent signal higher than this level will be counted as a positive cell. The cut- 
off at 0.3% was the best fit among the potential cut-off at 1%, 0.5%, 0.3% and 
0.1%, since it showed the best agreement between theoretical and observed 
values. The various theoretical values of %F+celis were obtained from the known 
percentages of the mixture of foetal red cells in adult red cells and the various 
theoretical values of %reticulocytes were obtained from reticulocyte count data 
from Sysmex SE-9500 blood cell analyser. Unfortunately, the theoretical values of 
percentages of adhesion molecule expressing cells were unavailable. None-the- 
less, the machine allowed the use of only one cut-off value that applied to all 
histograms. However, the cut-off value at 0.3% was the best fit for all histograms. 
(Refer to Coulter Epics XL-MCL instruction manual). 
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Gettinq the results 
In conclusion, the flow cytometer settings were used universally for all flow 
cytometric measurements in this thesis, since it covered all single-, double- and 
triple-colour channel histograms in one setting. In case of single- or double-colour 
flow cytometric measurements, only the appropriate histograms were considered to 
be the actual results. For examples, in the single-colour staining of F'cells by FITC 
conjugate only Hist. 1 and 2 were the appropriate results and for double-colour 
staining of reticulocytes by TO vs F+cells by TC conjugate only Hist. 1,2,4 and 6 
were the appropriate results. For the triple-colour staining all histograms were the 
appropriate results. (Refer to Coulter Epics XL-MCL instruction manual) (Figure 
2.5.1.5) 
lose II d" I 
fl I Tn FI? RPF 114 T( 
?H .1 
I[ Tu 11 1 11 fill" 
Figure 2.5-1.5 Histograms of triple-colour staining flow cytometer setting 
(See text for detail) 
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2.5.2. High pressure liquid chromatography (HPLC) 
Principles of HPLC for quantitative assay of haemoglobin 
High Pressure Liquid Chromatography (HPLC; BioRad Variant, USA) was 
employed for haernoglobin typing and quantitation by using a cation-exchange 
cartridge on haernolysate injected into the analysis stream according to a 
previously determined protocol (Tan et al., 1993). In this system, two dual-pistol 
pumps and a pre-programmed gradient are used to control the elution buffer 
mixture passing through the analysis cartridge. As the ionic strength of the mixture 
increases, more strongly retained haernoglobin eventually elutes from the 
cartridge. Changes in absorbance of the eluate are monitored at 415 nrn (with 690 
nm correction) and plotted against elution time. The amount of the different types 
of haernoglobin detected, which include HbF, HbA, HbA2/HbE, HbS and HbC, is 
calculated as a percentage of total haernoglobin (Figure 2.5.2.1). 
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Figure 2.5.2.1 Principles of HPLC 
(From Waters HPLC instruction manual). A haemolysate sample may contain 
many different types of haernoglobin each with a different net electric charge. The 
sample is injected into a cation-exchange cartridge and absorbed onto the 
negatively charged resin. A gradual increase in ionic strength of the elution buffer 
mixture displaces different types of haernoglobin from the cartridge with different 
elution times. The concentration of a particular type of eluted haernoglobin can be 
detected by the photometer and displayed as an optical density as a function of 
elution time. The result is processed by the computer and displayed as a print-out 
showing the percentage of different types of haemoglobin in the sample. 
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Foetal haemoglobin assay by HPLC 
Five ýd of heparinised whole blood was haemolysed with 1 ml haemolysing 
reagent in 1.5 ml sample vials. The haemolysate was stable for 24 hours at 40C 
prior to assay. Two hundred and fifty ýd of haernolysate was transferred into a 
sample vial. The reagents and haernolysate vials were placed into the sample tray 
in the following order, stat well = haernoglobin primer (a haernolysate standard 
sample for the beginning of each run), 1" well = deionised water (for blank control), 
2 nd well = HbA2/F calibrator (a haernolysate sample of known concentration of 
HbA2 and HbF for calibrating the machine), 3 rd well normal control (a 
haernolysate of normal healthy control subject), 4 th well abnormal control (a 
haemolysate of R-thalassaemic patient), 5 th to n th well = haernolysate samples to 
be run, n+1 th well = normal control, n+2 th well = abnormal control and the run 
commenced. The percentage of HbA, HbA2/HbE, HbF, HbS and HbC was 
reported for each sample. (Bio-Rad, Instruction Manual, 1996. ) (Figure 2.5.2.2) 
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Fiqure 2.5.2.2 Print-out results from BioRad HPLC 
The percentage of different types of haernoglobin in the sample and optical density 
plotted against elution time are shown. Left is a sickle cell patient (homozygous 
HbS or SS). Right is sickle cell trait (heterozygous HbS and HbA or AS) or a SS 
patient with approximately 50% normal HbA from blood transfusion. To differentiate 
these two conditions, the transfusion history is essential. 
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2.5.3. Enzyme linked immuno-sorbent assay (ELISA) 
Principles of ELISA 
Vascular endothelial growth factor (VEGF), the soluble form of endothelial 
selectin (sE-Selectin), the soluble form of vascular cell adhesion molecule 1 
(sVCAM-1), erythropoietin (Epo), R-thromboglobulin (BTG) and platelet factor 4 
(PF4) were all measured using antigen capture ELISA or sandwich ELISA. Inside 
the wells of a standard 96 well ELISA plastic plate are pre-coated with a specific 
monoclonal antibody against the antigen of interest. Test samples are added and 
the relevant antigen in the samples is captured by the antibody on the well. 
Unbound antigen in the sample is then washed out and the polyclonal antibody 
against another epitope of the same antigen conjugated to an enzyme is added to 
bind to the antigen. Unbound antibody is then washed out and a chromogen 
substrate is added to react with the enzyme on the bound antibody to produce a 
coloured product. The enzymatic reaction is then stopped at a certain of time. The 
optical density (OD) is measured by an ELISA reader. A series of different known 
concentrations of the specific antigen are assayed within the same run as the test 
samples and their OD are used to create a standard curve, where concentration 
and OD are plotted. The concentration of the specific antigen in the samples is 
read from the curve using its OD. (Figure 2.5.3) 
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Figure 2.5.3 Principles of sandwich ELISA 
(From Stites 1994) See text for detail. 
Vascular endothelial growth factor (VEGF) assay 
One hundred gl of assay diluent was dispensed into each well, which was 
pre-coated with monoclonal anti-human VEGF, and 100 gl serum or plasma was 
added, mixed well and incubated at room temperature (RT) for 2 hours (hr). The 
wells were washed 3 times with washing buffer and 200 gl polyclonal anti-human 
VEGF conjugated to horse-radish peroxidase (HRP) was added and incubated for 
2 hr at RT. The wells were then washed 3 times, 200 gl tetramethyl benzidine 
(TMB) substrate solution was added and incubated for 25 minutes (min) at RT in 
the dark, after that 50 gl stop solution (2N sulphuric acid) was then added. The 
absorbance was read at 450 nm within 30 min. A series of 4 known concentrations 
of VEGF were assayed within the same run along with the test samples to create a 
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standard curve, then the absorbances of the test samples were used for obtaining 
their VEGF concentrations. 
Erythropoletin (Epo) assay 
One hundred gl assay diluent was dispensed into each well, which was pre- 
coated with monoclonal anti-human Epo, and 100 gl serum or plasma was added, 
mixed well and incubated at RT for 2 hr. The liquid was then carefully aspirated 
and 200 gl polyclonal anti-human Epo conjugated to HRP was added and 
incubated for 2 hr at RT. The wells were then washed 4 times with washing buffer 
and 200 gl TMB substrate was added and incubated for 25 min at RT in the dark, 
100 gl stop solution (2N sulphuric acid) was added. The absorbance was read at 
450 nrn within 30 min. A series of 4 known concentrations of Epo were assayed 
within the same run along with the test samples to create a standard curve, then 
the absorbances of the test samples were used to obtain their Epo concentrations. 
Soluble endothelial selectin (sE-selectin) assay 
Serum or plasma samples were diluted 1: 20 with assay diluent. One 
hundred gl polyclonal anti-human E-Selectin conjugated to HRP was dispensed 
into each well, which was pre-coated with monoclonal anti-human E-Selectin, and 
100 ptl diluted serum or plasma was added, mixed well and incubated at RT for 1.5 
hr. The wells were then washed 6 times with washing buffer and 100 RI TMB 
substrate was added and incubated for 30 min at RT in the dark, 100 gl stop 
solution (2N sulphuric acid) was added. The absorbance was read at 450 nm 
within 30 min. A series of 4 known concentrations of sE-Selectin were assayed 
within the same run along with the test samples to create a standard curve, then 
the absorbances of the test samples were used to obtain their sE-Selectin 
concentrations. 
Soluble vascular adhesion molecule I (sVCAM-1) assay 
Serum or plasma samples were diluted 1: 50 with assay diluent. One 
hundred gl polyclonal anti-human VCAM-1 conjugated to HRP was dispensed into 
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each well, which was pre-coated with monoclonal anti-human VCAM-1, and 100 lul 
diluted serum or plasma samples was added, mixed well and incubated at RT for 
1.5 hr. The wells were then washed 6 times with washing buffer and 100 [d TMB 
substrate was added and incubated for 20 min at RT in the dark, 100 gl stop 
solution (2N sulphuric acid) was added. The absorbance was read at 450 nm 
within 30 min. A series of 4 known concentrations of sVCAM-1 were assayed 
within the same run along with the test samples to create a standard curve, then 
the absorbances of the test samples were used to obtain their sVCAM-1 
concentrations. 
13-Thromboglobulin (BTG) assay 
Serum or plasma samples were diluted 1: 10 with assay diluent. Two 
hundred ýd diluted serum or plasma was dispensed into each well, which was pre- 
coated with monoclonal anti-human BTG, and incubated at RT for 1 hr. The wells 
were then washed 5 times with washing buffer and 200 gl polyclonal anti-human 
BTG conjugated to HRP was added and incubated for 1 hr at RT. The wells were 
then washed 5 times and 200 gl orthophenylene diamine dihydro chloride (OPD) 
substrate was added and incubated for exactIV 3 min at RT in the dark, 100 [d stop 
solution (11 M hydrochloric acid) was added. The absorbance was read at 490 nm 
within 30 min. A series of 4 known concentrations of BTG were assayed within the 
same run along with the test samples to create a standard curve, then the 
absorbances of the test samples were used to obtain their BTG concentrations. 
Platelet factor 4 (PF4) assay 
Serum or plasma samples were diluted 1: 5 with assay diluent. Two hundred 
gl diluted serum or plasma was dispensed into each well, which was pre-coated 
with monoclonal anti-human PF4, and incubated at RT for 1 hr. The wells were 
then washed 5 times with washing buffer and 200 gl polyclonal anti-human PF4 
conjugated to HRP was added and incubated for 1 hr at RT. The wells were then 
washed 5 times and 200 lal OPID substrate was added and incubated for exactly 3 
min at RT in the dark, 100 gl stop solution (1 M hydrochloric acid) was then added. 
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The absorbance was read at 492 nm within 30 min. A series of 4 known 
concentrations of PF4 were assayed within the same run along with the test 
samples to create a standard curve, then the absorbances of the test samples 
were used to obtain their PF4 concentrations. 
2.5.4. The Griess Reaction 
Principles of the Griess Reaction 
Nitric oxide metabolites (NOx) can be measured colorimetrically using the 
Griess reaction (Nims et a/., 1995). Serum and plasma samples must be filtered 
through an ultra-filter with MW cut-off of 30 kDa to avoid interference from coloured 
proteins, for example bilirubin and haemoglobin, since there is no washing step. 
Nitrates in the sample are converted to nitrites by nitrate reductase and its co- 
factors. The nitrite is coupled to Griess reagent 1 (sulphanilamide) and Griess 
reagent 2 (N-(1-Naphthyl) ethylenediamine) to form a deep purple azo-product. 
The optical intensity (OD) of the final product is directly correlated with the 
concentration of total nitric oxide metabolites (NOx or nitrates plus nitrites). Serial 
dilution of known nitrite concentration solutions and their OD are used to create a 
standard curve. The concentration of NOx in the samples is obtained from the 
curve using their OD. (Figure 2.5.4) 
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Fiqure 2.5.4 Principles of the Griess Reaction 
(From Cayman Chemical, NO assay instruction manual) See text for detail. 
Nitric oxide metabolites (NOx) assay 
Serum or plasma samples were diluted 1: 4 with assay diluent, then they 
were ultra-centrifuged, passing through an ultra-filter with a 30 kDa molecular 
weight cut-off (Whatman Inc., USA. ) to eliminate interference from high molecular 
weight protein. Eighty [d of filtrated sample was then filled into the well of a 96 well 
plastic plate. Ten gl each of enzyme co-factor and nitrate reductase were added 
and incubated at RT for 3 hr. Griess Reagent R1 and Griess Reagent R2 (50 gl 
each) were added and the colour was allowed to develop for 10 min. The 
absorbance was read at 540 nm within 30 min and the concentration of NOx in 
each sample was obtained from standard curve, which was created by assaying a 
series of 7 known concentrations of NOx within the same run along with the 
samples. 
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2.5.5. Platelet activation experiment 
Platelet rich plasma from citrate blood samples form 6 normal control 
subjects were divided into 2 aliquots of 0.5 ml each. One aliquot was activated with 
100 [il thrombin activating protein (TRAP at a final concentration of 80 gM) and 100 
l. d PBS was added into another aliquot and then incubated at RT for 30 min. These 
two aliquots were centrifuged at 1500g for 10 min. The platelet poor plasma 
supernate with platelet activation (Platelet+) and without platelet activation 
(Platelet-) were collected and stored in -70('C for assaying of VEGF, NOx, sE- 
Selectin, sVCAM-1, BTG and PF4. 
2.5.6. Reticulocyte culture 
Twenty five lal EDTA fresh whole blood from 8 sickle cell patients was 
cultured in 25 CM2 flasks with 25 ml of RPMI-1640 culture medium in 5% C02 at 
370C for 15 days. Assays for AM expression on reticulocytes and red cells were 
carried out on cultured red cells on days 0 (within the first hour), 1,2,3,4,5,10 
and 15 of culture respectively. 
2.5.7. Calculation of enrichment ratio (ER) and adhesion molecule depletion 
ratio (AMDR) 
The enrichment ratio (ER) and adhesion molecule depletion ratio (AMDR) 
are defined as the ratio of the proportion of a specific population within total mature 
red cells to the proportion of the same population within total reticulocytes. In order 
to examine the effect of AM expression and HbF containing on red cell survival; ER 
and AMDR have been compared among the different groups of sickle cell patients 
and normal control subjects. 
F'cell enrichment ratio estimation 
The ratio of %F*mature red cells to %F+reticulocytes has been previously 
described as an enrichment ratio (Dover, 1978a). The formula for ER is shown 
below. 
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Number of F+mature red cells / Total number of mature red cells 
ER = 
Number of F+reticulocytes / Total number of reticulocytes 
Adhesion molecule depletion ratio estimation 
The ratios of %AM"mature red cells to %AM+reticulocytes were calculated 
and called the adhesion molecule depletion ratio (AMDR). The formula for AMDR 
is shown below: 
Number of AM'mature red cells / Total number of mature red cells 
AMDR = 
Number of AM+reticulocytes / Total number of reticulocytes 
Three-circle-overlapping diagram for triple-colour staining results 
In order to calculate percentages of many different sub-populations and their 
ER or AMDR more easily, the numbers of each red cell sub-population from triple- 
colour staining flow cytometry was put into the relevant area of three-circle- 
overlapping diagram (Figure 2.5.7). 
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9 Ordinary cells 
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Fiqure 2.5.7 Three-circle-overlapping diagram for triple-colour staining 
Each circle represents the positive population of each colour: green fluorescence 
for RNA or reticulocytes (R+), red fluorescence for adhesion molecule expressing 
cells (AM+) and deep-red fluorescence for HbF containing cells or F+cells (F+). 
Each overlapping area represents each double-colour positive population between 
the adjacent fluorescence. The middle area represents the triple-colour positive 
population. 
2.6. STATISTICS AND CALCULATION 
All statistics are shown as the mean + standard error of the mean (SEM) 
unless stated otherwise. The means of two groups were compared using a 
student's unpaired t-test, and the means for pre- and post-treatment were 
compared using student's paired Mest. The correlation coefficient (r) between two 
parameters was calculated to estimate the degree of correlation. All significant 
levels are shown using 95% confidence intervals or p value less than 0.05. 
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CHAPTER 3 
DEVELOPMENT OF FLOW CYTOMETRIC METHODS FOR 
F+CELL, F+RETICULOCYTE AND ADHESION MOLECULE 
EXPRESSING CELL ASSAYS 
3.1. DEVELOPMENT OF FLOW CYTOMETRIC METHODS 
In this chapter, the development and validation of flow cytometric methods 
for determination of the proportion (in percent) of F+cells, F+reticulocytes and 
adhesion molecule expressing cells is described. The possible advantages and 
applications of using flow cytometry for these purposes are given. 
3.1.1. Methods for HbF and F*cell assays 
HbF assay 
Foetal haernoglobin (HbF) can be measured by a number of different 
methods. Some methods are based on acid or alkali resistance of HbF 
compared to HbA and HbA2. In the alkali denaturation test (Betke et al. 1959), 
HbF is determined by using an alkali solution to precipitate other Hbs out of the 
haemolysate. The rest is HbF, which resists alkali denaturation. HbF is then 
measured by spectrophotometric method (at 540 nm) and compared to the total 
Hb in original haemolysate. This method has generally good reproducibility 
within the same laboratory but in different laboratories, it is highly variable. 
Therefore each laboratory should set their normal range with a sample size over 
50. However, an upper limit for normal values of either 1% or 2% is acceptable 
(Chanarin, 1989). No single method is suitable for measuring HbF levels across 
the whole range of 0-100% but the alkali denaturation test is the most widely 
used because of its simplicity. However, its tendency to overestimate at the very 
low levels and underestimate at the high levels has to be taken into account. 
Values for %HbF within the range of 5-50% are more reliable by this method. 
Electrophoresis (Steiman et al., 1985) and isoelectric focusing (Leary et al., 
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1983) can be employed to determine HbF based on differences in net electric 
charge on the different types of Hb (Manca et al., 1986). Since HbF has a greater 
net positive charge than HbA, it moves a longer distance than HbA and HbA2 in 
electrophoresis with citrate agar at pH 6.0. However, electrophoresis is normally 
only a qualitative assay for a haemoglobinopathy primary diagnosis and is not 
suitable for quantitative work. Immunodiffusion (Ouchterlony) using anti-HbF 
antibody is simple, sensitive but time consuming. This method is reliable for the 
quantitation of HbF at very low levels (under 2%) (Marti et al., 1983). Column 
chromatography is reliable at higher HbF levels (over 40%), but the technique is 
cumbersome and time-consuming (Rajantie et al., 1992). Radioimmuno assay 
is a sensitive method, which can detect very low levels (in picograms) of HbF, but 
needs expensive equipment (James et al., 1980). High performance liquid 
chromatography (HPLC) is convenient, sensitive and reproducible, but also 
needs expensive equipment (Huisman et al., 1981; Tan et al., 1993). The lowest 
detection limit (sensitivity) for %HbF of Bio-Rad HPLC is -1% (Waters, et al. 
1996). 
All of these methods can give an assay of total foetal haernoglobin (HbF) 
but give no indication of the distribution of HbF within the cells. This information 
is important in the interpretation of the relevance of HbF levels. For example; if 
20% of cells have 100% HbF in sickle cell patients, the impact on the disease 
may be quite different from 100% of cells having 20% HbF. Therefore knowledge 
of the distribution of HbF is potentially valuable. Determination of F+cells in the 
circulation is also used as a way of measuring foeto-maternal haemorrhage in 
the management of haemolytic disease of the new-born (HDN). 
F*cell assay 
F+cell assay is in common use in clinical practice because it is important 
to quantitate the haemorrhage of foetal cells (measured as F'cells) into maternal 
circulation in detecting the risk of HDN. The method traditionally used for this 
purpose is the Kleihauer test (Kleihauer, 1957). In this test, HbF resists acid- 
elution and remains in the cells, while the other types of Hb are eluted out leaving 
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cells of a ghost appearance after staining, in contrast to the dark positive 
appearance of F+cells. The limitations of the Kleihauer test include not sensitive, 
subjective and time consuming. Using anti-HbF antibody conjugated fluorescent 
dye or immunofluorescent staining (Osterhout et aL, 1996) on a fixed blood 
smear is more sensitive, but is still dependent on technical skills. These two 
methods require manual evaluation on fixed blood smears. The later method is 
easier, more rapid but still uses a blood smear, which is subjective depending 
on the morphological skill of the technician. These methods give information on 
about 1-7% of positive cells among a large number of negative cells. So a large 
number of total cells need to be counted manually to achieve statistical power, 
and this is time-consuming (Wood et al., 1975). Normally the total count of these 
methods is 1,000 or 5 high power fields (x400), which have approximately 200 
cells per field in a well spread and non-overlapping area of the blood smear. The 
sensitivity depends on the technical skill of the observer. Some observers 
recognise F+cells better than others and furthermore, when F+cells are scarce, a 
larger number of cells need to be analysed. 
Another way of measuring HbF containing red cells (F+cells) is by flow 
cytometry. Previously described flow cytometric methods have required stringent 
conditions of cold permeabilisation with acetone at -15 to -20 IC, which are not 
easy to handle and it takes time to prepare the samples (Thorpe et al., 1994). 
These methods are therefore not easy to perform. However, flow cytometry 
examines up to 50,000 cells within a few minutes and does not require much 
technical skill. This advantage makes it one of the most powerful analytical tools 
in biological field. 
Relationship of % HbF to % F"cells 
The proportion of F+ cells in normal adults is approximately 1-5% by the 
Kleihauer test (McKenzie, 1996). When the proportion is less than 1 %, there is an 
intrinsic error therefore a larger number of cells needs to be counted to overcome 
the error (Dacie & Lewis, 1970). Immunofluorescent staining gives a value of 0.2- 
7% which is comparable to flow cytometry (Wood et aL, 1975). The latter two 
110 
Chapter 3 
techniques use the same principle but differ in the detection. However, flow 
cytometry is much more reliable than microscopic immunofluorescence, 
because more cells are analysed. 
It has been estimated that the quantity of HbF per F+cell is approximately 5 
pg/cell (Wood et al., 1975). This value has been calculated from %F+cells 
obtained from the acid elution test, %HbF obtained from the alkali denaturation 
test and MCH obtained from full blood count (FBC) data. The formula is 
(HbF/F+celis = MCH x %HbF / %F+cells) (Maier-Redelsperger et al., 1994). 
Microscopic-single-cell-radial immunodiffusion also showed similar levels of 
HbF/F+ceIls at 4-8 pg/cell (Boyer et ah, 1975), which was a comparable value to 
that obtained using the calculation method. The %F+cells correlates well with 
%HbF in samples containing up to 5% HbF (Dacie & Lewis, 1991). This 
correlation suggests that in adult populations, the mean levels of HbF per F+cell 
remain almost constant. However, the amount of HbF per F+cell required for a 
cell to be recognised as a F+cell may vary with different techniques. Levels of HbF 
at 1 pglcell or approximately 3.5% of MCH are possibly high enough for sensitive 
methods such as immunofluorescence and flow cytometry. However, the acid 
elution test may need more HbF per cell than that to be recognised as a F+cell 
(Dacie & Lewis, 1991). Therefore, the %HbF and %F+cells are not the same 
parameters but their relationship is very close. The different levels of %HbF and 
%F+cells might influence the clinical outcomesdn sickle cell disorders to different 
degrees. 
HbF and Fcell distribution 
Normal adult blood contains 3 types of haernoglobin (96-98% HbA, 1.5- 
3.2% HbA2 and 0.5-2.0% HbF). Adult haernoglobin (HbA) appears in normal 
foetuses at about 5-10% from 6-12 weeks of gestation onward and increases 
sharply just before birth. The P-globin gene is expressed at low levels in early 
foetal life, but the main switch to adult haernoglobin occurs 3-6 months after 
birth, when synthesis of the y-globin chain is largely replaced by the P-globin 
chain. Methylation of the gene is thought to be a possible regulation of the 
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expression (expressed genes are usually hypomethylated and vice versa) 
(Hoffbrand, 1993). 
In normal adults, 0.5-2.0% of haemoglobin is HbF (McKenzie, et al. 1996) 
and this is distributed in only 1-7% of red cells, termed F+cells (Wood et al., 1975; 
Rochette et al., 1994; Thorpe et a/., 1994). In normal subjects, each F+cell 
contains about 20% HbF (or 4-7 pg of HbF per 30 pg of MCH) together with 
another 80% of HbA. However, in sickle cell patients, the %HbF may be raised to 
4-15% and this is distributed within approximately 4-40% F+cells (Dover et al., 
1978b). 
The proportion of F+cells is even higher in sickle cell patients undergoing 
hydroxyurea (HU) treatment. Up to 10-30% HbF (Saleh et a/., 1997) distributed 
within approximately 35-75% F+cells (Bridges et al., 1996; Charache et a/., 1992). 
In hereditary persistent of foetal haemoglobin (homozygous HPFH) only HbF is 
synthesised in the absence of HbA and HbA2. In other pathological states such 
as thalassaemia, %HbF and %F+cells are dependent on phenotype and 
genotype (Giampaolo et aL, 1984; Marcus et a/., 1997, Marinucci et aL, 1981; 
Rees et al., 1999). The %F+cells has also been a valuable parameter for 
monitoring sickle cell patients undergoing treatment with a HbF inducing agent 
such as hydroxyurea (Steinberg, 1997; Steinberg et al., 1997). 
3.1.2. Flow cytometric assay of %F4*reticulocytes 
Reticulocyte count 
In order to develop a flow cytometric method for F+reticulocytes, it is first 
necessary to have a simple and reliable flow cytometric method for reticulocyte 
count alone. Reticulocyte count is essential for monitoring the erythropoietic 
activity of the bone marrow, especially during therapy and therefore it is a routine 
test in haematology laboratories. Supravital staining with new-methylene blue is 
traditionally used in routine manual reticulocyte counts. However, staining of RNA 
inside reticulocytes in suspension using fluorescent dyes such as Thiazole 
orange (Chin-Yee et al., 1991), Acridine orange (Seligman et al., 1983), Pyronin Y 
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(Davis & Bigelow, 1990), Thioflavin (Sage et aL, 1983) or Auramine 0 (Davis & 
Bigelow, 1990; Tichelli et a/., 1990) with flow cytometric analysis is more 
sensitive, reproducible, objective and is now available on automated blood cell 
analysers. It was important to choose a method of reticulocyte staining which 
was applicable for double- and triple-colour staining. Thiazole orange (TO) was 
chosen because it has wavelengths of excitation at 509 and of emission at 533 
nm. These wavelengths are available on our flow cytometer (Coulter Epics XL- 
MCL, see Table 3.1.2). In addition, the TO emission wavelength does not overlap 
significantly with rhodamine phycoerythrin (RIPE, 576 nm) or Tri-color (TC, 670 
nm) which were considered as potential candidates for adhesion molecule and 
HbF staining respectively in the triple-colour staining. 
F-4'reticulocyte assay 
When the response to hydroxyurea is being monitored, an early response 
can be identified by examining the presence of young cells containing HbF rather 
than all F+cells in the total population (Maier-Redelsperger et a/., 1998). A 
method for measuring reticulocytes containing HbF (F+reticulocytes) was 
originally developed by Dover (Dover et al., 1978a) using microscopic-single-cell- 
radial immunodiffusion. However, this method is time consuming, cumbersome, 
and re quires a specialised and experienced technician. 
In principle flow cytometry can be employed to measure HbF and RNA 
content on the same cells, using double-colour staining. Reticulocytes and 
F+cells can be assayed by flow cytometry separately as described above. In order 
to perform a double-colour staining, the fluorescent emissions used for 
reticulocyte and F+cell assay should not significantly overlap. The available 
fluorochromes for RNA (reticulocytes) and monoclonal antibody against human 
HbF are shown in Table 3.1.2. 
The combination of TO for RNA staining and anti-HbF-TC conjugate for 
HbF staining were selected for the development of double-colour staining flow 
cytometry for F+reticulocyte assay. The original method was developed by Dr 
Bruch H. Davis (personal communication) but was not reported in the literature. 
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The method used in this thesis was slightly modified and necessary to be 
evaluated. The method gives quantitative information of F+reticulocytes (F+R+), F 
reticulocytes (F-R+), F+mature red cells (F+R-) and Fmature red cells (FIR"). The 
absolute numbers of these populations can also be estimated using red blood 
cell count data and the information above. 
Table 3.1.2 Availability of fluorochromes for RNA, anti-AM and anti-HbF 
conjugates 
(From Bauer, et al. 1993 and instruction manual of Coulter Epics XL-MCL) 
Fluorochrome Excite* Emit Colour Detector 
(nm) (nm) (on Epics XL) 
RNA Dye 
Thiazole orange 509 533 Green FL1 
Acridine orange 492 550 Orange None 
Pyronin Y 515 580 Orange FI-2 
Thioflavin 422 487 Green None 
Auramine 0 435 550 Orange None 
Ethidium Bromide 514 602 Red None 
Propidiurn Iodide 535 615 Red FL3 
Anti-HbF and anti-AM conjugates 
FITC 495 520 Green FL1 
RPE 495 & 564 576 Orange FL2 
TC 495 670 Deep Red FI-4 
*Coulter Epics XL-MCL has only one available excitation wavelength at 488 nm 
(range 458-518 nm). 
3.1.3. Adhesion molecule expressing cell assay by flow cytometry 
Some adhesion molecules (AMs) such as CD36, CD41 and CD49d are 
expressed on sickle red cells and are involved in the erythrocyte-endothelium 
interaction. Recent work has demonstrated the importance of this expression in 
sickle cell disorders (Moore et aL, 1996), because red cells expressing such 
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molecules are likely to be preferentially adherent to the endothelium. This in turn 
may contribute to slowing of blood flow in the microvasculature and may initiate 
vaso-occlusion in sickle cell disease. 
The relationship between erythrocyte adhesion molecule expression and 
the expression of HbF in erythrocytes has not been investigated previously and is 
potentially important for two reasons. Firstly, it may provide information about the 
nature of F+cells in normal individuals. In particular, whether F+cells express 
increased, decreased or normal levels of AMs and whether such cells survive 
normally. Secondly, in sickle cell disorders, whether co-expression of HbF and 
AMs accounts for the survival advantage of F+cells compared to F'cells. 
Therefore, flow cytometric methods for measurements of AM expressing 
cells (single-colour staining), AM expressing F+cells and AM expressing 
reticulocytes (double-colour staining) and AM expressing F+reticulocytes (triple- 
colour staining) were developed and employed in this thesis to addressed those 
questions above. 
3.2. DEVELOPMENT AND VALIDATION OF SINGLE-COLOUR STAINING 
3.2.1. Background 
Initial experiments were undertaken to evaluate F+cell assay by flow 
cytometry, using a previous described method (Davis et aL, 1998). Subsequent 
experiments were undertaken to improve the fixation/permeabilisation and 
staining procedures and to reduce the time taken for sample preparation. Prior to 
the work in this thesis, assay of F+cells in thalassaemia and sickle disorders 
had not been undertaken using the assay described below. Calibration and 
gating of the flow cytometer has been described in chapter 2. 
3.2.2. F+cell assay using the original procedure 
In order to adjust the number of red cells in the assay procedure, a full 
blood count (FBC) was obtained on every blood sample using the Sysmex SE- 
9500. Approximately 2.5 x 107 red cells (the actual sample volume was estimated 
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from red blood cell count data) were fixed with 1 ml ice-cold 0.05% 
glutaraldehyde in phosphate buffered saline pH 7.4, vortexed for 15 seconds 
(sec. ), incubated at room temperature (RT) for 10 minutes (min) and then 
washed twice with PBS. The red cells were then permeabilised by vortexing for 
15 sec. with 0.5 ml ice-cold 0.1% Triton X-100 in 0.1% bovine serum albumin in 
PBS (BSA-PBS) and incubated at RT for 5 min, then washed once with 0.1 %BSA- 
PBS, and re-suspended in 0.5 ml 0.1%BSA-PBS. Ten ýd of red cell suspension 
was then mixed with 20 [d of 1 in 10 diluted mouse monoclonal antibody (IgGl) 
against human HbF conjugated to fluorescein isothiocyanate (MoAb-HbF-FITC, 
green fluorescence) and 70 ýd 0.1%BSA-PBS, incubated in the dark at RT for 15 
min, then washed twice with 0.1%BSA-PBS and finally fixed with 0.5 ml 1% 
formaldehyde in 0.1 %BSA-PBS. The sample was then analysed by flow cytometry 
or stored at 40C in the dark for up to 1 week before analysis. An IgGl conjugated 
to FITC (isotype control) was used instead of MoAb-HbF-FITC as a negative 
control for non-specific binding. Using TC instead of FITC conjugate gave similar 
results (Figure 3.2.2). Gate setting of flow cytometer is described in Chapter 2. 
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Figure 3.2.2 Flow cytometric histograms of F+cell assay 
I HIM 
The left histogram shows red cell population, which is selected for analysis. The 
middle histogram shows fluorescent signal from FITC (green). The right 
histogram shows fluorescent signal from TC (deep-red) 
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3.2.3. F+cell assay using simplified procedure 
The original procedure for the F+cell assay has many washing or 
centrifugation steps and the sample volume to be used in the assay has to be 
calculated from red cell count data. In order to save time and make the procedure 
more convenient, the procedure was simplified. Firstly, the samples were 
adjusted to an approximately 45-50% haematocrit (Hct) by spinning the sample 
down for 10 minutes at 250 g at 40C, removing the plasma, then diluting the 
packed red cells with an equal volume of Alsever's solution : PBS (1: 1) mixture. 
Using this technique the sample volume is constant and no calculation is 
required. A second advantage is that the washing steps were unnecessary. 
Twenty gl of adjusted blood sample as above was fixed with 1 ml of ice- 
cold 0.05% glutaraldehyde in PBS, vortexed for 15 sec and incubated at RT for 10 
min. One hundred gl of the mixture was then vortexed for 15 seconds with 400 gl 
of ice-cold 0.1% Triton X-100 in 0.1%BSA-PBS and incubated at RT for 5 minutes 
for permeabilisation. Ten ld of this mixture (final dilution is approximately 1 in 
255) was then vortexed with 20 gl of a1 in 10 dilution of MoAb-HbF-FITC. Then 70 
gl of 0.1%BSA-PBS was added and the mixture was incubated in the dark at RT 
for 15 min. The sample was then fixed again by adding 0.5 ml of 1% 
formaldehyde in 0.1%BSA-PBS. The sample was then analysed by flow 
cytometry, but could be stored at 40C for up to 1 week before analysis. An IgGl 
conjugated to FITC (isotype control) was used instead of MoAb-HbF-FITC as a 
negative control for non-specific binding. 
3.2.4. Comparison of original and simplified procedures for F+cell assay 
Study design 
Four blood samples containing various known % of F'cells (5,25,50, and 
100% respectively) were prepared by mixing cord-blood-red cells with adult- 
blood-red cells and assayed for %F+cells using both original and simplified 
procedures (section 3.2.2 and 3.2.3 respectively). Twelve blood samples from 8 
sickle cell and 4 thalassaernic patients were assayed in parallel between 
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original and simplified procedures. Samples from 12 patients were analysed to 
compare the results obtained using the original and simplified procedures. 
Results 
Using the original procedure on the mixtures containing known %F+cells 
of 5,25,50 and 100% respectively, the results were 5.8,23.2,52.5 and 99.3% 
respectively. Using the simplified procedure on the same samples, the results 
were 5.7,21.8,52.5 and 98.5% respectively. The positive cut-off was set at 0.3% 
in both procedures. Aclear distinction between F+cells and F-cells are shown in 
Fiqure 3.2.4.1. 
fit LOG M LOG 
33.1 1 21-S I, 
ILI M ILI IN 
32.3 s 
ILI In' ILI LOG 
.... 
ILI IN ILI LOG 
Figure 3.2.4.1 Comparison histograms of original and simplified procedures 
Four mixtures of cord blood and adult red cells containing 5,25,50 and 100% 
cord blood red cells respectively, were assayed for %F+cells in parallel using 
both the original (left) and simplified (right) procedures. Using the cut-off setting 
at 0.3% above the negative control population, the difference between positive 
and negative population was clear in both procedures. There was no difference 
between these two set of results. 
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When samples from 12 patients were analysed to compare the results 
obtained using original and simplified procedures, the mean %F+cells were 
23.92+2.28% and 23.73+6.19% respectively without any significant difference. 
These results are shown in individual patients in Table 3.2.4. 
Table 3.2.4 Comparison of F+cell results of original and simplified procedures 
Sample Number Diagnosis Original Procedure Simplified Procedure 
1 SS steady 7.0 7.6 
2 SS steady 7.4 7.6 
3 SS crisis 8.9 9.5 
4 SS crisis 9.6 9.3 
5 SC crisis 11.3 11.4 
6 SC crisis 14.4 14.2 
7 SS crisis 13.8 13.1 
8 SS crisis 13.9 12.6 
9 Thalassaemia 33.4 34.8 
10 Thalassaemia 35.3 34.8 
11 Thalassaemia 64.5 63.9 
12 Thalassaemia 67.5 66.0 
Mean ± SE 23.92+6.28 23.73+6.19 
Blood samples were assayed for %F*'cells in parallel using the original and 
simplified procedures. There was no significant difference in the results between 
the 2 procedures. 
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3.2.5. Anticoagulants and sample stability for F+cell assay 
Study design 
In order to search for suitable anticoagulants and sample stability for the 
simplified procedure, the effect of different anticoagulants and duration of storage 
at 4"C was examined. 
Blood samples from a healthy volunteer (containing 0.6% HbF) and a 
sickle patient receiving hydroxyurea treatment (containing 17.6% HbF) were taken 
into EIDTA, citrate or heparin anticoagulants. The samples were assayed for 
%F'cells using the simplified procedure (see section 3.2.3) on the day of 
collection (day 1) then stored at 40C and re-assayed on days 2,4,10 and 15 
respectively. 
Results and discussion 
The %F+cells of the normal sample on day 1,2,4,10 and 15 in EDTA were 
2.80,2.78,2.75,2.73 and 2.75% respectively; in citrate were 2.73,2.75,2.72,2.74 
and 2.73% respectively and in heparin were 2.69,2.70,2.71,2.70 and 2.68% 
respectively (Figure 3.2.5.1). These values of the sickle cell sample in EDTA were 
57.30,60.95,60.61,63.05 and 63.72% respectively; in citrate were 56.06,60.48, 
59.06,58.27 and 63.58% respectively and in heparin were 59.36,61.74,56.82, 
60.33 and 61.79% respectively. There was no significant difference between 
them (Figure 3.2.5.2). 
These findings indicate that EDTA, citrate and heparin are all suitable for 
the F"cell assay using single-colour staining flow cytometry and the sample can 
be kept at 40C for up to 15 days prior to fixation and staining without affecting 
F+cell results. EDTA was chosen as it is the most convenient one, because 
blood remaining from a routine FBC could be used. 
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Figure 3.2.5.1 Effect of anticoagulants and stability of a normal blood sample 
A normal blood sample (0.6 %HbF) was taken into EDTA, citrate and heparin and 
then assayed for %F+cells on days 1 (the day of collection), 2,4,10 and 15. The 
samples were kept at 40C during the study period. 
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Finure 3.2.5.2 Effect of anticoagulants and stability of a sickle blood sample 
A sickle blood sample (17.6 %HbF) was taken into EDTA, citrate and heparin and 
then assayed for %F+cells on days 1 (the day of collection), 2,4,10 and 15. The 
samples were kept at 40C during the study period. 
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3.2.6. Reproducibility of simplified F+cell assay 
Study design 
The reproducibility of an assay can be estimated by the intra- and inter- 
assay percent coefficient of variation (%CV). In general, an intra-assay %CV 
: 510% and an inter-assay %CV : 520% are regarded as acceptable for most 
assays. The lower %CV is the better reproducibility. EDTA was used as the most 
convenient anticoagulant. 
EDTA blood samples were taken from sickle cell patients and normal 
healthy blood donors. Full blood count (FBC) with reticulocyte count was 
performed on the Sysmex SE-9500. Haemoglobin typing and quantitation was 
performed on the BioRad HPLC. Samples were centrifuged, the plasma was 
removed, and an equal volume of Alsever's solution : PBS (1: 1) mixture was 
added to the packed red cells to obtain an approximately 45-50 % haematocrit. 
The samples were then stored at 40C prior to assay. 
The %F+cells was assayed on three blood samples of low, medium and 
high HbF levels (2.1,5.6 and 9.4% respectively) using the simplified procedure 
(see section 3.2.3). Five replicates of intra-assay of each sample were obtained 
on the day of collection. The samples were then kept at 40C. Five replicates of 
inter-assay of each sample were obtained by performing a replicate daily for a 
further 4 consecutive days. The inter- and intra-assay %CVs were determined. 
Results and discussion 
The intra-assay %CVs of blood samples containing high, medium and low 
%HbF were 1.36,1.54 and 2.52% respectively, and the inter-assay %CVs were 
2.67,3.06 and 6.59% respectively (Table 3.2.6). 
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Table 3.2.6 Percentages of intra- and inter-assay coefficient of variation 
%F+cells Mean SD O/OCV Replicates 
Intra-assay 
Low 11.50 0.29 2.52 5 
Medium 25.26 0.39 1.54 5 
High 42.42 0.58 1.36 5 
Inter-assay 
Low 13.65 0.90 6.59 5 
Medium 23.20 0.71 3.06 5 
High 41.48 1.11 2.67 5 
Three EDTA blood samples of low, medium and high HbF levels (2.1,5.6 and 
9.4% respectively) were used for determination of the inter- and intra-assay 
%CVs. The intra-assay data were obtained on the first day of collection for 5 
replicates. The inter-assay data were obtained for another 4 consecutive days. 
The %CVs of the intra- and inter-assay fell within an acceptable range. 
3.2.7. Relationship between %HbF and %F"Cells 
Study design 
A total of 70 blood samples, regardless of diagnosis were selected to 
include various percentages of HbF, and assayed for both %HbF using HPLC 
(sections 2.4.2 ) and %F+cells using the simplified flow cytometric procedure 
(section 3.2.3). Samples included 25 normal control subjects, 37 sickle cell and 
8 thalassaernic patients. The correlation coefficient (r) between these two 
parameters was then determined. 
Results and discussion 
The correlation coefficient (r) between %HbF and %F+cells was 0.968 
(Figure 3.2.7). The correlation was weaker when HbF was : 51% (r=0.730, n=20) 
compared to the correlation when HbF was in between 1 -10% (r=0.924, n=42) or 
>10% (r=0.894, n=8) respectively. 
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The best correlation was found in the range of 1-10%HbF. However, the 
correlation was still good when the HbF was less than 1% and greater than 10%. 
The lowest detectable level of %F+cells was 0.3%, because the cut-off point on 
the flow cytometer was set at this level. The %HbF detection of BioRad HPLC at 
levels under 1% is not accurate (data from BioRad Variant instruction manual), 
where the detection limit lies between 0.5 and 1%. However, %HbF and %F+cells 
are not exactly the same. %HbF is the proportion of HbF in the total Hb in a 
haernolysate, while %F+cells is the proportion of HbF containing red cells in the 
total red cells. Any red cells that contain sufficient amounts of HbF to trigger the 
fluorescent detector will be counted as F+cells. Whereas in a haernolysate, a 
small amount of HbF may not be detected. 
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Figure 3.2. Relationship of %HbF and %F+cells 
The %HbF (measured by HPLC) and %F+cells (measured by the simplified 
procedure) were obtained from 70 blood samples with different levels of HbF 
regardless of diagnosis, including 25 normal donors, 37 sickle cell patients and 
8 thalassaernic patients. The overall coefficient of correlation (r) was 0.968 
(n=70). When %HbF was <1 % the r was 0.730 (n=20), when %HbF was between 
1-10% the r was 0.924 (n=42) and when %HbF was >10% the r was 0.894 (n=8). 
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Furthermore, the concentration of HbF in an F+cell may vary from 5 to 40% 
of total Hb within the cell. As a result, %HbF and %F+celis in the same individual 
are not regularly correlated but should be approximately correlated. For example, 
only 30% HbF may produce almost 100% F+cells, because every cell contains a 
certain amount of HbF which is high enough for the cell to be counted as a F+cell. 
On the other hand, 30% HbF may produce only 60% F+cells because the other 
40% of cells contain very low levels of HbF which are not enough to trigger the 
fluorescent detector. However in practice, %F+cells correlated well with %HbF. 
In conclusion, the simplified flow cytometry procedure for %F+cell assay 
correlated well with %HbF quantitation by HPLC. This finding suggests that 
assay of the %F+cells by flow cytometry may be useful if quantitative assay of 
%HbF is not available in the laboratory. 
3.2.8. Relationship between HbF and F+cells in different groups of subjects 
In this section, the relationship between %HbF and %F+cells in different 
groups of subjects was investigated, whether the relationship was different for 
patients with different diagnoses. 
Study design 
The correlation coefficient (r) of the different groups of patients was 
determined and compared using data from section 3.2.7. Seventy blood samples 
included 25 normal controls, 18 sickle cell patients in steady state (SS. std. ), 12 
sickle cell patients in crisis (SS. cri. ), 7 sickle cell patients receiving hydroxyurea 
treatment (SS. HU. ) and 8 thalassaernic patients (Thal. int. ). 
Results 
The correlation coefficient (r) was 0.863 in control group, 0.943 in SS. std. 
group, and 0.948 in SS. cri. group, 0.947 in SS. HU. group and 0.682 in Thal. int. 
group respectively. The correlation between these two parameters was highly 
significant (p<0.001) in all groups. 
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Figure 3.2.8 Relationship of %HbF and %F*celis in different group of patients 
The %HbF (measured by HPLC) and %F+cells (measured by the simplified 
procedure) were obtained from 70 blood samples. The correlation between 
these two parameters was highly significant (p<0.001) in all groups. 
Discussion 
In every group of subjects, the %F+cells were correlated with %HbF. Any 
individual, regardless of diagnosis, who had increased levels of HbF also had 
increased in F+cells. This probably indicates that the amount of HbF per F+cells 
is possibly nearly constant. However, in the normal and the thalassaemic group, 
the two parameters seem to show lesser correlation. 
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3.2.9. Comparison of FITC and Tri-color fluorochromes for F+cell assay 
Study design 
Monoclonal antibody (MoAb) to human HbF conjugated to two different 
fluorescent dyes, fluorescein isothiocyanate (FITC) and tri-color (TC). are 
available. Either conjugate can be used in single-colour staining for flow 
cytometry. The results of %F+cells obtained using these two different dyes should 
not be significantly different, since the antibody is the same. In order to ensure 
this, a comparison between using FITC and TC conjugates was performed. 
A total of 90 blood samples, regardless of diagnosis with various levels of 
HbF, were assayed using the simplified procedure (section 3.2.3). MoAb-HbF- 
FITC and MoAb-HbF-TC conjugates were used in parallel. The samples were 
collected from 17 control subjects, 20 thalassaernic and 53 sickle cell patients. 
The %F+cells obtained from these two conjugates were dot-plotted against each 
other and the coefficient of correlation (r) was determined. The mean values of 
the two groups of %F+cells obtained from using these 2 dyes were compared. 
Results and discussion 
The mean %F+cells obtained from using MoAb-HbF-FITC and MoAb-HbF- 
TC were 22.13+1.83 and 19.13±1.69 respectively with no significant difference. 
The coefficient of correlation (r) between these two dyes was 0.986 (Figure 3.2.9). 
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Figure 3.2.9 %F+cells obtained by using FITC and TC conjugates 
Ninety blood samples regardless of diagnosis were assayed in parallel for 
%F+cells by the simplified procedure using either anti-HbF FITC or TC conjugate. 
They were collected from 17 normal donors, 20 thalassaemic patients and 53 
sickle cell patients to include various levels of. HbF. There was no significant 
difference between overall mean values of %F+cells obtained from using these 
two dyes. The coefficient of correlation (r) was 0.986 (n=90). 
A good correlation was found between %F+cells obtained from using 
MoAb-HbF-FITC and MoAb-HbF-TC, and the overall mean values were not 
significantly different. However, the results obtained using FITC conjugate 
appeared slightly higher, probably because of the slightly higher intensity of the 
FITC signal. These findings show that either FITC or TC conjugate can be used 
without any significant effect on the results obtained. 
3.2.10. Reticulocyte assay using single-colour staining flow cytometry 
Thiazole orange (TO) is an RNA staining dye. It is excited at 509 nrn then 
emits green fluorescence at 533 nm, which can be detected by FLI on the 
Coulter Epics XL-MCL flow cytometer. TO easily penetrates the red cell 
membrane to stain RNA inside the cytoplasm of reticulocytes. It can be used as a 
single-colour stain for %reticulocyte assay by flow cytometry. The single-colour 
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staining flow cytometry for reticulocyte assay was used for comparison with either 
double- or triple-colour staining later. The method of staining are shown below. 
Twenty gl of whole blood, pre-adjusted to 45-50% haernatocrit by a mixture 
of Alsever's solution and PBS at the ratio 1: 1, was diluted with 1 ml 0.1%BSA- 
PBS, then 100 gl of this diluted sample was further diluted with 900 RI of 
0.1%BSA-PBS (final dilution is approximately 1 in 510). Twenty gi of final diluted 
sample was stained for RNA by adding 500 pl of 100 ng/ml Thiazole orange (TO) 
reagent (green) and incubating in the dark at RT for 30 min. This suspension 
was then analysed by flow cytometry within 3.5 hr. Since the fluorescent signal 
gradually fades. Non-stained control cells were prepared in the same way but at 
the last step 500 gl PBS was used instead of TO reagent. 
3.2.11. Adhesion molecule expressing cell assay using single-colour staining 
flow cytometry 
The single-colour staining flow cytometry for AM expressing cell (AM+cell) 
assay was used for comparison with either double- or triple-colour staining later. 
The monoclonal antibodies against each AM were used together with anti- 
mouse-globulin conjugated to rhodamine phycoerythrin (RPE). The method of 
staining are shown below. 
Twenty gl of whole blood, pre-adjusted to 45-50% haernatocrit by a mixture 
of Alsever's solution and PBS at the ratio 1: 1, was diluted with 1 ml 0.1%BSA- 
PBS, then 100 gl of this diluted sample was further diluted with 900 RI of 
0.1%BSA-PBS (final dilution is approximately 1 in 510). Twenty gl of the final 
dilution was separately incubated with 20 gl, 1 in 5 diluted monoclonal antibody 
to each adhesion molecule (MoAb to CD36, CD41 and CD49d) at RT for 2 hr, 
then washed twice with 0.1%BSA-PBS. One set of three tubes of the above 
sample (one tube for each AM or three tubes together for three AMs) was 
incubated with 10 ld of 1 in 10 diluted anti-mouse-globulin conjugated to 
rhodamine phycoerythrin (RPE, red) in the dark at RT for 2 hr, and then washed 
once. The samples were then diluted with 500 gl 0.1%BSA-PBS and were ready 
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to be analysed by flow cytometry. Isotype controls were used instead of MoAb- 
AMs as a negative controls for non-specific binding. 
3.3. DEVELOPMENT AND VALIDATION OF DOUBLE-COLOUR STAINING 
3.3.1. Double-colour staining for F*reticulocytes by flow cytometry 
Rationale 
Having evaluated single colour staining, the method was developed 
further with the aim of identifying a simple flow cytometric assay for F+reticulocyte 
determination. The challenge was to choose a method where the fluorochrome 
used for RNA staining did not interfere with the fluorochrome used for detection 
of HbF. It was also important that the red cells remained stable using the two 
colour analysis and that use of double staining did not affect F+cell assay. 
Method 
Blood samples were adjusted to approximately 45-50% Hct using the 
mixture of Alsever: PBS (1: 1), then 20 gl was fixed with 1 ml ice-cold 0.05% 
glutaraldehyde in PBS at RT for 10 min. One hundred gl of fixed red cell 
suspension was permeabilised with 400 gl ice-cold 0.1% Triton X-100 in 
0.1%BSA-PBS for 5 min (final dilution is approximately 1 in 255). Ten gl of 
fixed/permeabilised red cell suspension was then incubated with 20 gl of 1 in 10 
diluted MoAb-HbF-TriColor (TC) and 70 gl 0.1%BSA-PBS in the dark at RT for 30 
min. The total stained red cell suspension was then incubated with 500 gi 
Thiazole orange reagent (TO), in the dark at RT for 30 min. This suspension was 
analysed by flow cytometry within 3.5 hours (waiting longer than that the green 
fluorescence of TO may fade). An IgGII conjugated to TC (isotype control) was 
used instead of MoAb-HbF-TC and PBS was used instead of TO reagent as a 
negative control for non-specific binding. Representative histograms of double 
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staining for simultaneous assay of F+cells, reticulocytes and F+reticulocytes are 
shown in Fiqure 3.3.1. 
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Figure 3.3.1 Flow cytometric histograms of double-colour staining 
Top-left; This histogram shows red cell gate on a double channel (LogSS 
and FS) histogram. 
Top-right; This histogram shows TO (green: LogFL1) signal on the 
horizontal axis against cell count on the vertical axis (for reticulocytes). The cut-off 
point separating the positive and negative population was set at 0.3% (+3SD) 
above the negative control population. 
Bottom-left; This histogram shows TC (deep-red: LogFL4) signal on the 
horizontal axis against cell count on the vertical axis (for F+cells). The cut-off point 
was also set at 0.3% above negative control population. 
Bottom-right; This histogram shows a scatter plot of TO staining cells 
(reticulocytes) on the horizontal axis against TC staining cells (F+cells) on the 
vetcal axis (both on Log scale). The cut-off lines are obtained from the previous 
two histograms. The upper right quadrant represents the F+reticulocyte (F+R+) 
area, the lower right quadrant represents the HbF negative reticulocyte (F-R+) 
area, the lower left quadrant represents the HbF negative mature red cell (FIR-) 
area and the upper left quadrant represents the F+mature red cell (F+R-) area. 
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3.3.2. Reproducibility of double-colour staining 
Study design 
The reproducibility was determined from the intra-assay and inter-assay 
%CV as mentioned in single-colour staining. Three sickle cell blood samples, 
selected for their low, medium and high levels of HbF and reticulocytes, were 
simultaneously assayed for %F+cells, %reticulocytes and %F+reticulocytes using 
double-colour staining flow cytometry (section 3.3.1) in 6 replicates for both intra- 
assay and inter-assay. Each sample was assayed for 6 replicates in the same 
run on the day of collection for the intra-assay results. The samples were then 
assayed once daily on the other 5 consecutive days for the inter-assay results. 
The samples were stored at 40C during the study. 
Results and discussion 
Table 3.3.2 Intra- and inter-assay percent coefficient of variation of double- 
colour staining flow cytometry 
Intra-assay Inter-assay 
.............. m 
%F'cells 
m ................... 
%Retics 
.............. Wretics ............... %F+cells 
............ m ...... 
%Retics 
...... m ------ 
%F+retics 
Low 2.51 5.48 8.26 3.79 10.24 14.72 
Med 1.40 4.33 7.83 2.90 10.00 12.14 
High 1.19 2.52 6.30 2.21 7.42 8.36 
Intra- and inter-assay %CVs fell within the acceptable range (not exceeding 10% 
and 20% respectively). 
When double-colour staining for the simultaneous assay of F+cells, 
reticulocytes and F+reticulocytes was performed, the %CVs of all three 
parameters fell within the acceptable range of less than 10% for the intra-assay 
and less than 20% for the inter-assay. These findings demonstrated the good 
reproducibility of the method. Using of double-colour staining did not affect the 
reproducibility of the F+cell assay. 
132 
Chapter 3 
3.3.3. Effect of anticoagulant and sample stability on double-colour staining 
Study design 
Blood samples from a normal subject and a sickle cell patient were 
collected in EDTA, citrate, heparin and CTAD (a special anticoagulant for platelet 
activation study). The samples were simultaneously assayed for %F+cells, 
%reticulocytes and %F+reticulocytes (section 3.2.3) on the day of collection (day 
1) and for a further 5 consecutive days (day 2-6). The samples were stored at 
40C during the study. The mean results on each day were compared, in order to 
determine the effect of anticoagulants and sample stability. 
Results and discussion 
There was no significant difference between the results of %F+cells, 
%reticulocytes or %F+reticulocytes in normal and sickle blood samples taken 
into EDTA, citrate, heparin and CTAD. In addition, assaying every day up to 6 days 
on 40C stored samples showed only a very small fall in the values obtained 
which did not reach statistical significance (Figure 3.3.3). 
Any of the four anticoagulants used (EDTA, citrate, heparin and CTAD) 
appear suitable for the assay on samples stored at 40C up to 5 days. These 
findings suggest that the EDTA samples from routine haernatology laboratories, 
the citrate samples from coagulation laboratories or the heparin samples from 
special haematology laboratories are all suitable for the method, if they are 
stored at 40C less than 5 days. 
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Figure 3.3. Effect of anticoagulants and sample stability 
Blood samples from a sickle cell patient (top) and a normal subject (bottom) 
were collected into EDTA, citrate, heparin and CTAD. The plasma was removed 
and PBS: Alsever solution (1: 1) was added for haernatocrit of approximately 45- 
50%. The samples were assayed for %F+cells, %reticulocytes, %F+reticulocytes 
on the day of collection (day 1) and another five consecutive days (day 2-6). The 
samples were stored at 40C during the study. There was no significant difference 
in these three parameters between the types of anticoagulant used or the length 
of 40C storage up to 5 days. 
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3.3.4. Correlation between %F+celis obtaining from single- and double-colour 
staining flow cytornetry 
Study design 
In order to ensure that the Thiazole orange (TO) used for RNA staining in 
the double-colour staining method (simultaneous assay of F+cells, reticulocytes 
and F+reticulocytes) did not interfere with the assay of %F+cells. The %F+cells 
was compared between using single- and double-colour staining methods. 
A total of 90 blood samples regardless of diagnoses, which included 
various levels of HbF, were assayed for %F+cells in parallel by single- and 
double-colour staining flow cytometry (sections 3.2.3 and 3.3.1). The analysis 
included samples from 17 control subjects, 20 thalassaernic and 53 sickle cell 
patients. The coefficient of correlation (r) was determined and the overall mean 
results of both methods were compared. 
Results and discussion 
The overall %F+cells using single- and double-colour staining were 
19.13±1.69 and 18.59±1.61 respectively, and were not significantly different. The 
coefficient of correlation (r) between %F+cells obtained from single- and double- 
colour staining was 0.996 (n=90) (Figure 3.3.4). 
The %F+cells does not differ significantly between the 2 staining methods. 
Furthermore, an excellent correlation was obtained between these 2 methods. 
These findings indicate that TO staining for reticulocytes does not interfere with 
the %F+cell assay using TC in double-colour staining. 
135 
Chapter 3 
80 
co 60 
c 
40 
4) 
U 
+ 20 
LL 
ýo 0- 
0 
%F+celis (TC Double) 
Figure 3.3.4 Comparison of %F+celis obtained from single-colour and double- 
colour staining 
90 blood samples, collected from 17 normal donors, 20 thalassaernic patients 
and 53 sickle cell patients were assayed for %F+cells using single- and double- 
colour staining. 
3.3.5. Correlation between %F+cells obtained from double-colour staining flow 
cytometry and %HbF obtained from HPLC 
Study design 
From the above findings, it would be expected that %F+cells using the 
double-colour method would correlate with %HbF by HPLC in a similar manner 
to results obtained with the single-colour method. A total of 90 blood samples 
regardless of diagnosis, which included various levels of HbF, were assayed for 
both %F+cells using double-colour staining and %HbF using HPLC (sections 
3.2.3 and 2.4.3 respectively). They were collected from 17 control subjects, 20 
thalassaemic and 53 sickle cell patients. The coefficient of correlation (r) was 
determined and the overall mean results of both parameters were compared. 
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Results and discussion 
The correlation coefficient (r) between %HbF and %F+cells (double-colour 
staining) was 0.965 (n=90) (Figure 3.3.5). The overall mean %HbF was 4.87+ 
0.53 and the overall mean %F+cells was 18.59+1.61. 
The correlation between %F+cells and %HbF is similar to the same type of 
correlation when %F+cells was obtained from single-colour staining. As 
previously discussed, these two assays are different in principles but show a 
good correlation. The double-colour staining method does not differ in this 
aspect from single-colour staining. 
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Figure 3.3.5 Relationship of %HbF and %F*celis from double-colour staining 
A total of 90 blood samples collected from 17 normal donors, 20 thalassaernic 
patients and 53 sickle cell patients were assayed for %HbF using HPLC and 
%F+cells using double-colour staining flow cytometry for simultaneous assay of 
%F+cells, %reticulocytes and %F+reticulocytes. 
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3.3.6. Correlation of %reticulocytes obtained from single- and double-colour 
staining flow cytometry 
Study design 
It is important that the %reticulocytes obtained using the double-colour 
staining method is comparable to the value obtained from the single-colour 
staining. Atotal of 90 blood samples, regardless of diagnosis, which included 
various levels of reticulocytes, were assayed for %reticulocytes in parallel by 
single- and double-colour staining (sections 3.2.10 and 3.3.1). Samples were 
obtained from 17 control subjects, 20 thalassaernic and 53 sickle cell patients 
for this purpose. The coefficient of correlation (r) was determined and the overall 
mean results of both parameters were compared. 
Results and discussion 
The overall %reticulocytes obtained using single- and double-colour 
staining were 6.82+0.53 and 6.83+0.54 respectively. These values were not 
significantly different. The coefficient of correlation of %reticulocytes by single- 
and double-colour staining was 0.991 (n=90) (Figure 3.3.6). 
A good correlation was obtained between the %reticulocytes determined 
by single- and double-colour staining and the overall mean values were not 
significantly different. These findings indicate that TC does not interfere with the 
assay of %reticulocytes using TO and vice versa. 
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Figure 3.3.6 Comparison of %reticulocytes obtained from single-colour and 
double-colour staining 
A total of 90 blood samples, collected from 17 normal donors, 20 thalassaernic 
patients and 53 sickle cell patients were assayed for %reticulocytes using 
single- and double-colour staining. 
3.3.7. Correlation of %reticulocytes obtained from double-colour staining flow 
cytometry and Sysmex SE-9500 reticulocyte analyser 
Rationale 
Having established that double-colour staining for F+reticulocytes did not 
affect the assay of reticulocytes by TO, a further experiment was performed to 
compare the %reticulocytes obtained using double-colour staining flow cytometry 
and using Sysmex SE-9500 reticulocyte analyser. There are many RNA stains, 
which can be used for the assay of reticulocytes. These include Thiazole orange 
(TO) and Auramine 0. Sysmex SE-9500 uses Auramine 0 as the RNA dye and is 
available in routine haernatology laboratory at UCLH. In order to ensure that the 
%reticulocytes obtained using the double-colour staining flow cytometry were 
comparable with a standard reticulocyte analyser, samples were assayed in 
parallel using both methods. 
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Study design 
A total of 90 blood samples, regardless of diagnosis and including various 
levels of reticulocytes, were assayed for %reticulocytes in parallel by both 
Sysmex SE-9500 and double staining (section 3.3.1). Samples included 17 
control subjects, 20 thalassaemic and 53 sickle cell patients. The coefficient of 
correlation (r) was determined and the overall mean results from both methods 
were compared. 
Results and discussion 
The overall %reticulocytes by the double-colour staining flow cytometry and 
Sysmex SE-9500 were 6.83+0.54 and 6.05+0.48 respectively, with non- 
significant difference between them. The coefficient of correlation of 
%reticulocytes obtained using this two methods was 0.974 (n=90) (Figure 3.3.7). 
A good correlation was obtained between the %reticulocytes measured by 
double-colour staining and by Sysmex SE-9500 and the overall mean values 
were not significantly different. Slightly lower values were observed using the 
Sysmex SE-9500. This is possibly because TO staining give a slightly stronger 
signal than Auramine 0 used in Sysmex SE-9500. 
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Figure 3.3.7 Comparison of %reticulocytes obtained from double-colour 
staining flow cytometry and Sysmex SE-9500 reticulocyte analyser 
A total of 90 blood samples were collected from 17 normal donors, 20 
thalassaernic patients and 53 sickle cell patients. %Reticulocytes obtained from 
the double-colour staining method for simultaneous assay of %F+cells, 
%reticulocytes and %F+reticulocytes were compared with the %reticulocytes 
obtained from the Sysmex SE-9500 reticulocyte analyser. 
3.4. DEVELOPMENT AND VALIDATION OF TRIPLE-COLOUR STAINING 
3.4.1. Background 
A key goal in this thesis was to find a way of measuring red cell adhesion 
molecule expression on subpopulations of red cells. In particular, how to 
determine a co-distribution of AM expression, HbF content and RNA content of 
red cells. It was necessary therefore to develop a reliable surface staining for 
adhesion molecules on red cells while at the same time intracellular HbF and 
RNA can also be stained after permeabilisation. Thus the challenges were two 
fold; firstly to identify three fluorochromes which did not interfere with each other, 
and secondly to set up a method which allowed both surface and intra- 
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erythrocyte staining of the same red cells. Before going to triple-colour staining, 
three double-colour staining for the co-distribution of AMs on reticulocytes or on 
F+cells was undertaken. 
3.4.2. Three double-colour staining for co-distribution of RNA, AMs and HbF 
expressing cells 
Thirty gl of packed red cells were diluted with 1 ml 0.1%BSA-PBS, then 100 
gl of this diluted sample was further diluted with 900 [d of 0.1%BSA-PBS (final 
dilution approximately 1 in 340). Twenty gl of the final dilution was separately 
incubated with 20 gl 1 in 5 diluted monoclonal antibody to each adhesion 
molecule (AM-MoAbs to CD36, CD41 and CD49d) at RT for 2 hours (hr), then 
washed twice with 0.1%BSA-PBS. Three sets of reactions were prepared: one 
tube for simultaneous assay of F+cells, reticulocyte and F+reticulocytes, one set 
of 3 tubes for analysis of each AM expression on F+cells and another set for the 
analysis of AM expression on reticulocytes. 
For analysis of AM expression on F+cells, one set of three tubes of the 
above samples (one tube for each AM or three tubes together for all three AMs) 
was fixed with 600 gl ice-cold 0.05% glutaraldehyde in PBS at RT for 10 min, 
washed once with 0.1%BSA-PBS and permeabilised with 600 gl ice-cold 0.05% 
Triton X-100 in 0.1%BSA-PBS for 10 min. After this the cells were washed once, 
then incubated with 10 gl 1 in 10 diluted anti-mouse-globulin conjugated to RPE 
(red) in the dark at RT for 2 hr and then washed twice. The cells were incubated 
with 10 Id 1 in 5 diluted MoAb-HbF-FITC (green) in the dark at RT for 30 min, 
washed once, and finally diluted with 600 gl O. I%BSA-PBS. This suspension 
was then analysed by flow cytometry. 
For analysis of AM expression on reticulocytes, one set of three tubes of 
the above samples (one tube for each AM or three tubes together for all three 
AMs) was incubated with 10 gl 1 in 10 diluted anti-mouse-globulin conjugate to 
RPE (red) in the dark at RT for 2 hr, washed once, then stained for RNA by 
adding 600 gi TO reagent (green) and incubating in the dark at RT for 30 min. 
142 
Chapter 3 
This suspension was then analysed by flow cytometry, which was carried out 
within 3.5 hr. 
For simultaneous analysis of F+cells, reticulocyte and F+reticulocytes, one 
tube of 20 gl of the final dilution above was fixed with 600 gi ice-cold 0.05% 
glutaraldehyde in PBS at RT for 10 min and washed once with 0.1%BSA-PBS. 
Cells were permeabilised with 600 gl ice-cold 0.05% Triton X-100 in 0.1%BSA- 
PBS for 10 min, washed once and then incubated with 10 gl 1 in 5 diluted MoAb- 
HbF-TC (deep-red) in the dark at RT for 30 min and washed once. After this they 
were finally stained for RNA by adding 600 gl TO reagent (green) and incubating 
in the dark at RT for 30 min. This suspension was then analysed by flow 
cytometry, which was carried out within 3.5 hr. 
Isotype controls were used instead of anti-AMs and anti-HbF and PBS was 
used instead of TO reagent as negative controls for non-specific binding. 
Representative histograms of the three double-colour staining for simultaneous 
assay of F+cells, reticulocytes, F+reticulocytes and adhesion molecule 
expression on F+cells and on reticulocytes are shown in Figure 3.4.2. 
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Figure 3.4. Flow cytometric histograms of three double-colour staining 
Top row; Double staining of FITC (for F+cells) vs RPE (for AM+cells) 
Left; A single channel histogram of HbF containing red cells or F+cells, 
stained by MoAb-HbF-FITC is shown. Green fluorescent signal detected by FL1 is 
shown on X axis in a log scale. Number of cells (cell count) is shown on Y axis in 
a linear scale. The cut-off point was set at 0.3% above the negative population. 
Middle; A double channel histogram of F+cells and adhesion molecule 
expressing cells or AM+cells is shown. Green fluorescent signal (FITC) detected 
by FL1 is shown on X axis in a log scale. Red fluorescent signal (RPE) detected 
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by FL2 is shown on Y axis also in a log scale. The horizontal cut-off line was set 
at 0.3% above the negative population, to separate the positive and negative HbF 
(FITC) or F+cells and F-cells. The vertical cut-off line was also set at 0.3% above 
the negative population, to separate the positive and negative AM (RPE) cells. 
These two lines separate the histogram into 4 quadrants (Ql-Q4). The cell 
number is presented in dots and dot density. Q1 (top-left) represents ordinary 
F+cells since they are positive for only HbF but negative for AM. Q2 (top-right) 
represents AM+F+cells since they are positive for both HbF and AMs. Q3 (bottom- 
left) represents ordinary red cells since they are negative for both HbF and AMs. 
Q4 represents ordinary AM+cells since they are positive for only AM but negative 
for HbF. 
Right; A single channel histogram of AM expressing red cells or AM+cells, 
stained by MoAb-AM coupled with anti-mouse-globulin-RPE conjugate is shown. 
Red fluorescent signal detected by FL2 is shown on X axis in a log scale. 
Number of cells (cell count) is shown on Y axis in a linear scale. The cut-off point 
was set at 0.3% above the negative population. 
Middle row; Double staining of TO (for reticulocytes) vs RPE (for AM+cells) 
Left; A single channel histogram of RNA containing red cells or 
reticulocytes, stained by Thiazole orange (TO) be shown. Green fluorescent 
signal detected by FL1 is shown on X axis in a log scale. Number of cells (cell 
count) is shown on Y axis in a linear scale. The cut-off point was set at 0.3% 
above the negative population. 
Middle; A double channel histogram of reticulocytes and AM+cells is 
shown. Green fluorescent signal (TO) detected by FL1 is shown on Y axis in log 
scale. Red fluorescent signal (RPE) detected by FL2 is shown on X axis also in 
log scale. The horizontal cut-off line was set at 0.3% above the negative 
population, to separate the positive and negative RNA (TO) or reticulocytes and 
mature red cells. The vertical cut-off line was also set at 0.3% above the negative 
population, to separate the positive and negative AM (RPE) expressing cells. 
These two lines separate the histogram into 4 quadrants (Ql-Q4). The cell 
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number is presented in dots and dot density. QI (top-left) represents ordinary 
reticulocytes since they are positive only for RNA but negative for AM. Q2 (top- 
right) represents AM+reticulocytes since they are positive for both RNA and AM. 
Q3 (bottom-left) represents ordinary mature red cells since they are negative for 
both RNA and AM. Q4 represents AM+mature red cells since they are positive only 
for AM but negative for RNA. 
Right; A single channel histogram of AM expressing red cells or AM+cells, 
stained by MoAb-AM coupled with anti-mouse-globulin-RPE conjugate is shown. 
Red fluorescent signal detected by FL2 is shown on X axis in a log scale. 
Number of cells (cell count) is shown on Y axis in a linear scale. The cut-off point 
was set at 0.3% above the negative population. 
Bottom row; Double staining of TO (for reticulocytes) vs TC (for F cells) 
Left; A single channel histogram of RNA containing red cells or 
reticulocytes, stained by Thiazole orange (TO) be shown. Green fluorescent 
signal detected by FL1 is shown on X axis in a log scale. Number of cells (cell 
count) is shown on Y axis in a linear scale. The cut-off point was set at 0.3% 
above the negative population. 
Middle; A double channel histogram of reticulocytes and F cells is shown. 
Green fluorescent signal (TO) detected by FL1 is shown on X axis in a log scale. 
Deep-red fluorescent signal (TC) detected by FL4 is shown on Y axis also in a 
log scale. The horizontal cut-off line was set at 0.3% above the negative 
population, to separate the positive and negative HbF (TC) or F'cells and F'cells 
(F negative cells or non-F cells). The vertical cut-off line was also set at 0.3% 
above the negative population, to separate the positive and negative RNA (TO) or 
reticulocytes and mature red cells. These two lines separate the histogram into 4 
quadrants (Q`144). The cell number is presented in dots and dot density. QI 
(top-left) represents F+mature red cells since they are positive only for HbF but 
negative for RNA. Q2 (top-right) represents F+reticulocytes since they are positive 
for both HbF and RNA. Q3 (boftom-left) represents ordinary mature red cells 
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since they are negative for both HbF and RNA. Q4 represents ordinary 
reticulocytes since they are positive for only RNA but negative for HbF. 
Right; A single channel histogram of HbF containing red cells or F+cells, 
stained by MoAb-HbF-TC is shown. The deep-red fluorescent signal detected by 
FL4 is shown on X axis in a log scale. Number of cells (cell count) is shown on Y 
axis in a linear scale. The cut-off point was set at 0.3% above the negative 
population. 
3.4.3. Triple-colour staining flow cytometry for simultaneous assay of co- 
distribution of HbF, RNA and AMs 
Rationale 
Having shown the feasibility of simultaneous assay of AMs with either 
reticulocytes or F+cells using three double-colour staining, a further method was 
devised for simultaneous analysis of all three variables on the same cell. The 
triple-colour staining method is developed and described below. In subsequent 
sections, validation of the stability of the sample preparation is shown. 
Method 
Thirty gl of packed red cells was diluted with 1 ml 0.1 %BSA-PBS and 100 
gl of this diluted sample was then further diluted with 900 lal 0.1%BSA-PBS (final 
dilution approximately 1 in 340). Twenty gl of the final dilution4was separately 
incubated with 20 gl 1 in 5 diluted monoclonal antibody to each adhesion 
molecule (CD36, CD41 and CD49d, 1 tube each) at RT for 2 hr, then washed 
twice with 0.1%BSA-PBS. The suspension was incubated with 20 gl 1 in 10 
diluted anti-mouse-globulin conjugated biotin at RT for 2 hr, then fixed with 600 Rl 
ice-cold 0.05% glutaraldehyde in PBS for 10 min and washed once. This was 
then permeabilised with 600 gl ice-cold 0.05% Triton X-100 in 0.1%BSA-PBS for 
10 min and washed once. After this the suspension was simultaneously 
incubated with 10 lal 1 in 5 diluted MoAb-HbF-TC (deep-red) and 10 gl 1 in 10 
diluted streptavidin-RPE (red) in the dark at RT for 30 min and washed once. The 
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cell suspension was then incubated with 600 ýtl 100 ng/ml Thiazole Orange 
reagent (green) in the dark at RT for 30 min. This suspension was then ready for 
flow cytometric analysis within 3.5 hr. Isotype controls were used instead of anti- 
AMs and anti-HbF antibodies and PBS was used instead of TO reagent as 
negative controls for non-specific binding. The gate setting for triple-colour 
staining was described in chapter 2. Representative histograms of triple-colour 
staining for simultaneous assay of adhesion molecule expression on F+cells, 
reticulocytes, and F+reticulocytes are shown in Figure 3.4.3. 
ss 
t.: n 
FLI TO 
" F, Jý1. 
M To 
FLI TO 
FL2 RPL 
fLI TC 
I 11 Tt 
)L ii 'U 
tti± Lt F 
PRISrI 
Figure 3.4. Flow cytometric histograms of triple-colour staining 
Top, left--->right 
Ils' Histogram; A double-channel histogram for red cells is shown. The 
histogram shows forward scatter (FS) on the vertical axis in a linear scale and 
side scatter (SS) on the horizontal axis in a log scale. Side scatter represents cell 
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granularity whereas forward scatter represents cell size. The gated area 
represents the red cell population, which is selected for analysis. 
2 nd Histogram; A single channel histogram of RNA containing red cells or 
reticulocytes, stained by Thiazole orange (TO) is shown. Green fluorescent signal 
detected by FL1 is shown on X axis in a log scale. Number of cells (cell count) is 
shown on Y axis in a linear scale. The cut-off point (B) was set at 0.3% above the 
negative population. 
3rd Histogram; A single channel histogram of AM expressing red cells or 
AM+cells, stained by MoAb-AM coupled with anti-mouse-globulin-RPE conjugate 
is shown. Red fluorescent signal detected by FL2 is shown on X axis in a log 
scale. Number of cells (cell count) is shown on Y axis in a linear scale. The cut- 
off point (C) was set at 0.3% above the negative population. 
4 th Histogram; A single channel histogram of HbF containing red cells or 
F+cells, stained by MoAb-HbF-TC is shown. Deep-red fluorescent signal detected 
by FL4 is shown on X axis in a log scale. Number of cells (cell count) is shown 
on Y axis in a linear scale. The cut-off point (D) was set at 0.3% above the 
negative population. 
Bottom, left-ýright 
5 th Histogram; A double channel histogram of reticulocytes and AM+cells 
is shown. Green fluorescent signal (TO) detected by FL1 is shown on X axis in a 
log scale. Red fluorescent signal (RPE) detected by FL2 is shown on Y axis also 
in a log scale. The horizontal cut-off line (E) was set at 0.3% above the negative 
population, to separate the positive and negative AM (RPE) expressing cells. The 
vertical cut-off line (E) was also set at 0.3% above the negative population, to 
separate the positive and negative RNA (TO) or reticulocytes and mature red 
cells. These two lines divide the histogram into 4 quadrants (Ql-Q4). The cell 
number is presented in dots and dot density. Q1 (top-left) represents AM+mature 
red cells since they are positive only for AM but negative for RNA. Q2 (top-right) 
represents AM+reticulocytes since they are positive for both RNA and AM. Q3 
(bottom-left) represents ordinary mature red cells since they are negative for both 
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RNA and AM. Q4 represents ordinary reticulocytes since they are positive only for 
RNA but negative for AM. 
6 th Histogram; A double channel histogram of reticulocytes and F+cells is 
shown. Green fluorescent signal (TO) detected by FL1 is shown on X axis in a log 
scale. Deep-red fluorescent signal (TC) detected by FL4 is shown on Y axis also 
in a log scale. The horizontal cut-off line (F) was set at 0.3% above the negative 
population, to separate the positive and negative HbF (TC) or F+cells and F-cells. 
The vertical cut-off line (F) was also set at 0.3% above the negative population, to 
separate the positive and negative RNA (TO) or reticulocytes and mature red 
cells. These two lines divide the histogram into 4 quadrants (Ql-Q4). The cell 
number is presented in dots and dot density. QI (top-left) represent F+mature red 
cells since they are positive only for HbF but negative for RNA. Q2 (top-right) 
represents F+reticulocytes since they are positive for both HbF and RNA. Q3 
(bottom-left) represents ordinary mature red cells since they are negative for both 
HbF and RNA. Q4 represents ordinary reticulocytes since they are positive only 
for RNA but negative for HbF. 
7 th Histogram; A double channel histogram of F+cells and adhesion 
molecule expressing cells or AM+cells is shown. Deep-red fluorescent signal 
(TC) detected by FL4 is shown on X axis in a log scale. Red fluorescent signal 
(RPE) detected by FL2 is shown on Y axis also in a log scale. The horizontal cut- 
off line (G) was set at 0.3% above the negative population, to separate the 
positive and negative AM (RPE) expressing cells. The vertical cut-off line (G) was 
also set at 0.3% above the negative population, to separate the positive and 
negative HbF (FITC) or F+cells and F-cells. These two lines divide the histogram 
into 4 quadrants (Ql-Q4). The cell number is presented in dots and dot density. 
01 (top-left) represents ordinary AM + cells since they are positive only for AM but 
negative for HbF. Q2 (top-right) represents AM+F+cells since they are positive for 
both HbF and AM. Q3 (boftom-left) represents ordinary red cells since they are 
negative for both HbF and AM. Q4 represents ordinary F+cells since they are 
positive only for HbF but negative for AM. 
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8th Histogram; A triple channel histogram for the combination of TO 
(logFL1, green, for RNA), RPE (logFL2, red, for AMs) and TC (logFL4, deep-red, 
for HbF) is shown. The combination of these 3 colour signals was put together 
into this triple colour histogram. The histogram shows cell numbers in all 
combinations. Gate H represents all 3 negative (--) population for TO, RPE and 
TC respectively, while gates I (+--), J (-+), K (+-+), L (-+-), M (++-), N (-++) and 0 
( ... ) represent the other combinations respectively. The cut-off point to separate 
the positive and negative populations of each channel was set at 0.3% above the 
negative control population, which is greater than mean plus 3 SD of negative 
population using samples which were either unstained or stained with irrelevant 
isotype control antibodies. 
3.4.4. Comparison of adhesion molecule expressing cells obtained from 
double- and triple-colour staining 
Study design 
In the single-colour staining method for adhesion molecule expression on 
red cells and the double-colour staining method with TO for RNA in reticulocytes, 
fresh unfixed/unpermeabilised red cells were used. However, in the triple 
staining method with MoAb-HbF-TC for F+cells, it was necessary to use 
fixed/permeabilised red cells to enable the MoAb-HbF-TC to pass through the red 
cell membrane. It is important that the fixation and permeabilisation do not 
disturb the adhesion molecule expression. In this section therefore, the O/oAM 
expressing cells obtained from single-colour staining is compared with the 
values obtained from either double-colour or triple-colour staining. In order to 
determine whether the additional of another 1 or 2 colour affects the AM assay. 
A total of 20 blood samples from 7 normal control subjects and 13 sickle 
cell patients were assayed in parallel for percentages of adhesion molecule 
(CID36, CD41 and CID49d) expressing cells on fresh (single-colour staining, 
section 3.2.11) and fixed/permeabilised red cells (double- and triple-colour 
staining, see sections 3.4.2 and 3.4.3). The overall % red cells expressing AMs 
151 
Chapter 3 
obtained from these 2 treatments (fresh and fixed/permeabilised) were 
compared. The correlation of coefficient (r) between these 3 methods [1 fresh 
(single-colour staining) and 2 fixed/permeabilised (Double- and triple-colour 
staining)] were also determined. 
Results and discussion 
The overall %CD36+cells obtained from single-colour staining (fresh red 
cells), double-colour staining and triple-colour staining (fixed/permeabilised red 
cells) were 2.37±0.36,2.20±0.33 and 2.20±0.33% respectively. The %CD41 +cells 
obtained from these methods were 2.16±0.29,2.00±0.28 and 2.00±2.28% 
respectively and the %CD49d+cells were 2.03±0.30,1.93±0.30 and 1.93±0.31% 
respectively. There was no significant difference between %AM+cells within the 
same AM. The correlation coefficient (r) of %CID36+cells between single and 
double staining was 0.968 and between single and triple staining was 0.969 
(Figure 3.4.4.1). These correlation coefficients of %CD41+cells were 0.953 and 
0.954 respectively (Figure 3.4.4.2) and of CID49d+cells were 0.967 and 0.949 
respectively (Figure 3.4.4.3). Every correlation was highly significant (p<0.0001). 
These findings indicate that the fixing and permeabilisation has had a 
minimal effect on the expression of these three adhesion molecules. Therefore 
double- or triple-colour staining on fixed/permeabilised red cells is applicable. 
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Figure 3.4.4.1 Comparison of %CD36 expressing cells obtained from 
fresh/unfixed and fixed/permeabilised red cells 
A total of 20 blood samples were assayed for the percentages of CD36+cells on 
fresh/unfixed (single-colour staining) and fixed/permeabilised (double- and triple- 
colour staining) red cells. These were collected from 7 normal donors and 13 
sickle cell patients to include various levels of %AM"cells. The overall means of 
%CD36+cells comparing between fresh/unfixed and fixed/permeabilised red 
cells were not significantly different. 
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Figure 3.4.4.2 Comparison of %CD41 expressing cells obtained from 
fresh/unfixed and fixed/permeabilised red cells 
A total of 20 blood samples, collected from 7 normal donors and 13 sickle cell 
patients, were assayed for percentages of CD41+cells on fresh/unfixed (single- 
colour staining) and fixed/permeabilised (double- and triple-colour staining) red 
cells. The overall means of %CD41+cells comparing between fresh/unfixed and 
fixed/permeabilised red cells were not significantly different. 
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Figure 3.4.4.3 Comparison of %CD49d expressing cells obtained from 
fresh/unfixed and fixed/permeabillsed red cells 
A total of 20 blood samples, collected from 7 normal donors and 13 sickle cell 
patients were assayed for percentages of CD49d+cells on fresh/unfixed (single- 
colour staining) and fixed/permeabilised (double- and triple-colour staining) red 
cells. The overall means %CD49d+cells comparing between fresh/unfixed and 
fixed/permeabilised red cells were not significantly different. 
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3.4.5. Effect of anticoagulants and sample stability on the adhesion molecule 
expressing cell assay by triple-colour staining flow cytometry 
Study design 
As with the single- and double-colour staining methods, it was important 
to find whether different anticoagulants could affect the stability of the sample and 
how long the sample could reasonably be stored before analysis. Three 
conventional and 1 special anticoagulants were evaluated. Blood was collected 
and stored at 40C for 6 days in the respective anticoagulants and these samples 
were assayed for %AM+cells every day for 6 days. 
A blood sample from a sickle cell patient was collected in EDTA, citrate, 
heparin and CTAD. The samples were assayed for %AM+cells using triple-colour 
staining flow cytometry (section 3.4.3) on the day of collection (day 1) and for a 
further 5 consecutive days (day 2-6). Samples were stored at 40C during the 
study. The mean results on each day were compared. 
Results and discussion 
Percentages of AM+cells in the same sample collected into different 
anticoagulants are not significantly different within the first 3 days of collection 
(Figure 3.4.5). 
These results show that any of these 4 anticoagulants are suitable for the 
assay of AM expressing cells. Samples can be stored at 4"C for up to 3 days 
without any significant difference in the results. 
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Figure 3.4. Percentages of AM expressing cells obtained from triple-colour 
staining by days of storage in different anticoagulants 
See text for details. 
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3.4.6. Reproducibility of triple-colour staining flow cytometry for AM*cell assay 
Study design 
It is necessary to show that the AM+ceII assay is reproducible. The intra- 
and inter-assay coefficients of variation (%CVs) were therefore determined. An 
EDTA blood sample from a sickle cell patient was collected and stored at 40C 
during the study. The sample was assayed for %AM+cells (section 3.4.3. ) in 4 
replicates on the day of collection (day 1) and in another 3 replicates for a further 
3 consecutive days (day 2-4). The intra- and inter-assay %CVs were determined. 
Results and discussion 
The intra-assay %CVs for %CD36+cells, %CD41 +cells and %CD49d+cells 
were 7.62,8.23 and 7.89% respectively (n=4). The inter-assay %CVs for these 
AMs were 15.45,16.23 and 15.68% respectively. These findings show that the 
triple-colour staining flow cytometry was reproducible. This is despite the fact that 
the percentage of AM+cells is relatively low. During the above assays as with all 
assays reported in this thesis, a minimum of 50,000 cells were counted to 
reduce variability that might happen from counting low numbers of cells. 
3.4.7. Comparison of %F+celis and %reticulocytes obtained from single- and 
triple-colour staining flow cytornetry 
Study design 
It is necessary to ensure that triple-colour staining did not interfere the 
values of %F+cells and %reticulocytes. Comparisons between %F+cells and 
%reticulocytes obtained from single- and triple-colour staining were therefore 
performed. Atotal of 20 blood samples from 7 normal control subjects and 13 
sickle cell patients were assayed for %F+cells and %reticulocytes using single- 
colour staining (section 3.2.3 and 3.2.10 respectively) and triple staining (see 
sections 3.4.3). The overall %F+cells and %reticulocytes were compared. The 
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correlation coefficients (r) between these two methods were also determined for 
both %F+cells and %reticulocytes. 
Results and discussion 
The overall means %F+cells and %reticulocytes were not significantly 
different. The correlation coefficient (r) between these two methods for %F+cells 
and %reticulocytes were 0.998 and 0.996 respectively with highly significant 
correlation (p<0.0001). (Figure 3.4.7) 
These results show that the %reticulocytes obtained from the single- 
colour and triple-colour staining are comparable. Furthermore, the % F+cell 
obtained from these two methods are also comparable. Thus, the use of the 
three colour together does not interfere the results of %F+cells or %reticulocytes. 
Triple-colour staining are therefore valid and comparable to single-colour 
staining method. 
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Figure 3.4.7 Correlation between %F+celis and %reticulocytes obtained from 
single-colour and triple-staining methods 
A total of 20 blood samples from 7 normal control subjects and 13 sickle cell 
patients were assayed for %F+cells and %reticulocytes using single-colour 
staining and triple-colour staining. The overall means %F+cells and 
%reticulocytes were non significantly different. 
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3.5. CONCLUSIONS 
In this chapter, the development of single-, double- and triple-colour 
staining of F+cells, F+reticulocytes, AM expressing cells and their co-distributions 
has been described. The stability of the samples in a variety of anticoagulants 
was demonstrated and the reproducibility of the different assays was identified. 
The flow cytometric methods developed in this thesis are simple, rapid, and 
reproducible and do not need sophisticated equipment except a flow cytometer. 
The methods for fixation and permeabilisation are also simple and rapid. The 3 
conventional (EDTA, citrate and heparin) and one special (CTAD) anticoagulants 
are all suitable for these methods. Blood sample storage at 4"C is valid up to 15 
days for the F+cell assay, 6 days for the F+reticulocyte assay and 3 days for the 
AM+cell assay respectively. The simplified procedure without any washing step is 
even more simple and rapid and gives comparable results to the original one. 
It is important to show that assay of these variables simultaneously does 
not interfere with the values obtained for that particular variable using single- or 
double-colour analysis. The results show that the reproducibility and stability 
obtained from single-, double- and triple-colour staining is acceptable. 
Furthermore, the results obtained from single-, double- and triple-colour staining 
are comparable showing that the triple-colour staining gives reliable data. In 
particular, the assay of AMs does not interfere with the simultaneous assay of 
F*reticulocytes. Conversely, the value of AMs obtained is similar when these are 
assayed alone or in combination with F+cells or reticulocytes. This is important 
for the work described in the next chapter because it is important to ensure that 
the results of co-distributions are valid. 
In order to achieve these valid results, it is necessary to be careful of the 
two aspects of the analysis. Firstly the handling, permeabilisation and staining of 
the samples and secondly the setting up of the flow cytometer and choice of 
fluorochromes for single-, double- and triple-colour staining. Therefore the 
optimal gating and colour compensations to prevent interference from one colour 
into another were important. This approach has been described in chapter 2. 
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CHAPTER 4 
CONTRIBUTION OF FOETAL HAEMOGLOBIN AND RED 
CELL ADHESION MOLECULES TO SICKLE RED CELL 
SURVIVAL 
4.1. F+CELLS, F+RETICULOCYTES AND ENRICHMENT RATIO 
4.1.1. Background 
The method for quantitation of co-distribution of foetal haemoglobin (HbF) 
and reticulocytes has been described in Chapter 3. It is now possible to address 
in principle whether HbF containing red cells (F+cells) survive beyond the 
reticulocyte stage better than non-F cells or F-negative cells (F-cells). F+cells and 
HbF containing reticulocytes (F+reticulocytes) are increased in the majority of 
sickle cell patients. Previous methodology using microscopic single-cell radial 
immunodiffusion has shown that the ratio of the proportion of F+mature red cells 
(F+MRCs) to the proportion of F+reticulocytes, so called enrichment ratio (ER), is 
close to unity (1-00) in normal healthy subjects (Dover et aL, 1978a). This 
suggests that F+cells do not have any survival advantage in normal individuals. In 
sickle cell patients, there is generally a higher proportion of F+MRCs than 
F+reticulocytes, with the ER varying from 0.7 to 5.0 (Dover et aL, 1978b). This is 
consistent with the hypothesis that F+cells in sickle cell patients have a survival 
advantage over non-F cells (F'cells) due to the slower rate of HbS polymerisation 
when intra-erythrocyte HbF are present (Bertles & Milner, 1968). 
Another question is whether in patients receiving hydroxyurea (HU) 
treatment, this enrichment ratio differs significantly. Hydroxyurea is known to 
increase HbF and F"'cells in a substantial proportion of sickle cell patients but 
may also act through additional or alternative mechanisms such as decreasing 
numbers of white cells, reticulocytes and red cells expressing adhesion 
molecules. The double-colour staining flow cytometry for quantitation of F+cells, 
reticulocytes and F+reticulocytes can theoretically show whether any survival 
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advantage for F+cells beyond the reticulocyte stage is enhanced or diminished by 
hydroxyurea treatment. 
4.1.2. Distribution of F+cells 
Rationale 
In chapter 3, a simplified procedure for F+cell assay was developed and 
validated. In this section, the 06F + cells are compared between normal donors 
and sickle cell patients in steady state, in vaso-occlusive painful crisis or 
receiving hydroxyurea therapy. The proportion of F+cells is also compared with 
the proportion of HbF assayed by HPLC. Patients who had recently received red 
cell transfusion, as evidenced by the presence of HbA using HPLC analysis, 
were excluded from this study. 
Study design 
Sixty two blood samples were obtained from 25 normal donors (control), 
18 sickle cell patients in steady state (sickle std, no vaso-occlusive painful crisis 
and no hospitalisation at the time of blood sampling), 12 sickle cell patients in 
vaso-occlusive painful crisis (sickle cri, admitted to the hospital due to a painful 
crisis at the time of blood sampling) and 7 sickle cell patients undergoing 
hydroxyurea therapy (sickle HU, 0.5-2.0 g/day, for several weeks and having a 
steady level of %HbF at the time of blood sampling). None of the sickle cell 
patients had any HbA as measured by HPLC, confirming that they had not 
received any recent blood transfusion (at least within 4 months before blood 
sampling). 
The blood samples were collected into either EDTA, citrate or heparin 
vacutainers and were usually assayed within 2 weeks of 40C storage, since the 
results in chapter 3 show that any anticoagulant is suitable for the assay and the 
samples were stable for 2 weeks at 4'C. Analysis of %F+cells was carried out 
using the simplified procedure (section 3.2.3) and HbF was measured by HPLC 
(section 2.5.2). 
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Results and discussion 
In 25 control subjects the %HbF by HPLC was 0.96+0.55% and the 
%F+cells 3.03±0.36% respectively. In 18 sickle std, these values were 
4.06+0.77% and 17.57±2.81% respectively. In 12 sickle cri these values were 
2.92+0.51% and 14.77±1.83% respectively. In 7 sickle HU these values were 
15.83+2.00% and 54.09+8.45% respectively. (Figure 4.1.2) 
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Fiqure 4.1.2 Percentages of HbF and F4'cells 
%F cells 
Sixty two blood samples obtained form 25 normal donors (control), 18 sickle cell 
patients in steady state (sickle std), 12 sickle cell patients in crisis (sickle cri) and 
7 sickle cell patients on hydroxyurea therapy (sickle HU) were assayed for %HbF 
using HPLC and %F+cells using the simplified procedure. These two 
parameters in all three groups of patients were significantly higher than in the 
control group. (* significant higher than controls p<0.01, ** significantly higher 
than SS. std. p<0.001) 
The %HbF in normal controls (0.96±0.55%) is consistent with previous 
reports of not more than 2% (Rochette et al., 1994). Similarly the %F'cells in 
normal donors of 3.03±0.36% is consistent with the levels reported by other 
investigators using flow cytometry, such as 3.1% (Thorpe et al., 1994) and 4.4% 
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(Rochette et al., 1994) but appeared to be lower than 7% reported using 
immunofluorescent staining on blood smear (Wood et al., 1975). 
In all 3 sickle cell patient groups, both %HbF and %F'cells were 
significantly higher than in control subjects (p<0.01 and p<0.001 respectively). As 
expected, there was a marked increase in the %HbF and the %F+cells in sickle 
patients receiving hydroxyurea therapy, consistent with previous findings using 
other techniques (non-flow cytometry) (Bridges et al., 1996). The results confirm 
that F+cell production in sickle cell patients is higher than in normal control 
donors and the hydroxyurea treatment in sickle cell patients can induce very high 
levels of both %HbF and %F+cells. 
4.1.3. Distribution of F+ cells, reticulocytes and F+reticulocytes 
Rationale 
Reticulocytes are typically increased in sickle cell patients because of the 
compensation of their haemolytic anaemia. As shown in sections 4.1.2, F"cells 
are increased in patients with increased HbF levels. Measurement of the 
%F*reticulocytes (% of reticulocytes which contain HbF in the total reticulocytes) 
has been used previously to detect an early response to agents which increase 
HbF (Dover et aL, 1978a). In response to HU, it would be expected that increases 
in F+reticulocytes would be detected before increases in HbF or F+cells, since 
F+reticulocytes represent cells recently released from the bone marrow. On the 
other hand, HU may decrease the %reticulocytes by decreasing haemolysis or by 
decreasing proliferation in the bone marrow. In this section, the percentages of 
F+cells, reticulocytes, F+reticulocytes and HbF are compared between control 
subjects and sickle cell patients (both on and off HU therapy) to determine 
whether the measurement of F+reticulocytes by flow cytometry adds any useful 
information over the measurement of F+cells and reticulocytes separately. 
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Study design 
Sb4 seven blood samples were obtained from 20 normal donors 
(control), 23 sickle cell patients in steady state (sickle std), 18 sickle cell patients 
in crisis (sickle cri) and 6 sickle cell patients receiving hydroxyurea therapy (sickle 
HU, 0.5 -2.0 g/day for several weeks and having a steady level of %HbF at the 
time of blood sampling). All sickle cell patients showed an absence of HbA by 
HPLC confirming that none had received recent blood transfusion. The blood 
samples were collected into either EDTA, citrate or heparin vacutainers, stored at 
40C and usually assayed within 5 days after collection. These anticoagulants are 
all suitable for the method and such samples are stable up to 5 days at 40C 
(section 3.3.3). The samples were assayed for HbF levels using HPLC (section 
2.5.2) and simultaneous measurements of %F+cells, %reticulocytes and 
%F+reticulocytes (section 3.3.1). The %HbF (% of HbF in total Hb in the 
hemolysate), %F+cells (% of F+cells in total red cells), %reticulocytes (% of 
reticulocytes in total red cells) and %F+reticulocytes (% of F+reticulocytes in total 
reticulocytes) of these four groups were determined and compared. 
Results and discussion 
In the 20 controls, %HbF was 1.25+0.13%, %F+cells was 3.25+0.45%, 
%reticulocytes was 1.39+0.10% and %F+reticulocytes was 3.31±0.41% 
respectively. In 23 sickle std, these values were 6.07+0.86%, 28.55+3.37%, 
12.19±1.40% and 13.19+1.54% respectively. In 18 sickle cri, these values were 
5.05±1.16%, 20-89±3.33%, 11.61±1.40% and 18.70+2.20% respectively. In 6 
sickle HU, these values were 21.68+3.40%, 63-97+5.5%, 4.94+0.81% and 
34.08±3.71% respectively. (Figure 4.1.3) 
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Figure 4.1.3 Percentages of HbF, F+cells, reticulocytes and F+reticulocytes 
Sixty seven blood samples obtained from 20 normal donors (control), 23 sickle 
cell patients in steady state (sickle std), 18 sickle cell patients in crisis (sickle cri) 
and 6 sickle cell patients on hydroxyurea therapy (sickle HU) were assayed for 
%HbF by HPLC and %F+cells, %reticulocytes and %F+reticulocytes by double- 
colour staining flow cytometry. These four parameters in all three groups of 
patients were significantly higher than in the control group (*p<0.01). The %HbF, 
%F+cells and %F+reticulocytes in HU-treated patients were significantly higher 
than in sickle std at p<0.001. The %reticulocytes in HU-treated patients was 
significantly lower than in sickle std at p<0.05. Retics or retics = reticulocytes 
There are significantly higher levels of all four parameters (%HbF, 
%F+cells, %reticulocytes and %F+reticulocytes) in sickle cell patients over normal 
control subjects (p<0.01). However, there is no significant difference in these 
values between sickle cell patients in steady state and in crisis. In HU-treated 
sickle cell patients, %HbF, %F"cells and %F+reticulocytes were very high, 
consistent with a previous report, which used microscopic single-cell radial 
immunodiffusion for 174reticulocyte measurement (Charache et aL, 1992). It is 
noteworthy that %reticulocytes are significantly decreased in the HU-treated 
patients compared to non-HU-treated patients (p<0.05). This decrease has been 
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observed by other investigators (Dover et a/., 1986; Ferster et al., 1996) and is 
due to the cytostatic effect of HU. 
In patients who have been on HU for several weeks, the increase in 
%F+cells is more marked than that of %F+reticulocytes, possibly because F+cells 
survive longer than F-cells and supression of bone marrow by HU leads to 
reduce production of reticulocytes and also F+reticulocytes. Therefore in HU- 
treated patients, there is a lower proportion of young red cells containing HbF 
than mature red cells containing HbF. Since these patients had been on HU for 
several weeks, the observations represent not the initial response to HU, where 
F+reticulocytes might be increased before a general increase in F+cells was 
detected, but this is a situation where the majority of F+reticulocytes have already 
matured into F+mature red cells. Therefore, the fact that the % of F+mature red 
cells exceeds the % of F+reticulocytes suggests that F+cells have a survival 
advantage over cells which lack HbF (F'cells) in sickle cell patients. In contrast, 
the %F+cells is approximately the same as the %F+reticulocytes in control 
subjects, consistent with they're being no survival advantage of F+cells in control 
subjects. Thus the ER (ratio of %F+mature red cells to %F+reticulocytes) gives an 
indication of the survival advantage of cells containing HbF. This ratio was first 
reported by Dover et al. (1978a) using microscopic single-cell radial 
immunodiffusion techniques but has not been reported for HU treated patients. 
In the subsequent sections, this ratio is examined systematically. 
4.1.4. F*cell enrichment ratio (ER) 
Study design 
An advantage of the double-colour staining for simultaneous 
measurements of %F+cells, %reticulocytes and %F+reticulocytes over single- 
colour staining for F+cell measurement alone is the ability to determine the ER. 
Dover et aL (1 978a) reported an increased ER in sickle cell patients ranging from 
0.7-5.0. In order to confirm this finding using flow cytometric method, the ER was 
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determined in normal control subjects and in sickle cell patients. The F+cell ER 
was calculated from the data obtained in section 4.1.3 using the formula below. 
Proportion (%) of F+ mature red cells in total mature red cells 
Enrichment ratio = ---- 
Proportion (%) of F+reticulocytes in total reticulocytes 
Results 
The ER in the normal control subjects (n=20) was 0.999±0.038. In non- 
transfused sickle cell patients in steady state (n=23) was 2.186+0.145. In sickle 
cell patients in crisis (n=18) was 1.780+0.189. In sickle cell patients undergoing 
hydroxyurea therapy (n=6) was 1.610+0.259 respectively. (Figure 4.1.4) 
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Ficiure 4.1.4 The enrichment ratio (ER) of F*cells 
The ERs of 20 normal donors (control), 23 sickle cell patients in steady state 
(sickle std), 18 sickle cell patients in crisis (sickle cri) and 6 sickle cell patients 
on hydroxyurea therapy (sickle HU) were calculated from the data in section 4.1.3. 
The ER in all three groups of patients was significantly higher than in the control 
group. (* p<0.005) 
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Discussion 
The F+cell enrichment ratio (ER) in normal control subjects was close to 
unity (1.000), which indicates that there is no preferential survival of the F+cells 
over F-cells (normal HbA containing cells without HbF). This result confirms the 
previous findings (Dover et al., 1978a). In all 3 groups of sickle cell patients the 
ER was significantly higher than in the control subjects (p<0.005), which was 
also consistent with Dover's finding, but the method used in this thesis is more 
convenient. These results indicate that there is a survival advantage of F"cells in 
sickle cell patients. In sickle cell patients, a higher ER indicates a higher 
proportion of F+cells mature beyond the reticulocyte stage and on average they 
have an approximately two fold ER over normal control subjects. There is no 
significant difference between ER of SS. std. and SS. cri., but the ER in SSAU is 
lower than in SS. std. Oust reach the significant level, p<0.05). This finding 
indicates that at the peak of HbF production induced by HU, the difference 
between %F+cells and %F+reticulocyte is closer than in untreated patients. This 
is probably because in HU-treated patients, a higher proportion of red cells are 
F+cells when compared to non-treated patients. Therefore, the ER becomes 
more closer to unity (1.000). If HU has an absolute effect on inducing all newly 
released reticulocytes to become F+reticulocytes, shortly afterwards the mature 
red cell population would all become 100% F+cells. So the ER would be 1.000 
according to the formula. This phenomenon is probably found in homozygous 
HPFH individuals, who produce all 100% F+cells. 
4.2. ADHESION MOLECULE EXPRESSING RED CELLS, RETICULOCYTES AND 
F*CELLS 
4.2.1. Background 
The relationship between AM expression and HbF content on red cell 
survival has not been previously reported and is potentially important for two 
reasons. Firstly, it may provide information about the nature of F+cells in normal 
individuals, in particular whether proportion of AM expressing F+cells is 
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increased or decreased and whether such cells survive normally. Secondly, in 
sickle cell disorders it is not known whether the co-expression of HbF and AMs 
accounts for the better survival advantage of F"cells compared to Fcells (red 
cells containing only HbS without HbF). 
In this section, the proportion of red cells expressing AMs has been 
compared in total red cells, mature red cells, reticulocytes, F+cells and F'cells in 
healthy control subjects and sickle cell patients. The AMs examined were CD36, 
CD41 and CD49d. Three double-colour staining flow cytometric assay was 
employed (section 3.4.2). 
4.2.2. Proportions of total red cells, reticulocytes and F*cells expressing 
adhesion molecules 
Rationale 
The purpose of the work in this section was to examine two questions. 
Firstly whether AM expression is greater on reticulocytes than on mature red 
cells? Secondly whether AMs are expressed to the same degree on F"cell and F- 
cell populations? Previous investigators, have found that stress reticulocytes in 
patients with sickle cell disease express high levels of AMs, especially CD36 
(Browne & Hebbel, 1996). However these investigators did not examine the 
distribution of other AMs (CD41 and CD49d) on reticulocytes in controls and in 
sickle cell patients. In this section, 3 AMs (CD36, CD41 and CD49d) were 
therefore examined with respect to their co-distribution on F+cells and on 
reticulocytes. These co-distributions were then compared between sickle cell 
patients and control subjects. 
Study design and methodology 
Seventy blood samples were obtained from 23 normal donors (Control), 
23 non-transfused sickle cell patients in steady state (Sickle std), 14 non- 
transfused sickle cell patients in crisis (Sickle cri) and 10 sickle cell patients 
undergoing hydroxyurea therapy (sickle HU, 0.5-2.0 g/day for several weeks and 
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reaching a steady level of %HbF at the time of blood sampling) at University 
College Hospitals, London, UK. The percentages of AM expressing cells in the 
total population of red cells, in the reticulocyte population and in the F+cells 
population were determined using the three separated double-colour staining 
flow cytometric assays (section 3.4.2). Blood samples were obtained in either 
EDTA, citrate or heparin vacutainers, stored at 40C and assayed within 3 days. 
Results 
The results show that in sickle cell disorders, the %AM+cells is increased 
in the total red cell and in the F+cell populations but not in the reticulocyte 
population, when compared to the control subjects (Figure 4.2.2). The trends are 
similar for CD36, CD41 and CD49d. Therefore, the following discussion refers to 
all 3 AMs. 
AM expression in total red cells and reticuloWes 
In normal controls (n=23), the percentages of total red cell expressing 
CD36, CD41 and CD49d were 0.65+0.03,0.65+0.03 and 0.69±0.03% 
respectively. The percentages of total reticulocyte expressing these AMs were 
21.58±0.87,21.03±1.04 and 22.19±0.90% respectively. 
In steady state sickle cell patients (n=23) the % of total red cell expressing 
these AMs were 2.89+0.21,2.65+0.21 and 2.77+0.26% respectively, which was 
increased compared to the control subjects (P<0.001). However, the % of total 
reticulocyte expressing AMs (22.23+1.59,19.48+1.51 and 19.65+1.52% 
respectively) was not significantly different from the control subjects. Thus the 
increased % of AM+cells in the total population of red cells in steady state sickle 
cell patients reflects the higher proportion of reticulocytes (11.47+0.96%) 
compared to the controls (1.53+0.05%), does not reflect a difference in % of 
reticulocyte expressing AMs. 
In sickle cell patients in crisis (n=14), % of total red cells expressing these 
AMs and % of total reticulocytes expressing the same AMs are similar to the 
steady state patients. The % of total red cells expressing CD36, CD41 and 
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CD49d were 2.36±0.22,2.16±0.23 and 2.25+0.21% respectively and the % of 
total reticulocytes expressing these AMs were 22.19+3.24,21.41+3.76 and 
19.63+3.14% respectively. The % of reticulocytes in the crisis patients 
(9.20+0.92%) were also increased to a similar level as in steady state patients. 
In HU-treated sickle cell patients (n=10), the % of total red cell expressing 
these AMs (1.82+-0.57,1.92+0.35 and 1.56+0.12% respectively) was decreased 
to about two thirds of the levels in steady state patients. The % of reticulocytes 
was also decreased in HU-treated patients (5.38+0.89%) compared to the 
steady state patients (11.47+0.96%, p<0.05). However, the % of reticulocytes 
expressing these AMs (19.91±4.66,18.02+3.83 and 16.92+2.58% respectively) 
was slightly decreased with no significant difference to either the control subjects 
or steady state or crisis patients. 
AM expression in F*cells 
In control subjects, the % of F+cell expressing AMs (1.14+0.05,1.13+0.04 
and 1.15±0.04% for CID36, CD41 and CID49d respectively) appears to be greater 
than % of total red cells expressing AMs (0.65+0.03,0.65+0.03 and 0.69±0.03% 
respectively) (p<0.01). 
In steady state patients, the % of F"'cells expressing these AMs (2.46+0.26, 
2.39+0.26 and 2.36±0.26% respectively) was significantly higher than control 
subjects (p<0.05), but not significantly different from the % of total red cells 
expressing these AMs (2.89+0.21,2.65+0.21 and 2.77+0.26% respectively). 
Thus, unlike control subjects, the % of F+cells expressing AMs is about the same 
as the % of total red cells expressing AMs. In vaso-occlusive crisis patients, the 
% of F+cells expressing these AMs were 2.39+0.27,2.58+0.26 and 2.01+0.17% 
respectively. These values are significantly higher than the values in control 
subjects (p<0.01) but not significantly different from the values in steady state 
patients. In HU-treated patients, the % of F+cells expressing these AMs 
(1.49±0.10,1.72±0.09 and 1.35+0.10% respectively) was significantly reduced 
(p<0.05) compared to the steady state and crisis patients and was not 
significantly different from the control subjects. (Figure 4.2.2). 
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Figure 4.2.2 Percentages of cells expressing adhesion molecules in 
total RBCs, reticulocytes and F+cells 
A total of 70 blood samples from 23 normal donors (control), 23 sickle cell 
patients in steady state (sickle std), 14 sickle cell patients in crisis (sickle cri) and 
10 sickle cell patients receiving hydroxyurea therapy (sickle HU) were assayed for 
the proportion of cells expressing CD36 (upper), CD41 (middle) and CD49d 
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(lower) in total red cells, reticulocytes and F+cells using three double-colour 
staining flow cytometry. In sickle disorders, the % of AM+cells is increased in total 
RBCs and in the F+cell population, but not in the reticulocyte population. 
(*Significantly higher than controls p<0.01, ASignificantly lower than the sickle std 
p<0.05). 
Discussion 
The proportion of red cells expressing AMs in the total red cell population 
was significantly higher in all three groups of sickle cell patients compared to the 
control group (p<0.01). These findings are in agreement with previous reports 
(Brittain et a/., 1993; Browne & Hebbel, 1996; Joneckis et a/., 1993; Sugihara et 
al., 1992). However, this effect could be secondary to the increased proportion of 
reticulocytes in sickle cell patients, which increased significantly over the control 
subjects (p<0.01) in parallel with increases in AM+cells over the control subjects 
(p<0.01). (Figure 4.1.3) By examining AM expression in the reticulocyte 
populations, it is clear that there is no significant difference in the proportion of 
reticulocytes expressing AMs between sickle cell patients and control subjects. 
Thus the findings in this section disagree with a previous report by Styles et al. 
1997. These findings suggest that qualitatively there is little difference in AM 
expression between sickle cell patients and control subjects. Therefore, the 
increase in AM+cells in total red cells in sickle cell patients is dependent on the 
increase in reticulocytes, not due to the reduction of AM expressing reticulocytes. 
However in this chapter, the proportion of reticulocytes expressing AMs is not 
significantly different between control subjects and sickle cell patients. Thus, it 
clearly shows that the proportion of reticulocytes expressing AMs is unaltered in 
sickle cell patients compared to control subjects. 
Comparison of steady state sickle cell patients and HU-treated sickle cell 
patients, there is a small decrease in the % of total red cells expressing AMs 
(p<0.05). This is consistent with the previous finding that HU treatment not only 
increases HbF level but also reduces sickle red cell adhesion to endothelium 
(Noguchi etah, 1993). HU treatment also reduces soluble AMs in the plasma of 
sickle cell patients (Saleh et al., 1998; Saleh et a/., 1999). Styles et al (1997) 
reported that the reduction of AM expressing red cells with HU treatment was not 
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due to the decrease in reticulocytes. However, the findings in this study suggest 
that the decrease in AM expressing red cells in HU-treated patients is due to the 
fall in reticulocytes after HU-treatment. The percentage of reticulocytes in the HU- 
treated group was 5.6% compared to 11.5% in steady state sickle cell patients. 
The decrease in AM expressing red cells is from 2.7% in steady state to 1.6% in 
HU-treated patients. 
In the F+cell population, AM expression appears to be similar to the red 
cells as a whole, both in control subjects and sickle cell patients. This has not 
been previously reported. The %F+cells expressing AMs in steady state and in 
crisis patients were significantly higher than in control subjects and in HU-treated 
patients. 
4.2.3. Relative adhesion molecule expression in mature red cells and in 
reticulocytes 
Rationale 
Section 4.2.2. showed that in controls, less than 1% of the total red cell 
population expressed AMs and about 20% of reticulocytes express AMs in both 
healthy controls and sickle cell patients. Section 4.2.5 showed that, this 
difference is likely to reflect the shedding of AMs by reticulocytes. In this section, 
the loss of AMs between the reticulocyte stage and the mature red cell stage is 
examined in more detail. This is done in two ways; firstly the O/oAM expression is 
calculated in the R+ (reticulocyte) and R- (mature red cell) populations and 
secondly the %AM expressing cells in mature red cell population is divided by the 
O/oAM expressing cells in reticulocyte population to give an 'adhesion molecule 
depletion ratio' (AMDR). This ratio allows a comparison of the depletion of 
AM'cells in different patient and control groups. 
Study design 
A total of 70 blood samples were obtained from 23 normal donors 
(control), 23 non-transfused sickle cell patients in steady state (Sickle std), 14 
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non-transfused sickle cell patients in crisis (sickle cri) and 10 sickle cell patients 
undergoing hydroxyurea therapy (sickle HU; ranging from 0.5 to 2.0 g/day for 
several weeks and reaching the steady level of %HbF at the time of blood 
sampling). These samples are the same as in section 4.2.2. The percentages of 
AMs expressing cells in total mature red cells and in total reticulocytes were 
obtained and the AMDR of these 3 AMs were calculated. The formula is shown 
below. 
mature red cells expressing AMs 
Adhesion molecule depletion ratio = ------- --- - ------------ - --------- 
% reticulocytes expressing AMs 
Results 
Table 4.2. Percentages of mature red cells (MRCs) and reticulocytes (retics) 
expressing AMs and the adhesion molecule depletion ratio (AMDR) 
Control (23) SS stcl (23) SS cri (14) SS HU (10) 
%CD36'MRCs 0.35±0.02 0.6Q+_0.04* 0.55±0.09* 0.43±0.08* 
%CD36'redcs 21.58±0.87 22.23±1.59 22.19+3.24 19.91±3.67 
CD36 AMDR 0.010+0.005 0.027±0.014* 0.025±0.016* 0.022+0.015' 
%CD41"MRCs 0.34+0.02 0.67±0.04* 0.64+0.08* 0.55±0.07* 
%CD41+retics 21.03±1.04 19.48±1.51 21.41±3.76 18.02+3.83 
CD41 AMDR 0.016+0.005 0.034+0.016* 0.030+0.024' 0.031+0.029* 
%CD49d'MRCs 0.35±0.02 0.66+0.04* 0.63±0.06* 0.53±0.09* 
%CD49d'retics 22.19±0.90 19.65±1.52 19.63±3.14 16.92±2.58 
CD49d AMDR 0-01(ý±0.004 0.034+0.017* 0.032+0.021* 0.031+0.010* 
The pattern of %CD36, %CD41 and %CD49d expressing cells is similar 
and is referred to as AMs. %AM+reticulocytes are significantly higher than 
%AM+mature red cells in all groups. %AM+mature red cells are significantly 
higher in all groups of sickle cell patients than in control group (*p<0.01). 
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However, %AM+reticulocytes are not significantly different in all groups of sickle 
cell patients and in control group. The significant higher AMDRs in all groups of 
patients ("p<0.05) over the control group, reflects a higher proportion of red cells 
expressing AMs after the reticulocyte stage in sickle cell disorders. 
In HU-treated sickle cell patients, it appears to have similar patterns of 
changes between these 3 AMs. CD36 is expressed in 19.91% of reticulocytes 
compared to 22.23% of reticulocytes in the steady state patients, with no 
significant difference. CD36 is expressed in a lower proportion (p<0.05) of 
mature red cells in HU-treated patients (0.43%) than in steady state patients 
(0.60%). The rest of 2 AMs are also expressed in a similar trend as CD36. 
Discussion 
In both normal control subjects and sickle cell patients, the proportion of 
total mature red cells expressing AMs was significantly lower than those in total 
reticulocytes (p<0.0001). The AMDRs in the control subjects were all lower than 
0.02 indicating that the majority of AM+celIs (over 98%) shed their AMs completely 
or less than 2% of the cells carry the AMs when they mature from the reticulocytes 
to mature red cells. AMDRs in sickle cell patients were significantly higher than 
those in control subjects (p<0.05) and less than 7% of cells remain carrying AMs 
beyond the reticulocyte stage. A likely explanation is that the average age of red 
cells is significantly shorter in sickle cell patients than in healthy controls. Thus a 
relatively high proportion of cells in sickle cell patients are at an younger age 
where AMs have not been completely shed but are RNA negative (i. e. day 3-5 
after released from the bone marrow). This would mean that the proportion of 
AM+mature red cells relative to AM+reticulocytes would be greater in sickle cell 
patients than in control subjects, hence the AMDRs would be greater too. 
Therefore, the difference in AMDR between sickle cell patients and control 
subjects is likely to reflect the higher proportion of young red cells at the post- 
reticulocyte stage in sickle cell patients. 
In conclusion, the findings using double-colour staining in this section 
show that AMs are found on reticulocytes at a similar percentages in controls and 
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in sickle cell patients and suggest that AMs are rapidly shed from red cells, 
persisting only a few days beyond the reticulocyte stage. Unanswered questions 
from this section include whether AMs are expressed in similar proportions in 
F+reticulocytes and F+reticulocytes in sickle cell patients and in control subjects. 
A further question is how hydroxyurea treatment affects this. Triple-colour staining 
offers the possibility of answering these questions and is described in section 
4.3. 
4.2.4. Relative adhesion molecule expression in F positive and F negative 
populations 
Rationale 
In section 4.2.2, the finding in control subjects of a higher %F+cells 
expressing AMs than in the red cell population as a whole, suggests that F"'cells 
express more AMs than F'cells. In this section, the difference is formally 
compared. The expression of AMs in F+cells and F-cells is potentially important 
because HU treatment typically increases the number of F+cells. It is not 
presently known whether F+cells express more or less AMs than F'cells, either in 
healthy controls or in sickle cell patients. In order to compare the proportion of PM 
expressing cells in F+cell and F-cell populations, normal control and sickle cell 
blood samples were assayed using three double-colour staining flow cytometry. 
Study design 
A total of 70 blood samples were obtained from 23 normal donors 
(control), 23 non-transfused sickle cell patients in steady state (sickle std), 14 
non-transfused sickle cell patients in crisis (sickle cri) and 10 sickle cell patients 
undergoing hydroxyurea therapy (sickle HU) (the same samples as topic 4.2.2). 
These were assayed for the proportion of AM expressing cells in HbF positive 
and HbF negative populations. 
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Results 
The results show that in control subjects, AMs are expressed in a 
significantly lower % of F-cells than F+cells. In sickle cell patients in steady state 
and in crisis, the proportion of AM+cells is about the same in F-cell and F+cell 
populations. However, in HU-treated sickle cell patients there are significantly 
higher AM+cells in the F-cell than F+cell populations. (Figure 4.2.4. ) 
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Figure 4.2.4 Comparison of the percentages of cells expressing adhesion 
molecules in HbF positive and HbF negative populations 
A total of 70 blood samples from 23 normal donors (control), 23 sickle cell 
patients in steady state (sickle std), 14 sickle cell patients in crisis (sickle cri) and 
10 sickle cell patients receiving hydroxyurea therapy (sickle HU) were assayed for 
the proportion of cells expressing CD36 (top), CD41 (middle) and CD49d 
(bottom) on F+cell and F-cell populations using three double-colour staining flow 
cytometry. (^Significant lower than F+cells p<0.001, *Significantly higher than 
F+cells p<0.05). 
The percentages of AM expressing cells in F+cell and F-cell populations are 
shown in Table 4.2.4 
Table 4.2.4 Percent AM expressing cells in F+cell and F-cell populations 
%AM'cells Control (23) SS. std. (23) SS. cri. (14) SS. HU. (10) 
%CD36'(F*cells) 1.14±0.05 2.46±0.26 2.32±0.31 0.90±0.12 
%CD36' (Fcells) 0.64±0.03 3.26±0.28 2.42±0.21 1.75±0.37 
%CD41' (Fcells) 1.13±0.04 2.39±0.26 2.53±0.21 1.43±0.23 
%CD41'(F-cells) 0.62±0.03 2.98±0.27 2.09±0.27 1.97±0.43 
%CD49d' Pcells) 1.15±0.04 2.36±0.26 2.12±0.17 1.20±0.17 
%CD49d' (F-cells) 0.67±0.03 3.14±0.33 2.30±0.24 2.12±0.35 
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Discussion 
It is clear that AM expression is higher in steady state and crisis sickle cell 
patients than in normal controls, both in F+cells and F'cells. In control subjects, 
the proportion of AM expressing cells in the F+cell population is significantly 
higher (p<0.001) than in Fcell population. One possibility is that the age 
distribution of F+cells and F-cells differs, with F+cells being more primitive. In 
healthy individuals, F+cell survival is similar to ordinary red cells, which contain 
HbA alone (Boyer et aL, 1975). Their age different between F+cells and F'cells is 
unlikely to be the reason for carrying more AMs in F+cells. It is possible that in 
healthy individuals, F+cells are qualitatively different from F'cells at the time of 
release from bone marrow in ways, which are unrelated to HbF content, as 
demonstrated here by carrying a higher proportion of AMs. Only limited data 
about the detailed phenotype of F+cells as compared with F-cells are available 
(Burns et al., 1988). Ii antigen expression (Maniatis et a/., 1979) or carbonic 
anhydrase isoenzymes or 'y to 'y ratio (Rees et al. 1996) show no qualitative 
difference in F+cells and F'cells. Therefore the reason for high proportion of PM 
expressing cells in the F+cell population in normal healthy individuals is 
unknown. 
A further finding in this section is that, in sickle cell patients the proportion 
of AM expressing cells in the F+cell population is relatively similar to that in the F 
cell population unlike in control subjects. Indeed, the proportion of F'cells 
expressing AMs tends to be greater than the proportion of F+cells expressing 
AMs, and this reaches significant level only in HU-treated patients. A possible 
reason may be because Fcells survive less well than F+cells in sickle cell 
disease (section 4.1.4), so that the F-cells are younger than F+cells. Thus, if AMs 
are shed or preferentially removed as a function of ageing (section 4.2.5), then it 
would be expected that there would be less AMs in the F+cell population, which 
survives better in sickle cell disorders. 
In HU-treated patients, the proportion of F-cells expressing AMs is 
significantly greater than in F+cells. A possible explanation is that F'cells after HU 
treatment represent a significantly younger population than F+cells because F 
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cells are removed more rapidly from the circulation as a result of more rapid HbS 
polymerisation than in F+cells. This question is addressed directly in section 4.3 
where AM expression is compared in reticulocytes and mature red cells of 
F+cells and F'cells using triple-colour staining. 
This is the first study to examine AM expression in F+cells and F-cells. 
These findings provide the first evidence of differences in AM expression 
between F+cells and Fcells in healthy individuals. These are also the first 
findings showing that the distribution of AMs in F+cells and F-cells differs in sickle 
cell patients and healthy control subjects. The clinical significance of the findings 
will be discussed further at the end of the chapter. In order to learn these findings 
better, it is necessary to understand more about the effect of red cell ageing on 
AM expression. No previous studies addressing this issue are found and 
therefore in vitro sickle reticulocyte culture experiment is performed to determine 
the effect of red cell ageing on AM expression. 
4.2.5. AM expression as a function of sickle reticulocyte maturation during in 
vitro culture 
Rationale 
The findings in 4.2.2 show that 1% of red cells express AMs whereas 
about 20% of reticulocytes express AMs. This suggests that either AMs are 
rapidly shed from red cells, before or shortly after the reticulocyte stage, or that 
AM expressing reticulocytes are preferentially removed from the circulation. Little 
is known about AM loss from reticulocytes. In order to address this question, 
measurement of AM expression as a function of time in culture of red cells taken 
from patients with sickle cell disease was performed. After 3 days of culture most 
reticulocytes typically become mature red cells, no longer containing RNA. If the 
shedding hypothesis is correct, after 3 days in culture there should be a reduced 
proportion of cells expressing AMs. On the other hand, if the clearing hypothesis 
is correct, the same or nearly the same proportion of cells should express AMs 
as at the start of the culture. The double-colour staining developed in chapter 3 
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allowed us to examine whether AM expression changes at a faster or slower rate 
than the disappearance of reticulocytes. 
Study design 
A total of 8 blood samples from sickle cell patients in steady state were 
collected in EDTA vacutainers. The blood samples were cultured in vitro for 15 
days (section 2.5.6). The samples were assayed for proportions of AM 
expressing cells and reticulocytes on days 0 (within the first hour of culture), 1,2, 
3,4,5,10 and 15 respectively, using three double-colour staining flow cytometry 
(section 3.4.2). 
Results 
Mean percentages of reticulocytes (n=8) on days 0,1,2,3,4,5,10 and 15 
of culture were 9.0±2.0,3.4+0.8,2.0+0.3,1.2+0.1,1.0+0.1,0.9+0.1,0.8±0.1 and 
0.7+0.1% respectively. Each consecutive day showed a significant reduction 
(p<0.05) in the mean % of reticulocytes compared to the previous day for the first 
3 days, whereas the reductions between day 3 and day 4 through day 15 were 
not significantly different. 
Mean %CD36+cells from the above samples were 1.5+0.08,1.2+0.06, 
1.0+0.06,0.8+0.06,0.7+0.06,0.6+0.04,0.6+0.04 and 0.5+0.04% on each day 
respectively. Reductions on consecutive days were significant (p<0.01) when 
compared to the value of the previous day, except for reductions between day 5 
and day 10 and between day 10 and day 15 where the reductions were not 
significantly different. 
Mean %CID41+cells from the above samples were 1.6+0.10,1.2+0.07, 
1.1±0.05,1.0+0.03,0.9+0.04,0.8+0.04,0.7±0.03 and 0.7+0.04% respectively. 
The reductions were as same as of %CD36+cells above. 
Mean %CD49d+cells of the same samples as above were 1.7+0.14, 
1.4±0.10,1.2+0.07,1.1±0.05,1.0+0.03,0.8+0.04,0.8+0.04 and 0.7±0.03% on 
each day respectively. The reductions were as same as of %CD36+cells above. 
(Figure 4.2.5) 
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Figure 4.2.5 Reductions in percentages of reticulocytes and AM expressing 
cells in culture in vitro 
A total of 8 sickle cell blood samples were cultured in RPMl-1 640 supplemented 
with CPD, FCS, penicillin and streptomycin at 370C, in 5% C02 atmosphere for 15 
days. Percentages of reticulocytes and AM (CD36, CD41 and CD49d) expressing 
cells were determined by three double-colour staining flow cytometry. 
Percentages of reticulocytes were significantly lower than the value of the day 
before for the first 3 days (p<0.05). Percentages of all 3 AM expressing cells were 
significantly lower than the value of the day before for the first 5 days (p<0.01). 
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Discussion 
The results clearly show a reduction in the % reticulocytes over 3 days in 
culture. Levels fell from 9% on day 0 to approximately 1% by day 3, indicating that 
nearly all sickle reticulocytes became mature red cells within 3 days of culture. 
This finding is consistent with the reticulocyte maturation rate of about 3 days 
(McKenzie, 1996). 
The results also show that proportions of all 3 AM expressing cells fell 
within the first few days in culture, reaching baseline levels at 5 days. Thereafter 
the levels do not fall further. It is likely that these levels represent the limit of 
detection of the assay. 
These findings are important in the interpretation of results in section 4.2.2 
and 4.2.3 and also confirm the findings of other investigators (Swerlick et al. 
1993; Gee et al. 1995; Styles et al. 1997). The implications are that the small % of 
AM*mature red cells seen both in healthy subjects and in sickle cell patients 
primarily reflects shedding of AMs from reticulocytes within 5 days of release 
from the bone marrow. Therefore changes in the % of cells expressing AMs 
could occur as a result of changes in the mean age of the cell population being 
studied. A younger population of reticulocytes would be expected to express 
more AMs than an older population. Therefore HU, which can prolong red cell 
survival by increasing HbF, decreases the proportion of reticulocytes and PM 
expressing cells, but might also be expected to allow a greater number of 
F'reticulocytes to age into red cells. The results in Table 4.2.3 show a small 
decrease (with no significant difference) in the % of reticulocytes expressing AMs 
in HU-treated patients compared to non-HU-treated patients (from about 20% to 
18%) which is consistent with the cells ageing because of reduction in 
haemolysis. This finding differs from Styles et al. 1997, who found a significant 
decrease in the % of reticulocyte expressing AMs. However the patients in that 
study were all children (aged between 2-15 years) and mainly males (7 male and 
1 female), while in this thesis a mixture of both children and adult (aged between 
12-57 years) and more balanced gender (6 male and 4 female) were studied. 
These factors may give a different outcomes 
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4.3. CO-DISTRIBUTION OF ADHESION MOLECULES AND FOETAL HAEMOGLOBIN 
4.3.1. Background 
Triple-colour staining flow cytometry for determination of the co-distribution 
of AMs (CD36, CD41 and CD49d), HbF (F+cells) and RNA (reticulocytes) was 
employed (section 3.4.3) in this section. Using this method, the red cells are 
divided into many sub-populations, which can be grouped into 3 groups. Single 
variables consist of AM+, AM', F+, F, R+ and R" subpopulations. Double variables 
consist of AM+F+, AM+F, AKF+, AM-F, AM+R+, AM+R-, AM-R+, AM-R7, F+R+, F+R', F 
R+ and FR-. Triple variables consist of AM+F+R+, AM+F+R7, AM+FR+, AM-F+R+, 
AM+FR', AM-FR+, AM-F+R- and AM-FR-. Questions that can in principle be 
answered with triple-colour analysis are as follows. 
Does the proportion of F+cells expressing AMs differ from the proportion of 
F-cells expressing AMs at the reticulocyte (R+) stage? This is potentially important 
because if recently released F+reticulocytes from the bone marrow are 
qualitatively different and express more AMs than Freticulocytes, then the 
beneficial effect of HU treatment on increasing F+cells could be counteracted by 
an increase in AMs on such cells. 
To what extent can the presence of HbF in sickle red cells affect the 
proportion of cells with residual AM expression beyond the reticulocyte stage (R' 
or mature red cell stage) in sickle cell disorders? 
How does HU treatment affect the distribution of AMs on F+cells and Fcells 
at the reticulocyte stage? If HU treatment decreases AM expression on 
F+reticulocytes then there could be a double benefit on red cell survival. 
Does HU treatment decrease the AM expressing cells simply by 
decreasing the reticulocyte numbers or does the HU-treatment reduce % of AMs 
expressing reticulocytes? 
Does the effect of HU on HbF and AM expression have a similar kinetic or 
does the decrease in AM expression begin first? 
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4.3.2. Comparison of single variables obtained from triple-colour and double- 
colour staining 
Rationale 
In section 4.2, a number of single variables were measured using double- 
colour staining. In this section the same variables were investigated using the 
triple-colour staining procedure. If the analysis is valid, then the proportions of 
cells in each category should be approximately the same as using double-colour 
staining procedure. The patient groups studied here are similar but using 
different groups of patients and control subjects. Therefore the values obtained 
will not be identical. However in section 3.4.4 and 3.4.7, these values were 
comparable using double- and triple-colour staining. 
Study design 
Blood samples from 30 normal control subjects (Control), 35 non- 
transfused sickle cell patients in steady state (SS. std. ), 22 non-transfused sickle 
cell patients in crisis (SS. cri. ) and 10 sickle cell patients undergoing HU therapy 
(SS. HU. ) at University College London Hospitals (UCLH), London, UK were 
taken into either EDTA, citrate, heparin or CTAD. Plasma was removed then 
Alsever : PBS (1: 1) was added to the red cells to give approximately 45-50% 
haernatocrit and the suspension was kept at 40C. The samples were assayed 
using triple-colour staining flow cytometry (section 3.4.3) within 3 days of 
collection. %HbF was assayed by HPLC (section 2.5.2). 
Results 
Percentages of red cell sub-populations in control subjects (n=30), SS. std. 
(n=35) SS. cri. (22) and SS. HU. (n=10) are shown in Table 4.3.2.1. 
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Table 4.3.2 Comparison of patient data and single variables 
Variable Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
Age (yr. ) 
Sex (m: f) 
RBCs (106/gl) 
Hb (g/dl) 
HbF (%) 
Pcells % 
number 
Retics % 
number 
CD36*cells % 
number 
CD41 *cells % 
number 
CD49d*cells % 
N. D. 
N. D. 
4.70±0.074 
13.86±0.23 
0.78±0.10 
4.22±0.21 
199.23±10.78 
1.57±0.05 
74.02±2.92 
0.66±0.02 
31.02±1.32 
0.65±0.03 
30.97±1.46 
0.69±0.03 
25.69±2.32 30.09±2.12 35.20±4.88 
15: 20 10: 12 6: 4 
2.87±0.12A 2.78±0. JOA 2.69±0.14A 
8.02±0.19A 7.77±0.29A 8.64±0.44A 
6.43±0.69* 5.10±0.5 1* 22.18±1.76* 
29.96±2.53* 24.43±2.13* 59.38±3.41*1 
822.05±63.41 * 660.94±55.71 1584.07±102.35*1 
11.14±0.68* 9.74±0.74* 7.37±0.89* # 
319.00±20.64* 
3.05±0.29* 
92.35±11.44* 
2.88±0.30* 
86.87±11.52* 
3.04±0.32* 
265.81±20.98* 
2.66±0.24* 
73.73±6.78* 
2.40±0.19* 
66.72±5.83* 
2.74±0.29* 
196.68±26.83* 
1.96±0.21 ** 
52.92±6.86* 
2.00±0.17** 
54.14±5.94* 
2.08±0.20** 
number 32.71±1.46 92.29±12.3 1* 75.73±7.49* 56.16±6.83* 
All parameters are presented as mean±SEM, SS = sickle cell patients, std = in 
steady state, cri = in crisis, HU = on hydroxyurea treatment, N. D. = No data, m: f 
= male : female, Retics = reticulocytes 
A significantly lower than control p<0.001, * significantly higher than control 
p<0.001,9 significantly higher than SS. std. p<0.001, * significantly lower than 
SS. std. P<0-05, 
Discussion 
In these groups of controls and patients, the findings broadly are similar to 
those in section 4.2. As expected, the RBC and Hb are lower in sickle patients 
than in controls. The number and % of reticulocytes are higher in sickle cell 
patients than controls (*p<0.001) and lower in HU-treated patients than in steady 
state patients ýp<0.05). The numbers and % of F+cells are higher in sickle cell 
patients in steady state than in controls (*p<0.001) and higher in HU-treated 
patients than in steady state patients (p<0.001). The numbers and % of AM 
expressing cells is higher (p<0.001) in sickle cell patients in steady state than in 
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controls and lower in HU-treated patients than in steady state patients (p<0.05). 
These findings agree with section 4.2. 
4.3.3. Comparison of double variables obtained from triple-colour analysis and 
double-colour analysis 
Study design 
In this section, the co-distributions of HbF in reticulocytes and mature red 
cells; of RNA in F+cells and F"cells; of AMs in reticulocytes and mature red cells 
and of AMs in F+cells and F'cells were measured using triple-colour staining. 
The results should broadly agree with those in sections 4.1 and 4.2, if the triple- 
colour staining is valid. In addition to sections 4.1 and 4.2, absolute numbers of 
these populations as well as proportions are determined. 
Results and discussion 
HbF expression in reticuloc&e (RNA+-) and mature red ce/l (RNA--) populations 
In section 4.1.3, the proportions of F+reticulocytes and F+cells were 
compared. In this section, absolute numbers are measured as well as 
proportions. Additionally F+cells are compared, specifically in reticulocyte (R) 
and mature red cell (R') populations, rather than in the total red cell population as 
in section 4.1.3. 
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Table 4.3.3.1 HbF expression in reticulocyte (R+) and mature red cell (R-) 
populations (to be compared with 4.1.3) 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
Freticulocyte % 4.36±0.20 
number 3.21±0.20 
12.88±0.88* 
39.42±3.13* 
13.13±1.37* 26.25±2.43** 
Fmature red cell % 4.23±0.21 
number 195.90±10.70 
P enrichment ratio 1.00±0.04 
34.35±3.99* 48.54±5.95*" 
32.19±2.78* 1 25.70±2.27*1 62.22±3.71*"l 
789.40±60.37*1 626.59±53.06*1 1535.98±100.26*'ý 
2.51±0.15* 2.62±0.26* 2.12±0.15* 
All parameters are presented as mean±SEM, number = X103 / CU. MM. ' 
SS. = 
Sickle cell patients, std. = in steady state, cri. = in crisis state, HU. = on 
hydroxyurea, F= foetal haernoglobin (HbF), R= RNA (reticulocytes) 
* significantly higher than control p<0.05, # significantly higher than SS. std. 
p<0.05,5 significantly higher than F+reticulocytes p<0.001, 
These findings show that in control subjects, the proportion of F+cells in 
reticulocytes and mature red cells is similar. This means that the distribution of 
F+cells and F'cells in healthy controls is likely to be similar. This has not been 
shown previously. In section 4.1.3, the % of F+reticulocytes was compared with 
F+cells in the total red cell population, but the analysis in this section is more 
precise because it compares reticulocytes (R) with mature red cells (R-) rather 
than the total red cell population. 
As expected, the number of F+mature red cells is greater than the number 
of F+reticulocytes, because the number of red cells is greater than the number of 
reticulocytes. In all groups of sickle cell patients, the proportion of F+mature red 
cells exceeds that of F+reticulocytes by about two fold, as reflected by the ER over 
2.00. These ERs are in agreement with section 4.1.4, which was obtained from 
double-colour staining. (Table 4.3.3.1) 
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Reticulocyte distribution in F' and F populations 
Table 4.3.3.2 Reticulocyte (RNA) expression in F+cell and Fcell populations 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
R* (Fcells) % 1.66±0.11 
number 3.21±0.20 
R' (Fcells) % 1.57±0.06 
5.16±0.40* 
39.42±3.13* 48.54±5.95*" 
15.56±1.03*1 11.36±0.91*1 14.56±2.28*1 
5.21±0.44* 
34.35±3.99* 
3.10±0.38* 
number 70.81±2.811 278.74±19.22*1 231.52±19.91*1 148.14±22.27*1^ 
All parameters are presented as mean±SEM, number = x10*3 / cu. mm., SS. = 
Sickle cell patients, std. = in steady state, cri. = in crisis state, HU. = on 
hydroxyurea, F= foetal haemoglobin (HbF), R= RNA (reticulocytes), R+(F+cells) 
=% of F+cells containing RNA or F+retics in total F+cells, R+(F-cells) =% of F 
cells containing RNA or Fretics in total F-cells, retics = rteticulocytes. 
* significantly higher than control p<0.05, § significantly higher than F+cells 
p<0.01, * significantly higher than SS. std. p<0.05, Asignificant lower than SS. std. 
P<0.01 
These findings show that F+cells and F'cells contain the same proportion 
of reticulocytes in healthy controls and that therefore the age distribution up to the 
reticulocyte stage is similar in F+cell and F-cell populations. Thus the observed 
difference in the proportions of AMs in F+cell and F-cell populations seen in 
section 4.2.4 is unlikely to be due to the age differences of the cells. This 
suggests that in healthy controls, F+cells contain more AMs than F"cells. This 
question can only be answered directly using triple-colour analysis for co- 
distribution of F+, R+ and AM+, which is performed, in section 4.3.4. 
In all sickle cell patient groups, the %reticulocyte is lower (p<0.001) in 
F*cell than in F'cell populations, consistent with a higher % of cells maturing 
beyond the reticulocyte stage in F+cell than in F-cell populations. The data 
comparing the number and %reticulocytes within F+cell and F-cell populations 
has not been presented before. (Table 4.3.3.2) 
When absolute numbers of F+cell and F'cell populations are examined, in 
patients on HU treatment, the number of R+F+cells increases compared with 
steady state patients (p<0.01), whereas the number of R+F-cells decreases 
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(p<0.01). This is consistent with an increase in release of F+reticulocytes from 
the bone marrow following HU treatment. 
Distribution of AM expressing cells in reticulocyte and in mature red ce// 
pQpulations 
In this section the distribution of AMs in reticulocytes and mature red cells 
is compared. The results in this section are directly comparable with those in 
4.2.3; the difference being that the data were obtained from triple-colour staining 
rather than double-colour staining. The patient and control samples were 
independent of section 4.2.3, but the sample size was larger. Despite these 
differences, the results are essentially similar to those of section 4.2.3. 
Table 4.3.3.3 Distribution of AM expressing cells in reticulocyte and mature 
red cell populations (to be compared with 4.2.3) 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
CD36'mature red cells % 0.32±0.02 0.76±0.15* 0.64±0.07* 0.64±0.10* 
number 15.03±0.99 21.19±4.95 15.88±1.90 15.88±2.66 
CD36"reticulocytes % 22.63±0.985 23.09±1.651 22.31±1.931 19.23±1.401 
number 16.17±0.82 71.21±7.46*1 57.86±5.84*1 37.04±5.05*1 
CD36* AMDR 0.015±0.001 0.034±0.003* 0.032±0.004* 0.035±0.006* 
CD4 I"mature red cells % 0.31±0.020 0.85±0.17* 0.71±0.07* 0.77±0.07* 
number 14.69±0.99 23.08±5.20 17.20±1.36 19.34±1.98 
CD41*reticulocytes % 22.14±1.021 20.52±1.441 20.20±2.311 18.17±1.331 
number 16.27±0.98 65.49±8.39*1 49.52±5.65*1 37.18±5.23*1 
CD41" AMDR 0.015±0.001 0.044±0.005* 0.047±0.006* 0.046±0.006* 
CD49d'mature red cells % 0.33±0.02 0.86±0.17* 0.77±0.12* 0.81±0.09* 
number 15.25±1.06 23.23±5.07 18.57±2.55 20.16±2.46 
CD49d'reticulocytes % 23.43±1.061 21.43±1.651 21.64±1.961 18.45±1.431 
number 17.44±0.91 69.07±8.35*1 55.42±5.33*1 36.47±5.70*1 
CD49d* AMDR 0.014±0.001 0.042±0.004* 0.041±0.006* 0.047±0.007* 
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All parameters are presented as mean±SEM, number = X103 / CU. MM. ' 
SS. = 
Sickle cell patients, std. = in steady state, cri. = in crisis state, HU. = on 
hydroxyurea, F= foetal haemoglobin (HbF), R= RNA (reticulocytes), 
* significantly higher than control p<0.05,6 significantly higher than mature red 
cells P<0.001, 
Distribution of AM expressing in F"cel/ and Fce// populations 
In this section, the distribution of AMs in F+cells and F-cells is compared. 
The results in section are directly comparable with those in 4.2.4; the difference 
being that the data were obtained from triple-colour staining rather than double- 
colour staining. The patient and control samples were independent of section 
4.2.4 but the sample size was larger. Despite these differences, the results are 
essentially similar to those of section 4.2.4. 
Table 4.3.3.4 Distribution of AM expressing cells in F+cell and Fcell 
populations (to be compared with 4.2.4) 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
CD364 (Pcells) % 1.35±0.13 2.09±0.23* 1.89±0.24* 0.76±0.08* 
number 2.56±0.22 15.44±1.44* 11.81±1.83* 12.87±1.94* 
CD36* (F-cells) % 0.63±0.02A 3.64±0.35* 2.97±0.30* 4.07±0.63*1 
number 28.62±1.271 76.73±10.73*1 61.92±6.22*1 40.31±6.12*1" 
CD41* (Pcells) % 1.29±0.11 2.07±0.24* 2.09±0.23 * 0.98±0.09* 
number 2.50±0.22 15.39±1.75* 12.76±1.5 1* 15.60±1.75* 
CD41+ (F-cells) % 0.62±0.03 A 3.43±0.36* 2.58±0.25* 3.93±0.54*1 
number 28.44±1.361 71.47±10.40*1 53.97±5.71*1 38.93±5.48*1* 
CD49d* (Pcells) % 1.33±0.12 2.13±0.29* 1.86±0.16* 0.97±0.09" 
number 2.49±0.20 16.58±2.52* 11.34±1.05* 15.79±2.23* 
CD49d* (Fcells) % 0.67±0.03A 3.65±0.37* 3.04±0.36* 3.95±0.57*1 
number 29.91±1.361 76.24±10.83*1 62.65±6.5 1 *1 40.83±6.00*1" 
All parameters are presented as mean t SEM, number = xlOa / cu. mm., SS. = 
Sickle cell patients, std. = in steady state, cri. = in crisis state, HU. = on 
hydroxyurea, F= foetal haemoglobin (HbF), R= RNA (reticulocytes) 
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* significantly higher than control p<0.05,5 significantly higher than F+cells 
p<0.05 ,A significantly lower than F+cells p<0.01, significantly lower than SS. std. p<0.05, 
Discussion 
The percentages of F+cells, F+mature red cells and F+reticulocytes in 
sickle cell patients both with hydroxyurea therapy (SS. HU) and without (SS. std. 
and SS. cri. ) are significantly higher than in control subjects and these 
proportions in SS. HU. are also significantly higher than SS without HU as 
expected. The %reticulocytes are also increased in sickle cell patient groups 
compared to the control group, but in SS. HU. the %reticulocytes were significantly 
lower than in SS without HU. These findings show the effectiveness of 
hydroxyurea in increasing the production of HbF and its ability to suppress bone 
marrow, which is shown by a reduction in the %reticulocytes. 
The %AM+cells in SS. HU. are significantly lower than in SS without HU 
(SS. std. and SS. cri), but in all sickle cell patient groups %AM+cells were 
significantly higher than in the control group. This reconfirms the previous 
findings of increased AM+cells in total red cells of sickle cell patients. However, 
hydroxyurea treatment appeared to reduce these proportions. This may be the 
explanation of improvement of the clinical symptoms that occurs even before the 
increasing in HbF levels. 
These findings are in agreement with section 4.2 where double-colour 
staining was used. This indicates that either double- or triple-colour staining 
gives roughly the same results for both single and double variables. 
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4.4. INFLUENCE OF FOETAL HAEMOGLOBIN ON ADHESION MOLECULE 
EXPRESSION 
Rationale 
The advantage of triple-colour staining is the ability to determine triple 
variables such as AM+F+R+, AM+F+R-, AM+FR+, AM-F+R+, AM+FR7, AM-F+R-, AM-F 
R+ and AM-FR- subpopulations. Mature red cells are defined as R'cells or red 
cells without RNA, while reticulocytes are defined as R+cells or red cell with RNA. 
These variables may provide a greater understanding of the contribution of HbF, 
AMs and ageing status on the survival of red cells in sickle cell disorders 
especially when the patients has been treated with hydroxyurea. 
Study design 
In this section, triple-variables are obtained from triple-colour staining in 
order to compare these variables in control subjects and sickle cell patients in 
steady state, in crisis and on HU treatment. The patient groups and samples are 
identical to those in section 4.3.2. 
Results and discussion 
Fý'reticylocyfes and Freticulocytes Wressing A 
The results are shown in absolute numbers in Table 4.4-1. and in % in 
Ficiure 4.4.1. 
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Table 4.4.1 Absolute numbers of F+reticulocyte and Freticulocyte expressing 
AMs 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
AM expressing F+ve reticulocytes 
CD36'PRetics 1.08±0.09 9.37±1.02* 7.59±1.52* 4.83±1.29** 
CD41+F+Retics 1.05±0.09 8.12±0.9 1* 6.77±1.06* 5.47±1.30** 
CD49d+F+Retics 1.04±0.08 8.70±1.22* 6.33±0.90* 5.33±1.26*" 
AM expressing F-ve reticulocytes 
CD36*F-Retics 15.09±0.78 58.44±6.22* 50.26±5.3 1* 32.47±5.27** 
CD41'F-Relics 15.24±0.95 51.61±6.09* 42.74±5.31 * 29.73±5.13*" 
CD49d*FRetics 16.40±0.89 56.98±6.81 49.09±5.19* 31.13±5.70*" 
AM negative F+ve reticulocytes 
CD36-F*Retics 2.11±0.14 29.72±2.53* 27.51±3.96* 43.11±6.66*4 
CD4 I TRefics 2.19±0.15 30.69±2.63* 27.22±3.50* 45.28±5.22*' 
CD49d-F'Retics 2.17±0.15 30.07±2.77* 27.62±3.88* 41.60±5.66*1 
AM negative F-ve reticulocytes 
CD36-F-Retics 54.17±2.44 206.19±14.03* 180.92±16.25* 11 3.73±15.24** 
CD4 I T-Retics 55.82±2.60 212.32±13.94* 183.12±17.45* 117.5 1± 19.09 
CD49d-F-Retics 55.71±2.53 215.60±13.18* 185.75±18.65* 11 9.84±20.2 1 
Absolute number at x1 0' cells/ýd, SS. = Sickle cell patients, std. = in steady state, 
cri. = in crisis state, HU. = on hydroxyurea, F= HbF (foetal haemoglobin), R 
RNA (reticulocytes), Retics = reticulocytes 
significantly higher than control p<0.05, significantly higher than SS. std. 
A 
p<0.05, significantly lower than control p<0.01, significantly lower than SS. std. 
P<0.05, 
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Figure 4.4.1 Percentages of F+reticulocytes and Freticulocytes expressing 
AMs CID 36 (top), CD41 (middle) and CD49d (bottom). 
In control subjects, there are about 15 times more number of 
F+reticulocytes expressing AMs than number of Freticulocytes expressing AMs. 
This is compatible with the greater number of Freticulocytes about 23 times 
(70.81 X103/CU. MM. ) than F+reticulocytes (3.21 X, 03/CU. MM. ) previously shown in 
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Table 4.3.3.2, suggesting an enrichment of AM expression in F+reticulocytes 
relative to Freticulocytes. In order to confirm this, an analysis of the %AM+celis in 
F+reticulocytes and Freticulocytes was undertaken and this is shown in Figur 
4.4.1. AM expressing cells are present in a greater proportion in F+reticulocytes 
than in Freticulocytes in control subjects. This suggests that F+reticulocytes differ 
from Freticulocytes not only in expressing HbF but also in retaining a greater % 
of AMs. This finding is the first demonstration of a difference between 
F+reticulocytes and Freticulocytes, apart from HbF content, and would be 
compatible with the idea that F+reticulocytes represent a subpopulation which 
has been released from the bone marrow having undergone less divisions and 
being more primitive than Freticulocytes. The finding here of more AM 
expression in newly released F+reticulocytes than in Freticulocytes is the first 
evidence to support this concept. 
In patients with SS (steady state or crisis), the proportion of F+reticulocytes 
and Freticulocytes expressing AMs is approximately the same, unlike in control 
subjects. A likely explanation is that the survival advantage of cells containing 
HbF leads to an older age distribution in F+reticulocytes related to Freticulocytes. 
In other words, F-cells are being preferentially removed even at the reticulocyte 
stage compared to F+cells. In HU treated patients it would be expected that this 
effect would be even more marked if the HbF content and % of F+reticulocytes is 
increased. 
In HU treated patients, the %F+reticulocytes expressing AMs is significantly 
less than the %F-reticulocytes expressing AMs, consistent with the idea that a 
higher proportion of F+cells survive long enough to lose more of their AMs than F 
cells which survive shorter in HU treated patients. In section 4.5, evidence will be 
provided that there is indeed a higher HbF content in HU treated patients, further 
supporting this explanation. In Figure 4.2.5. AMs fall to undetectable levels after 5 
days in culture. In the same culture, reticulocytes fell more rapidly, reaching 
undetectable levels by day 3. The findings in Figure 4.4.1 therefore suggest that if 
the survival difference in F+reticulocytes and Freticulocytes explains the 
decreased %F+reticulocytes expressing AMs following HU treatment, then many 
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cells would be removed from the Freticulocyte population within 3 days of 
release from the bone marrow. In section 4.5 this question is addressed again, 
in paired analysis of the same patients before and after HU treatment. 
Overall in this section, it is clear that AM expression in F+reticulocyte differs 
from Freticulocyte populations. However control subjects, SS and HU-treated SS 
patients differ in AM expression. It is hypothesised that the expression of AMs in a 
higher proportion of F+reticulocytes than Freticulocytes in the controls is a 
reflection of an accelerated release of F+reticulocytes from the bone marrow. 
Additionally, lowering of the %AM+F+reticulocytes in SS patients and further 
lowering of this % in HU-treated SS patients reflects the relative survival 
advantage of high HbF content in F+cells in patient with SS and thus because of 
the older age distribution of F+cells in the SS patients that leads F+cells to have 
more time to shed more AMs. 
F"mature red cells and Fmature red cells Wressing A 
Having shown differences in AM expression in F+reticulocytes and F 
reticulocytes, analysis of this variable in mature red cells (R-) was undertaken to 
determine whether the same trend was observed in cells after the reticulocyte 
stage. (Table 4.4.2 and Figure 4.4.2) 
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Table 4.4.2 Absolute numbers of triple variables in F+mature red cell and F 
mature red cell populations 
Parameter Control (30) SS. std. (35) SS. cri. (22) SS. HU. (10) 
AM expressing F+ve mature red cells 
CD36'F'MRCs 1.47±0.15 6.20±0.7 1 4.22±0.50* 8.03±1.75* 
CD41*F'MRCs 1.46±0.16 7.21±1.05* 5.98±0.78* 9.84±1.02* 
CD49d+F'MRCs 1.44±0.15 7.25±1.17* 5.01±0.64* 10.46±1.74* 
AM expressing F-ve mature red cells 
CD36'F-MRCs 13.52±1.01 14.24±4.41 11.66±1.62 7.85±1.38* 
CD41'F-MRCs 13.24±0.98 15.20±4.34 11.23±0.98 9.49±1.38" 
CD49d'F-MRCs 13.81±1.06 15.16±4.05 13.56±2.12 9.70±1.39' 
AM negative F+ve mature red cells 
CD36-F'MRCs 195.81±11.18 766.45±62.14* 621.27±51.35* 1568.05±112.47*1 
CD41 F+MRCs 195.19±10.73 769.57±62.05* 618.00±52.37* 1528.09±094.70*ý 
CD49d-F'MRCs 192.73±10.19 771.15±62.68* 625.33±55.75* 1511.95±100.53*" 
AM negative F-ve mature red cells 
CD36-F-MRCs 4419.03±69.07 1721.70±149.2311 1869.65±109.65 A 910.93±113.99^" 
CD41-F-MRCs 4416.50±69.19 1683.71±139.73 A 1880.50±112.18A 943.58±125.58A' 
CD49d-F-MRCs 4417.36±68.85 1761.79±143.43 A 1862.76±113.88A 959.00±123 . 90A* 
Absolute number at x1 0' cells/ýtl, SS. = Sickle cell patients, std. = in steady state, 
cri. = in crisis state, HU. = on hydroxyurea, F HbF (foetal haemoglobin), MRCs 
mature red cells or RNA-cells 
significantly higher than control p<0.05, siqnificantly higher than SS. std. 
A 
p<0.05, significantly lower than control p<0.01, significantly lower than SS. std. 
p<0.05, 
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Figure 4.4. Percentages of AM expressing F+rnature red cell and F-mature red 
cell populations CD36 (top), CD41 (middle) and CD49d (bottom). 
In control subjects, the numbers of AM expressing F+mature red cells 
(F'MRCs) and FIVIRCs are similar as in reticulocyte population. This is possibly 
because R-cells (MRCs) exceed R+cells (reticulocytes) in control subjects by 50- 
100 fold, so the proportion of R-cells expressing AMs in both F+cell and F-cell 
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populations should be about 0.1-0.2 times that of R+cells. Indeed the proportion 
of F+cells and F'cells expressing AMs in Figure 4.4.2 is about 0.2 times that of 
reticulocytes (Figure 4.4.1). The numbers and proportions of R'cells expressing 
AMs are consistent with the in vitro culture data. If AM+cells is seen for up to 5 
days in culture and R+cells is seen for up to 3 days, then one would expect 
approximately half of the AM+cells to reside in the R+ and R- fractions. This is 
confirmed the findings in control subjects in Tables 4.4.1 and 4.4.2. It is not 
certain whether a presentation of a small %AM+celIs beyond a few days after the 
reticulocyte stage is due to a lack of validity of detection by flow-cytometry, which 
is unreliable below 1.0% of any cell subpopulation. Nevertheless, the very low 
proportions of R'cells expressing AMs after 5 days in culture is consistent both 
with the observed rate of AM loss in the controls and SS patients. 
As with the reticulocyte (R) population, the trend of relative proportions of 
R-cells in the F+ and F fractions expressing AMs is similar in SS and HU-treated 
SS patients. Thus there are approximately equal proportions of F+ and F in R' 
population expressing AMs in steady state patients and lower % of F+cells than F 
cells expressing AMs after HU treatment. The likely explanation for this is similar 
to that for R+cells. After HU treatment, F+MRCs have a survival advantage over F 
MRCs and therefore a smaller proportion of F+cells still carry AMs, because they 
survive longer then they have more time to shed more AMs. 
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4.5. PAIRED DATA ANALYSIS IN STEADY STATE AND CRISIS PATIENTS 
Rationale 
In the previous sections, there was no significant difference in PM 
expression in F+cells and F-cells between SS in steady state or in crisis. 
However, in those previous sections, the comparison between sickle patients in 
steady state and in crisis was done in different groups of patients. Therefore 
values were not compared in and out of crisis in the same patients and it is 
possible that trends in AM expression could have been obscured by an 
unintentional selection bias between the two groups. In this section, the 
comparison was done on the same patients during their steady state and vaso- 
occlusive crisis. 
Study design 
A total of 7 pairs of sickle cell patient samples in their steady state 
(SS. std. ) and crisis state (SS. cri. ) were collected and stored at 40C. The samples 
were assayed using triple-colour staining flow-cytometry (section 3.4.3) on the 
day of collection or not later than 3 days after collection. Paired data were 
compared between these two groups of samples. 
Results and discussion 
Comparison of paired data for the same sickle cell patients in steady state 
(SS. std. ) and in crisis state (SS. cri. ) are shown in Table 4.5. There is no 
significant difference between SS. std. and SS. cri. for any parameter in this group 
of patients. Thus in both paired and unpaired studies there is no difference in AM 
expression in any subpopulation of red cells (F+, F-, R+, R-). This suggests that 
vaso-occlusion does not result in a selective removal of populations expressing 
AMs or HbF. This does not exclude small numbers of cells being removal locally 
at vaso-occlusion sites but suggests that there is not a generalised process of 
removal of specific red cell populations on the basis of AM expression or HbF 
content during vaso-occlusion. 
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Table 4.5.1 Paired data of sickle cell patients in steady state and in crisis 
Parameter SS. std. (7) SS. cri. (7) 
Single variables 
RBCs (10'/gl) 2.71±0.12 2.64±0.21 
WBCs 12.73±1.38 14.09±1.78 
PItS 420.43±59.41 371.43±41.15 
mcV (fl) 85.30±2.17 84.07±3.02 
MCH (pg) 28.73±1.04 28.14±1.13 
Hb (g/dI) 7.73±0.35 7.13±0.43 
HbF (%) 4.17±0.92 4.67±1.00 
HbF/F+cells (pg) 5.07±0.70 5.29±0.52 
%Retics 9.44±0.99 10.57±1.22 
%F'cells 22.59±2.8429 22.80±3.83 
%CD36+cells 2.77±0.19 3.30±0.56 
%CD41+cells 2.72±0.17 2.64±0.39 
%CD49d+cells 2.88±0.30 3.42±0.69 
Double variables 
%F'retics 9.21±0.88 10.96±2.35 
AM expressing reticulocytes 
%CD36'refics 26.78±4.01 24.73±4.22 
%CD41+retics 25.64±3.69 21.74±4.86 
%CD49d+retics 26.50±4.69 24.13±3.85 
AM expressing mature red cells 
%CD36+MRCs 0.55±0.07 0.88±0.14 
%CD41+MRCs 0.59±0.05 0.70±0.15 
%CD49d+MRCs 0.63±0.11 1.07±0.31 
AM expressing rcells 
%CD36+(F'*ceIIs) 1.41±0.41 2.37±0.62 
%CD41+(FceIIs) 1.45±0.48 2.19±0.48 
%CD49d'(FceIIs) 1.35±0.41 2.02±0.32 
AM expressing Fnegative cells 
%CD36+(Fcells) 3.20±0.32 3.73±0.73 
%CD41+(Fcells) 3.14±0.29 2.92±0.54 
%CD49d'(FceIIs) 3.36±0.43 3.99±0.91 
SS. = Sickle cell patients, std. = in steady state, cri. in crisis state, AM 
adhesion molecule, F= foetal haemoglobin (HbF), Retics = reticulocytes, 
MRCs = mature red cells (R- or RNA7) 
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4.6. PAJRED AND SEQUENTIAL DATA FOR PRE- AND POST-HYDROXYUREA 
TREATMENT 
In the previous sections, the effect of hydroxyurea (HU) on AM expression 
in red cell sub-populations was compared for two groups of patients either on or 
off HU treatment but not done in the same patients. Therefore values were not 
exactly comparable and it is possible that trends in AM expression could have 
been obscured by an unintentional selection bias between the two groups. In this 
section, the comparison was done on the same patients before starting HU 
therapy and at the steady high levels of HbF after a period of HU therapy. 
4.6.1. Paired data analysis in pre- and post-hydroxyurea treatment in the same 
patien s 
Study design 
A total of 5 pairs of samples from 5 patients before HU therapy (SS. pre. ) 
and after a period of HU therapy (SS. post) were collected. HU doses ranged from 
0.5 to 1.5 g/day at mean duration of 34 weeks (range 30-40 weeks). The 
samples were tested using triple-colour staining flow cytometry (section 3.4.3) on 
the day of collection or not later than 3 days after collection. Paired data were 
compared between these two groups of blood samples. 
Table 4.6.1.1 General data for hydroxyurea treated sickle cell patients 
Patient Age Sex Diagnosis Dose Duration 
years g/d weeks 
1. 12 male Soo thal 0.5 36 
2. 57 male ss 0.5-1.0 32 
3. 22 female ss 0.5-1.0 40 
4. 22 female Soo thal 0.5-1.0 30 
5.52 female ss 1.5 32 
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Results and discussion 
Comparison of paired data for the same sickle cell patients before 
(SS. pre. ) and after (SS. post. ) HU therapy are shown in Tables 4.6.1.2 and 4.6.1. . 
In Table 4.6.1.2, a large number of statistically significant differences are seen 
before and after HU treatment, which are largely in agreement with reports of the 
effect of HU in SS patients previously reported (Charache et al., 1992; Shetty et 
al., 1998; Steinberg et al., 1997) as well as being in agreement with the unpaired 
data in section 4.3. Thus there is a significant reduction in white blood cell count 
(WBC), platelet count (PIts) and reticulocyte count (retics) after HU treatment. 
There is also a significant increase in MCV, HbF and F+cells post HU treatment. 
Conversely, there is a significant reduction in the % and absolute numbers of 
total red cells expressing CD36, CD41 or CD49d but only absolute numbers of 
reticulocytes expressing AMs are significantly reduced. A reductions in 
%CD36+reticulocytes with increment in %CD36+mature red cells as well as 
reductions in %CD49d+mature red cells and %CD49d+reticulocytes after HU 
treatment have been reported previously (Styles et al., 1997). However in that 
report, CD41 has not been investigated following HU treatment. 
Analysis shows that average HbF content per F+cell (F/Fc) doubles post 
HU (from 7.6 to 13.1 pg/cells), similar to the finding in a previous report (Maier- 
Redelsperger et al., 1998). This suggests that not only do the number of F+cells 
increase but the content of HbF per F+cell also increases. These findings 
suggest that prior to HU treatment about one quarter of the Hb in a F+cell is HbF 
on average, whereas post HU treatment nearly half the Hb in an F+cell is HbF. 
This increased HbF content would be expected to slow the rate of HbS 
polymerisation in each F+cell. The %F+reticulocytes increases post HU 
treatment, in agreement with previous reports (Dover et al., 1986; Osterhout et al., 
1996) but the absolute number of F+reticulocytes (F+R+) has decreased, because 
the number of total reticulocytes has decreased (from 376 to 172 X1 03 
cells/cu. mm. ). 
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Table 4.6.1.2 Paired data for pre- and post-hydroxyurea treatment 
Parameter 
------- 
SS. pre. (5) ------- 
SS. post. (5) 
Percent (%) Number (xlO3/gl) Percent (%) Number (x I O3/gl) 
Single variables 
RBCs NA 3060.00±494.00 NA 2806.00±400.00 
WBCs NA 10.42±2.12 NA 8.18±1.351% 
Plts NA 484.20±158.40 NA 379.20±130.74A 
mcv NA 85.06±8.02 NA 96.12±5.86* 
MCH (pg) NA 27.92±3.45 NA 31.98±2.37* 
Hb (g/dI) NA 8.02±0.68 NA 8.64±0.57 
HbF (g/dI) 11.68±1.61 0.94±0.15 26.78±2.20* 2.35±0.32* 
HbF/Fc (pg) NA 7.56±0.60 NA 13.09±1.20* 
Fcells 42.70±6.30 1251.52±248.42 65.50±4.57* 1800.65±202.12* 
Retics 13.11±2.98 376.33±79.27 6.30±1.35, % 172.86±35.84A 
CD36'cells 5.55±1.59 186.31±71.81 2.54±0.34A 72.45±14.74A 
CD41"cells 5.57±1.60 186.43±70.52 2.45±0.43A 69.96±15.60A 
CD49d*cells 5.83±1.60 195.87±72.02 2.68±0.39, % 76.33±16.071% 
Double variables 
Frefies (R*) 21.67±3.56 73.75±13.81 33.36±4.70* 57.96±8.26 
FMRCs (W) 46.36±7.61 1177.76±244.93 67.86±4.68* 1748.69±198.50* 
W(F'cells) 6.51±1.39 73.75±13.81 2.96±0.48 51.96±8.26 
W(F-cells) 19.53±6.11 296.69±70.36 12.92±3.55 120.90±31.00 
AM expressing reticulocytes 
CD36*retics (R*) 31.55±6.98 110.00±35.74 26.78±3.85 45.56±10.32A 
CD41*retics (R*) 27.75±5.56 106.71±34.22 26.41±3.79 43.35±10.41A 
CD49d*retics (R*) 30.58±6.35 113.11±36.58 26.77±4.40 44.90±11.21A 
AM expressing mature red cells 
CD36'MRCs (W) 2.38±0.99 76.35±35.89 1.02±0.14A 26.89±4.79A 
CD41*MRCs (R-) 2.57±1.08 79.72±37.10 1.01±0.19A 26.61±5.58A 
CD49d'MRCs (R: ) 2.73±1.11 82.75±36.44 1.19±0.13 A 31.42±5.27 A 
AM expressing Fcells 
CD36'(Pcells) 2.91±0.73 36.98±13.02 1.43±0.34A 25.84±6.14 
CD4 V (Pcells) 3.19±0.93 40.10±13.02 1.45±0.39A 25.32±5.43 
CD49dý (Pcells) 3.90±1.35 45.37±15.02 1.56±0.28 A 28.15±5.22 
AM expressing F negative cells 
CD36" (Fcells) 7.25±1.73 149.37±64.00 4.69±0.42A 46.62±10.08A 
CD41* (Fcells) 7.21±1.65 146.34±61.46 4.82±0.47 A 44.64±11.37 A 
CD49d' (Fcells) 7.26±1.48 150.49±60.21 4.84±0.56A 48.17±11.92A 
All absolute cell numbers = x10*2 cells / gl of blood, SS. = sickle cell patients, pre. 
= pre-hydroxyurea, post. = post-hydroxyurea, RBCs = red cell count, WBCs = 
white cell count, Plts = platelet count, Hb = haemoglobin, HbF = foetal 
haemoglobin, HbF/Fc = HbF per F'cell, F= foetal haernoglobin (HbF), Retics 
reticulocytes, R= RNA (reticulocytes), MRCs mature red cells. 
Asignificantly lower than pre-HU treatment, significantly higher than pre-HU 
treatment 
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Table 4.6.1.3 Paired data of triple variables in absolute numbers for pre- and 
post-hydroxyurea treatment 
Parameter SS. pre. (5) SS. PoSt. (5) 
AM expressing F+ve reticulocytes 
CD36+F'Retics 14.01±2.75 9.75±3.04 
CD41+F'Retics 14.30±2.03 9.44±3.09 
CD49d+F'Retics 15.50±3.62 9.70±2.60 
AM negative F+ve reticulocytes 
CD36-F'Retics 60.90±14.91 42.42±7.40 
CD41-F'Retics 61.77±11.96 42.39±5.76 
CD49d-F'Retics 57.49±13.45 41.66±6.22 
AM expressing F-ve reticulocytes 
CD36'FRetics 95.92±34.78 35.82±8.23h 
CD41*FRetics 92.41±32.62 33.92±8.65A 
CD49TFRetics 97.62±33.41 34.68±9.37A 
AM negative F-ve reticulocytes 
CD36-FRetics 187.64±44.80 88.03±23. JOA 
CD41-FRetics 224.27±56.11 86.65±29.80A 
CD49d-FRetics 207.11±49.82 83-59±22.44A 
AM expressing F+ve mature red cells 
CD36*F'MRCs 23.05±12.28 16.09±3.18 
CD41'PMRCs 25.79±12.10 15.88±2.80 
CD49d*PMRCs 29.89±13.30 17.94±2.79 
AM negative F+ve mature red cells 
CD36-FMRCs 1169.41±254.50 1736.82±210.08* 
CD41*F'MRCs 1175.58±245.05 1767.07±193.88* 
CD49d-FMRCs 1107.00±204.88 1746.05±185.61* 
AM expressing F-ve mature red cells 
CD36'FMRCs 53.37±29.33 10.80±2.32A 
CD41+FMRCs 53.93±28.87 10.72±3.45A 
CD49d+FMRCs 52.89±26.82 13.49±3.34A 
AM negative F-ve mature red cells 
CD3&FMRCs 1455.70±313.93 866.27±210.77 A 
CD41-FMRCs 1411.95±289.19 839.93±260.97A 
CD49d-FMRCs 1492.54±330.25 859.89±233.83A 
All absolute cell numbers are shown in x10" cells / gl of blood, SS. = sickle cell 
patients, pre. = pre-hydroxyurea, post. = post-hydroxyurea, Hb = haemoglobin, 
HbF = foetal haemoglobin, HbF/Fc = HbF per F+cell, F= foetal haernoglobin 
(HbF), Retics = reticulocytes, R= RNA (reticulocytes), MRCs = mature red cells 
Asignificantly lower than pre-HU treatment, * significantly higher than pre-HU 
treatment 
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The mean RNA fluorescent intensity in various red cell sub-populations 
was determined for these 5 paired samples of pre- and post-hydroxyurea 
treatment, in order to estimate age different among these sub-populations. 
(Table 4.6.1.4) 
Table 4.6.1.4 Mean RNA fluorescent intensity in red cell sub-populations of 
pre- and post hydroxyurea treatment 
Sub-population F+ F F+ +F 
Re kcs (R+) Pre-HU 2.358+0.243 2.772+0.234 2.652+0.259 
Post-HU 
MRCS (R') Pre-HU 
Post-HU 
Allred cells Pre-HU 
2.416±0.187 
0.133+0.009 
0.161±0.014 
0.280±0.037 
3.692+0.320* 
0.146+0.013 
0.178+0.019 
0.602+0.172* 
3.224+0.213 
0.138+0.013 
0.166+0.015 
0.441+0.088 
Post-HU 0.233+0.022 0.579+0.133* 0.344+0.063 
Significantly higher than F* population (p<0.05), 
ASignificantly lower than pre-HU (p<0.05) 
Retics = reticulocytes, MRCs = mature red cells 
In mature red cells, the number and proportion of cells expressing HbF 
increases significantly. As previously discussed, AM expression in reticulocytes 
decreases significantly In terms of absolute numbers but not in % values. This is 
partly in agreement with a previous report (Styles et a/., 1997), who found 
reduction in both number and % of reticulocyte expressing CD49d after HU 
treatment. In this thesis the degree of change for % CD36 and CD49d 
expressing reticulocytes Is less than that report. 
Changes in AM expression in F+cell and Fcell populations have not been 
previously compared. In Table 4.6.1.2. there are significant decreases in % of 
both F+cell and Fcell populations expressing AMs post HU treatment, 
comparable with the unpaired data (Tables 4.2.4 and 4.3.3.4 for data obtained 
from double- and triple-colour staining procedures respectively). The O/oAM 
expressing F*cells has decreased more than the I/oAM expressing F'cells. This 
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was likely to be secondary to the survival advantage of F+cells with higher HbF 
content leading to an older age distribution and therefore greater AM loss after 
HU treatment. In other words F-cells are younger than F+cells. This hypothesis is 
confirmed by a significant higher in the mean RNA fluorescent intensity (reflecting 
more RNA content) in F-cells than F+cells (Table. 4.6.1.4). It is also confirmed 
again by the higher %reticulocytes (R+) in F-cells than the F+cells in both pre- and 
post-HU treatment (Table 4.6.1.2). The findings in this paired study are 
consistent with this hypothesis. However the absolute numbers of AM expressing 
F+cells are not significantly reduced after HU treatment, probably because the 
total number of F+cells is increased. Unlike the significant reduction in the 
absolute numbers of AM expressing F-cells, because the total number of F-cells 
is also reduce after HU treatment. 
Table 4.6.1.3 shows the data obtained from 3 colour analysis in absolute 
values, displayed in a similar layout to the results obtained using unpaired 
patient groups in Tables 4.4.1 and 4.4.2. The same trends are largely present in 
the paired samples as in the unpaired samples. The most significant reductions 
in absolute numbers are found in the F-cell populations, both R+ (reticulocyte) 
and R- (MRCs) as well as AW and AM-. These reductions in F+cell population are 
generally less marked, possibly because total F+cells are increased. However, 
the post HU increments for AM-F+mature red cells are clearly marked. This 
subpopulation is the one predicted to be of most benefit to the patients because 
of the high HbF content and the absence of AMs. 
The percentages of reticulocytes expressing AMs in the F+cell and F-cell 
populations of pre- and post-HU treated patients are shown in Figure 4.6.1.1. 
The %AM+reticulocytes seem to decrease in both F+reticulocytes and F 
reticulocytes post-HU treatment but does not reach the significant level. However, 
the trend of reduction is higher in F+reticulocytes than Freticulocytes consistent 
with the finding that F+reticulocytes are older because they survive longer and 
therefore they lose more AMs. The mean RNA fluorescent intensity for 
F+reticulocytes is shown significantly lower than Freticulocytes post-HU 
treatment, which is consistent with this hypothesis (Table 4.6.1.4). 
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The %mature red cells expressing AMs in the F+cell and F-cell 
populations, pre- and post-HU treatment are shown in Ficlure 4.6.1.2. AM 
expression in F+cells falls but not in F-cells. This is again compatible with a 
survival advantage of F+cells leading to an older population with less AM 
expression or more AM shedding. By contrast AM expression in F-cells has not 
changed after HU treatment. This suggests that the conclusion of Styles et al. 
1997 that changes in AM expression post-HU treatment are due to a decrease in 
%AM+reticulocyte populations is unlikely, because these cells have no survival 
advantage in sickle cell patients. We conclude that the main reduction in AM 
expression post HU is secondary to a decrease in total reticulocytes and an 
increase in F+cells and HbF content in F+cells, leading to better survival of both 
reticulocytes and red cells after the reticulocyte stage. 
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Fiqure 4.6.1.1- Percentages of AM expressing F+reticulocytes and F 
reticulocytes in pre- and post-hydroxyurea treatment 
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Figure 4.6.1.2 Percentages of AM expressing F+mature red cells and Fmature 
red cells in pre- and post-hydroxyurea treatment 
(ASignificant lower than pre-hydroxyurea treatment at p<0.05; *significant higher 
than F+cells at p<0.05) 
4.6.1.2. Follow up of a sickle cell patient on hydroxyurea treatment 
In the above paired study, samples were taken pre-HU and then after 30- 
40 weeks of HU treatment. A supplementary study was performed in one patient 
to examine the rate at which AM expression changed with HU treatment, relative 
to other variables. 
Study design 
A 12 year old male with Spo thal of Cypriot origin was followed before HU 
was given (defined as day 0) and on days 14,28,49,84,97,140,161 and 273 of 
HU therapy. Oral HU was given at 500 mg/day from day 0 to Day 273. All blood 
samples were assayed using triple-colour flow cytometry (section 3.4.3) within 3 
days after collection. This is the first patient in Table 4.6.1. 
213 
Chapter 4 
Results and discussion 
The O/oAM expressing cells fell at approximately the same rates in 
reticulocytes and mature red cells. Also the rate of decrease in AM expressing 
cells appears similar in both F+cell and F-cell populations. In all of these 
subpopulations, the nadir value for O/oAM expression is achieved at about 140 
days (20 weeks or 5 months ) of treatment. Styles et al. 1997, found that nadir 
values of CD49d were achieved at 3 months on HU (1 5mg/k/day) therapy. 
It is interesting that HbF and F+cells continue to rise after the nadir point of 
AM expression and is still increasing at 273 days (39 weeks or nearly 10 
months). By contrast, the nadir reticulocyte count is reached sooner at about 84 
days (12 weeks or 3 months) after starting the HU therapy, while MCV and %HbF 
were still rising. In Styles's report, AM expression was not compared in F+cell and 
F-cell populations. 
There are a number of kinetic differences between this thesis and Styles's 
report. While the kinetics of changes in AM expression on reticulocytes in this 
thesis are similar to those for CD49d in Styles's report, but values for CD36 in all 
populations are higher in Styles's report. However, an increase in CD36+mature 
red cells in Styles's report is disagreement with the finding in this thesis where 
they were significantly reduced after HU treatment Table 4.6.2.2). Since the 
kinetics and % changes were similar for all 3 AMs in this thesis. Therefore the 
values show in this thesis are possibly more valid. Antibodies to AMs used in 
Styles's report are different from those used this thesis, which could explain the 
differences in % cells stained. The findings in this thesis with 3 independent 
(rather than 2) AMs shows almost exactly the same changes with all 3 AMs 
suggesting a similar mechanism of regulation. 
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Figure 4.6.2.1 Follow up data of a sickle cell patient during Hydroxyurea 
treatment (cells = red blood cells, retics = reticulocytes, F/Fc = HbF per F+cells) 
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Styles concluded that changes in adhesion molecule expression were not 
caused by a decrease in reticulocytosis with HU therapy. This was based on the 
observations that the % of CD36 and CD49d+retciculocytes appeared to 
decrease post-HU treatment but that mean cell RNA fluorescence did not change 
with HU therapy. In this thesis however, the % of reticulocytes expressing AMs 
pre- and post-HU treatment are not significantly different either in the non-paired 
analysis (Figure 4.2.2) or in the paired analysis (Table 4.3.3.3). Our findings 
show that the mean reduction in the % and absolute number of reticulocytes at 
30-40 weeks is 52% and 54% respectively. The reduction in %reticulocytes 
expressing AMs was only 15% whereas the decrease in absolute number was 
61%. 
In F+cells however, there is a significant reduction in the proportion of cells 
expressing AMs (Figure 4.2.4, Tables 4.2.4 and 4.6.1.2). Although in this thesis a 
lack of change in mean reticulocyte RNA fluorescence pre- and post-HU 
treatment (Table 4.6.1.4) was also found. However, the influence of HbF content 
as a separate variable has been studied. 
In Table 4.6.3, mean cell fluorescence is significantly higher in Fcells than 
F+cells (both in reticulocyte stage and mature red cell stage), consistent with an 
older age and survival advantage of F+cells. It is also clear that the proportion of 
F+cells and F+reticulocytes increases post-HU (Table 4.6.1.2). Thus the 
decrease in AM expression appears secondary to an increase in the proportion 
of F+cells. This is consistent with the lower mean cell fluorescence in 
(combination of F+ and F) cells post-HU treatment of all cells (Table 4.6.1.4), 
reflecting a higher proportion of F+cells. This argues against the conclusion of 
Styles et aL 1997 that effects on AM expression were 'independent of effects on 
reticulocyte age'. The findings in this thesis suggest that changes in AM 
expression in reticulocytes post-HU treatment are secondary to reduction of 
%reticulocytes and increments in F+cells and HbF content in F+cells, leading to a 
higher proportion of cells with a survival advantage and therefore lower AM 
expression. 
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4.7. CONCLUSIONS 
In this chapter, the effect of HbF content as an independent variable on MA 
expression and cell survival beyond the reticulocyte stage have been observed in 
control subjects and in sickle cell patients before and after HU therapy. This has 
not been previously described and shows important differences in MA 
expression between F+ and F' populations. 
It is clear that HbF content enriches for cells maturing beyond the 
reticulocyte stage in sickle patients but not in control subjects. This is the first 
use of flow cytometry for this purpose and the findings are consistent with other 
investigators about to the enrichment ratio (ER) (Dover et ah, 1978a; Dover et al., 
1978b). This ratio has not been described previously for patients on HU 
treatment. It appears that there is no additional increase in the enrichment ratio 
for patients on HU therapy. 
The effect of red cell ageing on AM expression has not been studied 
previously in detail. In this thesis, previous findings that AM expression on mature 
red cells is less than on reticulocytes (Styles et al., 1997) is confirmed. However 
in vitro culture shows that AMs are shed by reticulocytes at a rate slightly slower 
than the rate of RNA loss. This has not been described previously and suggests 
that AM expression is an indirect indicator of red cell age. Thus the higher the 
proportion of reticulocyte and red cells less than 1 week older than the 
reticulocyte stage, the higher the % of cells expressing AMs. 
In this thesis 3 AMs have been measured independently unlike previous 
studies where only 2 AMs were measured (Styles et al., 1997). The findings in 
this thesis indicate that all three AMs measured are expressed and are shed at 
similar frequencies and rates. The suggestions by Styles that different AMs 
respond to HU differently is not supported by the findings in this chapter. 
Previously the influence of HbF content on AM expression has not been 
studied. This potentially important for two reasons. Firstly it is important to know 
whether F+cells are qualitatively different in control subjects from F'cells. In this 
thesis, it is clear that in control subjects AMs are expressed in a higher 
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proportion in F+cells than in F-cells (Figure 4.2.4) and in F+reticulocytes than in F 
reticulocytes (Figure 4.4.1). This the first demonstration of a difference between 
F+ cells and F-cells even though other differences have not been found. The 
finding (in healthy control subjects) is consistent with F+cells being a population 
of cells which are less mature possibly having undergone less divisions prior to 
release from the bone marrow than F-cells. 
The second reason why HbF content being potentially important for 
understanding AM expression came from the studies in pre- and post-HU 
treatment. The findings in this chapter show that in sickle cell patients, unlike in 
control subjects, the O/oAM expressing cells is lower in F+cell than F-cell sub- 
populations. The likely explanation of this finding is the improved survival beyond 
the reticulocyte stage for F+cells, which allows more AMs to shed. This 
observation is critical to the interpretation of the effects of HU treatment on PM 
expression on red cells. The findings in this chapter suggest that the reduced PM 
expression on red cells following HU treatment results from two independent 
effects. The first is a reduction in reticulocyte count. The second is secondary to 
increased proportions of F+cells, which survive longer and therefore express less 
AMs. 
220 
Chapter 5 
CHAPTER5 
ENDOTHELIAL FACTORS IN SICKLE CELL DISORDERS 
5.1. BACKGROUND 
5.1.1. Endotheliall factors and hypoxia in vaso-occlusion 
In this chapter, the central hypothesis examined is whether local hypoxia 
resulting from vaso-occlusion increases vascular endothelial growth factor 
(VEGF) release from the microvasculature and adjacent ischaemic tissues, 
which in turn can be measured in the blood. A secondary hypothesis is whether 
hypoxia induced VEGF leads to a secondary increase in nitric oxide (NO) 
concentration. Hypoxia causes both the mRNA and VEGF protein increases in ex 
vivo perfusion lung tissues Juder et a/., 1995) and in vitro cultured hepatocytes 
(Sandner et al., 1997). Hypoxia also increases the expression of a number of 
genes encoding vascular cell mitogens produced by vascular endothelial cells 
(VECs) including platelet-derived growth factor B (PDGF-B), endothelin-1 (ET-1), 
and VEGF (Kourembanas et al., 1997). VEGF then upregulates endothelial nitric 
oxide synthase (eNOS) and stimulates NO production (Hood et a/., 1998). In 
human umbilical vein endothelial cells (HUVECs), the activation of VEGF 
receptor-2 (Flk-l/KDR) upregulates both eNOS and iNOS (inducible NOS), while 
stimulation of VEGF receptor-1 (Flt-1) did not generate such a signal. This 
indicates that VEGF can upregulate NO production and release from VECs and 
other cell types. If this hypothesis is correct, and other sources of VEGF and NO 
independent to local ischaemia do not swamp such changes, then the onset of 
vaso-occlusive crisis might be associated with an increase in both VEGF and NO 
levels in the blood. NO and VEGF are synthesised in a number of cell types, 
including endothelium and platelets. Both of these cells have been reported to be 
activated in sickle cell disorders. It is therefore also important to examine 
whether NO and VEGF levels are associated with changes in markers of 
endothelial and platelet activation. 
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5.2. LEVELS OF VEGF AND NOx IN SERUM AND PLASMA 
5.2.1. Rationale 
It was predicted that in sickle cell patients, localised vaso-occlusion could 
increase VEGF and NOx levels in the circulation. Vaso-occlusion and consequent 
local hypoxia could potentially induce VEGF production from a variety of cell types 
in the microcirculation, as VEGF synthesis is regulated by a hypoxia sensitive 
element. 
Vaso-occlusion could also increase NO synthesis, which could be 
mediated in a variety of ways. In endothelial cells, hypoxia is known to induce 
eNOS, which is mediated by intracellular Ca 2+ fluxes. Increased NO synthesis 
could then lead to compensatory vasodilatation. However eNOS can produce 
only small amounts of NO which may not be detectable as a change in the 
plasma level. Furthermore, NO is highly reactive with certain molecules that it 
encounters, most NO will interact with red cell haemoglobin to form nitrosyl-Hb, 
while a proportion will be rapidly metabolised to nitrites and nitrates, measured 
collectively as NOx. In non-endothelial cells, such as macro ph ag es/mon ocytes, 
iNOS is activated by TNF-(x, which has been reported to be increased in sickle 
cell patients (Malave, 1993; Francis, 1992). This could also increase plasma NOX 
levels. 
In order to measure plasma VEGF and NOx, it was important to establish 
the optimal method for sample collection and whether values obtained were 
affected by the anticoagulant used. The levels of VEGF and NOx were therefore 
compared in serum, EDTA and CTAD plasma between healthy control subjects 
and sickle cell patients in steady state and in crisis. 
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5.2.2. VEGF levels in blood samples from different anticoagulants 
Study design 
Serum samples were collected from 16 healthy control subjects (control. ), 
10 sickle cell patients in steady state (SS. std. ), 4 sickle cell patients in crisis 
(SS. cri. ) and 4 sickle cell patients undergoing hydroxyurea treatment (SS. HU. ). 
Steady state was defined as samples taken in outpatients who were pain free. 
Crisis state was defined as an acute painful episode requiring admission to 
hospital for management of pain. Hydroxyurea treatment was defined as 
receiving 0.5-2.0 g/day for several week and HbF levels reach a steady levels. All 
patients had samples taken for Hb typing and quantitation (by HPLC) and 
samples containing transfused red cells, as indicated by the presence of HbA, 
were excluded. The EDTA plasma samples were collected from 20 control, 8 
SS. std., 8 SS. cri. and 7 SS. HU. The CTAD plasma samples were collected from 
21 control., 13 SS. std., 7 SS. cri. and 8 SS. HU. Control blood samples were taken 
from University College London postgraduate students and laboratory personnel. 
Sickle blood samples were taken from patients at University College London 
Hospitals (UCLH). Serum, EDTA and CTAD plasma were stored at -700C. Full 
blood count (FBC) with reticulocyte count was assayed on a blood cell analyser 
(Sysmex SE-9500). Samples were assayed for VEGF and NOx levels as 
described in Chapter 2. 
Results 
Levels of VEGF (pg/ml) in normal controls, SS. std., SS. cri. ) and SS. HU. 
were compared between anticoagulants used. In serum, VEGF levels were 
151+17 in control (n=16), 517±76 in SS. std. (n=10), 476+40 in SS. cri. (n=4) and 
463+109 in SS. HU. (n=4) respectively. In EDTA plasma were 22+2.6 in control 
(n=20), 115.4+51.6 in SS. std. (n=8), 73.4±9.9 in SS. cri. (n=8) and 170.0±53.3 in 
SS. HU. (n=7) respectively. In CTAID plasma were 10.7±0.4 in control (n=21), 
18.0±1.1 in SS. std. (n=13), 23.0+3.3 in SS. cri. (n=7) and 23.5+3.6 in SS. HU. (n=8) 
respectively. (Figure 5.2.2) 
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Figure 5.2.2 Levels of VEGF in samples from different anticoagulants 
Serum samples of control subjects (n=16), sickle cell patients in steady state 
(SS. std., n=10), sickle cell patients in crisis (SS. cri., n=4) and sickle cell patients 
undergoing hydroxyurea treatment (SS. HU., n=4); EDTA plasma of control (n=20), 
SS. std. (n=8), SS. cri. (n=8) and SSAU. (n=7) and CTAD plasma of control (n=21), 
SS. std. (n=13), SS. cri. (n=7) and SS. HU. (n=8) were assayed for VEGF (pg/ml) 
using commercial ELISA kits. *Indicates significantly higher than control group 
(p<0.01). There was no significant difference between 3 SS groups. 
Discussion 
VEGF levels in sickle cell patients were significantly higher than in control 
subjects in serum (p<0.001), EDTA (p<0.01 ) and CTAD (p<0.001). There were 
no significant differences between the 3 groups of sickle cell patients. Levels in 
serum were significantly higher than in EDTA and CTAD for both SS and control 
subjects. The higher values in serum could reflect in vitro platelet activation. 
Levels were further reduced in all patient types in CTAD, supporting this 
hypothesis. The effects of platelet activation on plasma VEGF are explored in 
subsequent sections. 
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5.2.3. NOx levels in blood samples from different anticoagulants 
Results 
Study design and blood samples are as same as in section 5.2.2. NOx 
levels were measured using commercial test kits. In serum, levels of NOx (ýIIVI) 
were 24+2.1 in control, 26+4.4 ýN in SS. std., 27+7.2 in SS. cri. and 27+3.4 in 
SSAU. respectively. In EDTA plasma, the values were 27+3.0 in control, 25+2.4 
in SS. std., 25+2.1 in SS. cri. and 28+4.9 in SS. HU. respectively. In CTAID plasma 
the levels were 20+1.5 in control, 22+1.7 in SS. std., 23+2.9 in SS. cri. and 24+2.4 
in SSAU. respectively. Thus there was no significant difference in NOx levels 
between sickle cell patient groups and control group. (Figure 5.2.3) 
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Figure 5.2.3 Levels of NOx in samples from different anticoagulants 
Serum samples of control subjects (n=16), sickle cell patients in steady state 
(SS. std., n=10), sickle cell patients in crisis (SS. cri., n=4) and sickle cell patients 
undergoing hydroxyurea treatment (SS. HU., n=4); EDTA plasma of control (n=20), 
SS. std. (n=8), SS. cri. (n=8) and SSAU. (n=7) and CTAD plasma of control (n=21), 
SS. std. (n=13), SS. cri. (n=7) and SS. HU. (n=8) were assayed for NOx 
concentration ([tM) using commercial Griess reaction test kits. There was no 
significantly difference. 
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Discussion 
The lack of difference in NOx levels between SS and control subjects 
contrasts with the findings of Rees et a/, 1995, who found raised levels, 
particularly in SS. cri. However Lopez et al, 1996 reported that SS. cri. patients did 
not always show raised NOx levels. They separated SS. cri. patients into 3 groups 
according to pain score measured by a 10-cm visual analog scale (VAS) and 
found that high pain score was associated with low levels of NOx and vice versa. 
However, the method used by Rees was colorimetry and by Lopez was 
chemiluminescence. In this thesis colorimetry was used but there were two 
differences from Rees's method. Firstly NOx levels in lithium-heparin plasma 
samples were assayed by Rees and using Cadmium as the nitrate reductant, 
whereas in this thesis 3 types of sample (serum, EDTA and CTAD plasma) were 
assayed and nitrate reductase enzyme was used. It is not clear whether these 
differences could influence the findings however. A further and potentially more 
important difference is that samples in this thesis were pre-ultrafiltrated to 
eliminate Hb and bilirubin, whereas in Rees's study, a de-proteinisation was 
used with no methodology detail. As the Griess reaction is a colorimetric assay, 
any coloured substance may interfere with the endpoint absorbance especially at 
540 nm. This could therefore have led to falsely increased in NOx levels, 
particularly as SS crisis is often associated with increased jaundice. 
The same patients were not compared in steady state and in crisis or on 
and off HU in this section. It is therefore possible that small differences between 
different subjects could occur. The timing of samples in vaso-occlusive crisis 
may also influence NOx levels. A recent report showed that NOx levels were 
lower in patients who had experienced more and longer pain (Lopez et al, 2000). 
Samples taken in vaso-occlusive crisis in this thesis were all taken from patients 
who had experienced pain for more than 1day and therefore the reduced levels 
reported in early SS crisis by Lopez would not have been observed. Lopez 
suggested that the low levels of NOx seen in patients with prolonged vaso- 
occlusive pain could reflect a relative inability to increase NOx production in 
response to local hypoxia. It is possible that the patients reported by Lopez, who 
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made low NOx, are more likely to experience prolonged pain than those who 
produce higher levels. This is unproven at the present. Although sequential 
samples were not taken in crisis, the findings in this thesis provide no evidence 
to support the idea that NOx levels are significantly higher or lower than in control 
subjects, either in SS in crisis or in steady state. 
5.2.4. VEGF and NOx levels in the same samples taken in different 
anticoagulants 
Study design and results 
In the previous sections, comparisons between VEGF and NOx levels 
obtained from serum, EDTA and CTAD plasma samples were not in the same 
subjects and not taken at the same time. Further experiments were therefore 
performed comparing measured levels of VEGF and NOx in serum, EDTA and 
CTAD plasma taken from the same healthy individuals. In 8 paired samples, the 
levels of VEGF in serum, EDTA and CTAD plasma were 131±23.4,14+1.0 and 
10±0.4 pg/ml respectively, confirming the findings of the previous section of 
significantly lower VEGF levels in EDTA and CTAD plasma than that in the serum 
(p<0.005) and the level in CTAD plasma was significantly lower than in EDTA 
plasma (p<0.05). The NOx levels in serum, EDTA and CTAD plasma were 
24±2.5,27±2.7 and 22+2.4 [tM respectively, showing no significant difference 
(Figure 5.2.4). 
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Figure 5.2.4 Levels of VEGF and NOx in paired samples using different 
anticoagulants 
Eight paired samples from the same normal control subjects and taken at the 
same time but using different anticoagulants, were assayed for VEGF and NOx 
levels by commercial test kits. AIndicates significantly lower than serum samples 
(p<0.005) and AA indicates significantly lower than EDTA plasma samples 
(p<0.05). 
Discussion 
These findings show that VEGF values are substantially higher in serum 
samples than in EDTA or CTAD plasma. The difference between VEGF in EDTA 
and CTAD plasma is less than that observed in the unpaired samples, but is still 
significantly higher in EDTA than in CTAD plasma (p<0.05). The NOx values are 
unaffected by the types of sample collection and anticoagulant used. 
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5.2.5. Effect of CTAD on ELISA assays for VEGF 
Study design and results 
In order to ensure that the lower VEGF levels seen in CTAID samples 
above were not due to an inhibitory effect of CTAID on the ELISA assay, six pairs 
of normal serum samples, with and without addition of CTAD anticoagulant at the 
same concentration as in the CTAID blood collection tubes, were assayed for 
VEGF (section 2.5.3). 
The levels of VEGF in serum samples without and with addition of CTAID 
prior to the assay were 105.8+7.1 and 103.7+7.4 pg/ml, this was non-significantly 
different Table 5.2.5). 
Table 5.2.5 Comparison of VEGF levels without and with CTAD addition 
SampleNumber VEGFwithoutCTAD VEGF with CTAD addition 
1. 120 110 
2. 98 99 
3. 113 116 
4. 76 70 
5. 105 107 
6. 123 120 
Mean ± SE 105.8±7.1 103.7±7.4 
Six serum samples regardless of diagnosis, were assayed for VEGF without and 
with addition of CTAD anticoagulant at the similar concentration of CTAD in the 
CTAD blood collection tube, in order to determine whether there is any effect of 
CTAD on ELISA assay of VEGF. The mean VEGF levels of both groups were not 
significantly different. 
5.2.6. Discussion and conclusions 
These findings show a significant increase in VEGF in sickle patients over 
control subjects irrespective of the anticoagulant used (p<0.001). However VEGF 
levels were substantially lower both in control subjects and in sickle cell patients 
when in vitro platelet activation was inhibited by CTAD (p<0.05). In paired control 
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serum, EDTA and CTAD plasma samples (section 5.2.4), VEGF in serum is 131 
pg/ml compared to 14 pg/ml in CTAD representing nearly a 10 fold difference. 
This large difference is not due to inhibition of the assay by CTAD and must 
represent a difference resulting from inhibition of platelet activation in vitro by 
CTAD. This has been previously described and suggested that the majority of 
VEGF levels reported in the literature using serum were measuring platelet 
derived VEGF that was liberated in vitro, after sample collection (Adams et al., 
2000; Maloney et al., 1998; Salgado et al., 1999; Salven et al., 1999; Verheul et 
al., 1997; Webb et al., 1998). It is clear from the results in this section that in vitro 
platelet activation contributes to the majority of measured VEGF in serum and 
EDTA plasma and such an effect is likely to swamp small differences in the 
blood levels of VEGF in vivo. 
The differences between VEGF levels in SS and control subjects are seen 
in all types of sample collection. The question arises as to whether the higher 
VEGF in CTAD plasma reflects endothelial activation or residual increased 
platelet activation in vivo. It must be remembered that the platelet count in sickle 
cell patients is often higher than control subjects and this could lead to increased 
VEGF levels. 
There is no evidence for differences in NOx between SS and control 
subjects. Furthermore, levels are not different between patients in crisis and in 
steady state. 
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5.3. EFFECT OF PLATELET ACTIVATION IN VITRO ON VEGF, NOx AND OTHER 
MARKERS 
Rationale 
The findings in section 5.2 suggest that in vitro platelet activation may 
contribute to measured levels of VEGF, especially when the sample are not taken 
into CTAD anticoagulant. In this section, it was decided deliberately to induce 
platelet activation, using thrombin activating protein (TRAP), to determine the 
effect on VEGF and NOx and to compare this with known markers of platelet 
activation, such as beta-thromboglobulin (BTG) and platelet factor 4 (PF4). 
Markers considered to be specific for endothelial activation, soluble endothelial 
selectin (sE-selectin) and soluble vascular cell adhesion molecule 1 (sVCAM-1), 
were included as negative controls. 
Study design 
Six citrate platelet rich plasma samples from sickle cell patients were 
collected and deliberately activated using thrombin activating protein (TRAP) 
(section 2.5.5). In this experiment, citrate plasma was used instead of CTAD 
plasma because CTAD was designed for preventing platelet activation and such 
activation could not be performed. CTAD also contains citrate as anticoagulant 
together with theophylline, adenosine and dipyridamole for preventing platelet 
activation. There is no evidence of any interferace by citrate or CTAD on the ELISA 
assay as shown in section 5.2.5. 
Results 
The levels of VEGF without and with platelet activation in vitro (n=6) were 
17±11.8 and 55±12.8 pg/ml (p<0.03); of NOx were 21±11.6 and 25+11.8 PM (non- 
significance; NS); of BTG were 68±23.4 and 626±90.0 JU/ml (p<0.002); of PF4 
were 24±10.0 and 121+12.0 lU/ml (p<0.003); of sE-Selectin were 39.5+3.4 and 
33.7±2.6 ng/ml (NS); of sVCAM-1 were 271+23 and 264+20 ng/ml (NS) 
respectively (Figure 5.3). 
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Figure 5,. 3 Comparison of parameters from samples without and with platelet 
activation 
Six paired citrate plasma samples without (-) and with (+) platelet activation were 
assayed for VEGF (pg/ml), NOx (gM), BTG (x1O IU/ml), PF4 (x1O IU/ml), sE- 
Selectin (x1O ng/ml) and sVCAM-1 (x1O ng/ml) using commercial test kits. * 
Indicates significantly higher than without platelet activation samples (p<0.03). # 
Indicates x1O of ordinary units. 
Discussion 
In platelet activated samples, VEGF, BTG and PF4 levels and BTG/PF4 
ratio were significantly increased over their values in the samples without platelet 
activation. However neither NOx, sE-selectin nor sVCAM-1 levels were 
significantly changed by platelet activation. This confirms that platelet activation 
plays an important role in modulating measured VEGF serum levels and that 
platelets are a rich source of VEGF. The increase in citrate plasma VEGF 
following platelet activation (about 3 fold) is less than that seen with BTG (about 9 
fold) or PF4 (about 5 fold). This suggests that platelets are an important source 
of serum VEGF, (because in serum, platelets are activated by the clotting 
process), but other sources are more likely to contribute to plasma VEGF levels. 
Human megakaryocytes are known to produce and secrete VEGF in an inducible 
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manner and purified megakaryocytes express mRNA of the three VEGF isoforms 
(121,165, and 189 amino acids) (Mohle et a/., 1997). The presence of VEGF 
within platelets has implications for processes involving platelet and endothelial 
cell interactions. e. g. wound healing, and in tumor metastasis (Banks et al., 
1998). Platelet aggregation and thrombosis at the site of vessel injury secrete 
VEGF into that microenvironment, thus promoting neovascularisation. It is now 
known that VEGF is also secreted from platelets during the in vitro aggregation of 
platelet-rich plasma induced by thrombin, collagen, epinephrine, and ADP 
(Maloney et al., 1998). It is not yet known whether activated platelets secrete all of 
their VEGF content or only part of it. On the other hand, levels of VEGF in citrate 
plasma, even after compensating for the slight dilution in addition of TRAP, seem 
to be lower than in serum samples. It is possible that some of the VEGF in 
serum samples results from activation of leukocytes (Salven et al, 1999) such as 
monocytes (Xiong, 1998) and neutrophils (Webb, 1998). It is clear that plasma 
VEGF especially CTAD plasma (with minimal platelet activation in vitro) gives a 
better reflection of in vivo levels than serum VEGF. As a result of this finding, it 
was decided to use CTAD plasma as the preferred measure of plasma VEGF. 
5.4. RELATIONSHIPS OF VEGF AND NOx IN CTAD PLASMA 
Blood samples 
In this section and in subsequent sections through section 5.10 except 
section 5.9, the same group of patients with sickle cell disease and control 
subjects were studied. Their clinical and haematological data are shown below 
in Table 5.4.1.1 and Table 5.4.1.2. 
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Table 5.4.1.1 Clinical data of normal healthy control subjects 
Number Age Sex Crisis day HU WBC Pit RBC Hb HbF 
Normal control donors (n=21) 
1. 36 M 6.8 277 4.71 14.5 0.4 
2. 24 M- - 5.1 193 4.75 14.8 0.0 
3. 26 F- - 6.7 292 4.33 12.1 0.8 
4. 27 M- - 7.5 234 4.47 13.1 0.6 
5. 36 F- - 7.9 171 4.96 13.9 0.1 
6. 28 M- - 8.4 222 4.92 14.2 0.5 
7. 39 M- - 7.2 198 5.44 15.0 0.4 
8. 27 F- - 9.6 187 4.91 13.6 0.5 
9. 30 F- - 6.1 297 4.26 13.4 0.3 
10. 29 F- - 4.2 305 4.15 13.4 0.9 
11. 39 M- - 8.6 245 5.20 16.4 0.6 
12. 35 M- - 9.1 192 4.77 13.9 0.4 
13. 27 M- - 6.7 170 5.22 15.2 0.9 
14. 26 M- - 6.1 256 5.17 14.7 0.7 
15. 25 F- - 5.8 208 4.25 13.2 0.1 
16. 28 M- - 7.5 227 5.55 15.1 0.6 
17. 24 F- - 5.8 203 4.44 12.0 0.4 
18. 30 F- - 5.5 177 4.16 12.5 0.9 
19. 40 M- - 8.5 215 4.94 14.0 0.8 
20. 45 M- - 3.7 139 4.75 12.7 1.0 
21. 31 M- - 7.8 220 4.67 13.0 1.0 
Mean 31 13/8, 6.9 220 4.76 13.8 0.6 
SEM 1.3 (M/F) 0.3 9.8 0.09 0.25 0.07 
Age (Years) Sex (M=male F=Female) i 3 HU=on hydroxyurea WBC (1 03/M M3) /MM ) p1t (1 O RBC (105/m m3) Hb (g /dl) HbF 
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Table 5.4.1.2 Clinical data of sickle cell patients 
Number Age Sex Crisis day HU WBC Pit RBC Hb HbF 
Sickle cell patients in steady state (n=13) 
1. 9 M-- 15.5 381 1.82 6.0 3.5 
2. 30 F-- 5.6 282 3.89 11.8 2.5 
3. 23 M-- 16.7 455 3.85 10.7 6.2 
4. 44 F-- 10.5 345 2.23 6.7 1.4 
5. 8 F-- 14.1 322 2.66 8.0 5.2 
6. 10 F-- 9.0 233 3.45 9.5 9.8 
7. 26 M-- 14.9 207 3.37 9.9 7.0 
8. 20 M-- 10.0 387 3.82 9.8 3.4 
9. 31 F-- 7.8 295 2.20 6.7 4.0 
10. 47 M-- 7.6 253 2.53 8.1 8.2 
11. 23 F-- 9.9 317 2.73 8.7 9.6 
12. 33 M-- 10.6 581 3.41 9.0 1.1 
13. 57 M-- 7.8 174 2.18 6.6 1.6 
Mean 
SEM 
28 
4.2 
7/6 
(M/F) 
10.8 
0.96 
326 
30.3 
2.93 
0.20 
8.6 
0.5 
4.9 
0.8 
Sickle cell patients in crisis (n=7) 
14. 25 M 1 - 10.6 146 3.59 7.7 7.0 
15. 28 F 37 - 5.8 233 3.78 8.4 1.8 
16. 26 F 3 - 9.4 230 2.21 6.8 3.3 
17. 26 M 3 - 22.3 147 3.05 8.8 4.1 
18. 51 F 7 - 12.2 326 2.32 7.3 7.6 
19. 32 M 6 - 15.6 308 2.85 7.9 2.9 
20. 30 M 10 - 11.7 454 2.06 5.2 3.8 
Mean 
SEM 
31 
43.4 
4/3 
(M/F) 
12.5 
1.9 
263 
41.3 
2.84 
0.26 
7.4 
0.5 
4.4 
0.8 
Sickle cell patients on hydroxyurea (n=8) 
21. 23 F Yes 12.1 528 2.74 8.4 16.2 
22. 46 F- Yes 5.5 113 3.35 8.9 9.0 
23. 33 F 31 Yes 6.0 342 2.04 7.1 11.0 
44. 33 M1 Yes 9.1 242 1.99 9.1 20.3 
25. 57 M- Yes 4.5 186 3.13 10.2 17.8 
26. 23 F- Yes 17.5 547 2.34 7.3 17.6 
27. 35 M- Yes 8.4 210 2.88 9.8 23.7 
28. 13 M- Yes 10.6 574 2.60 7.5 27.3 
Mean 33 414 9.2 342 2.63 8.5 18.5 
SEM 4.9 (M/F) 1.5 64.7 0.17 0.4 2.5 
Age (Years) Sex (M=male, F=Female) HU = on hydroxyurea 
WBC (1 03/Mrn3) pit (103/MM3) RBC (106/MM3 ) Hb (g/dl) HbF 
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Overall results 
Levels of CTAD plasma VEGF, NOx, platelet activation markers (BTG and 
PF4), endothelial activation markers (sE-Selectin and sVCAM-1) and anaemic 
markers (Hb and Epo) in normal control, SS. std., SS. cri. and SS. HU are shown in 
Table 5.4.2.1 and Table 5.4.2.2. 
Table 5.4.2.1 Measured variables in normal healthy control subjects 
Number VEGF NOx BTG PR sE-selectin sVCAM-1 Epo 
Normal Control Donors (n=21) 
1. 9 28 42 22 50 351 4 
2. 12 13 15 6 33 391 5 
3. 10 20 47 16 35 271 2 
4. 17 29 36 13 37 351 3 
5. 9 17 28 10 49 340 5 
6. 12 20 23 7 39 317 5 
7. 12 27 26 10 34 267 4 
8. 10 20 16 8 54 380 6 
9. 9 13 15 5 30 340 3 
10. 8 19 27 11 31 350 4 
11. 12 41 52 21 19 372 3 
12. 10 26 21 8 49 312 4 
13. 12 15 15 6 21 274 10 
14. 11 12 24 8 28 291 5 
15. 11 15 19 9 28 229 8 
16. 10 19 13 5 49 330 5 
17. 11 20 19 10 21 278 5 
18. 9 15 11 4 27 388 2 
19. 9 22 23 8 32 356 1 
20. 10 18 46 15 40 409 5 
21. 12 19 33 12 42 374 5 
mean 11 20 26 10 36 332 4.5 
SEM 0.4 1.5 2.6 1.1 2.2 10.6 0.4 
VEGF (pg/ml), NOx ([tM), BTG (IU/ml), PF4 (IU/ml), sE-selectin (ng/ml), 
sVCAM-1 (ng/ml), Epo (mlU/ml), 
236 
Chapter 5 
Table 5.4.2.2 Measured variables in sickle cell patients 
Number VEGF NOx BTG PR sE-selectin sVCAM-1 Epo 
Sickle cell patients in steady state (n=13) 
1. 18 21 114 39 133 1229 122 
2. 12 11 92 27 42 301 16 
3. 14 12 107 36 58 727 41 
4. 15 31 110 24 98 924 52 
5. 19 24 202 53 191 1022 60 
6. 14 20 159 32 198 913 125 
7. 23 24 229 52 58 517 54 
8. 22 33 149 29 76 501 15 
9. 14 26 156 63 62 770 73 
10. 23 20 63 12 88 953 71 
11. 20 20 170 40 75 391 28 
12. 19 25 221 58 71 565 32 
13. 21 21 121 38 32 942 119 
mean 18 22 145 39 91 750 62 
SEM 1.1 1.7 14.1 4.1 15.6 76.8 10.7 
Sickle cell patients in crisis (n=7) 
14. 13 18 87 37 52 1004 52 
15. 15 17 123 36 79 931 55 
16. 18 25 150 18 38 575 74 
17. 38 18 92 18 99 660 83 
18. 22 39 168 99 178 588 40 
19. 27 26 145 42 56 611 59 
20. 28 20 225 74 40 845 53 
mean 23 23 141 46 77 745 59 
SEM 3.3 2.9 17.9 11.3 18.7 67.3 5.5 
Sickle cell patients on hydroxyurea (n=8) 
21. 10 13 44 15 54 598 42 
22. 17 20 19 4 39 825 93 
23. 13 20 94 22 44 684 137 
24. 21 32 146 30 61 903 60 
25. 35 19 165 42 37 872 41 
26. 23 25 210 54 78 572 38 
27. 32 32 112 44 31 432 142 
28. 37 28 231 60 73 583 89 
mean 24 24 128 34 52 684 80 
SEM 3.6 2.4 26.5 6.9 6.1 59.3 14.9 
VEGF (pg/ml), NOx (gM), BTG (IU/ml), PF4 (IU/ml), sE-selectin (ng/ml), 
sVCAM-1 (ng/ml), Epo (mlU/ml), 
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Results 
VEGF levels in CTAD in Fiqure 5.2.2 is not clearly shown because of the 
scale used. Therefore, it is shown again in Figure 5.4.1. The dot-plot relationship 
between VEGF and NOx levels in CTAD plasma was shown in Figure 5.4.2. 
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Figure 5.4.1 Comparison of CTAD plasma VEGF and NOx levels 
A group of 21 normal control subjects, 13 sickle cell patients in steady state 
(SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 sickle cell patients 
undergoing hydroxyurea treatment (SS. HU. ) were assayed for VEGF (pg/ml), NOx 
(gM). *Indicates significantly higher than the control group (p<0.001). 
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Figure 5.4.2 Dot-plot relationship between CTAD plasma VEGF and NOx levels 
A group of 21 normal control subjects, 13 sickle cell patients in steady state 
(SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 sickle cell patients 
undergoing hydroxyurea treatment (SS. HU. ) were assayed for VEGF (pg/ml) and 
NOx ([M). There was no correlation between VEGF and NOx in any group of 
subjects. The correlation coefficient (r) were all lower than 0.50. The r values 
were 0.32 in all subjects together, 0.31 in control group, 0.40 in SS. std. group, 
0.02 in SS. cri. group and 0.44 in SS. HU. group respectively. 
Discussion 
In Fiqure 5.4.2, it is clear that there is no correlation between VEGIF and 
NOx in any patient group. Thus if hypoxia is a trigger for either VEGF and/or NO 
synthesis, this is not demonstrated by a change in these parameters at the 
same moment. This could be because the kinetics of changes in VEGF and NO 
synthesis and/or release are different. A primary increase in VEGF could lead to a 
secondary local increase in NO but this would occur several days later. 
Alternatively, NO synthesis may be modulated by factors independent of hypoxia 
and VEGF, which obscure changes associated with these molecules. Finally, for 
reasons already discussed, measurement of NOx in peripheral venous blood is 
unlikely to be an accurate indicator of changes at the microvascular level. These 
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observations, although not demonstrating a direct relationship between VEGF 
and NO in SS, cannot exclude such a relationship at the microvascular level. 
5.5. RELATIONSHIP OF CTAD PLASMA VEGF AND NOx TO PLATELET COUNT 
Study design 
Having shown that platelet activation is likely to account for the high VEGF 
values in serum samples, it was important to determine whether variation in 
VEGF and NOx values between different SS groups could be accounted for by 
variation in platelet count. If CTAD plasma VEGF correlated with platelet count, 
this would suggest that plasma VEGF reflect platelet activation in vivo. If however 
plasma VEGF were independent of platelet count, this would suggest that other 
sources of plasma VEGF (e. g. endothelial VEGF) might account for the variability 
in plasma VEGF between the SS groups. CTAD plasma from controls (n=21), 
SS. std. (n=13), SS. cri. (n=7) and SS. HU. (n=8) were assayed for VEGF and NOx 
levels. These levels were then plotted against each other and against platelet 
count obtained from FBC. 
Results 
The mean platelet count (Xlo3/MM3) were 220+9.8 in controls, 326+30.3 in 
SS. std., 263±41.3 in SS. cri. and 343+64.7 in SS. HU. respectively. The dot-plot 
relationship between VEGF and platelet count was shown in Figure 5.5.1 and 
between NOx and platelet count in Figure 5.5.2. 
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Fiqure 5.5.1 Dot-plot relationship between VEGF and platelet count 
There was no correlation between VEGF and platelet count in CTAD plasma. The 
r values were 0.24 in all subjects together, 0.15 in control group, 0.15 in SS. std. 
group, 0.16 in SS. cri. group and 0.06 in SS. HU. group respectively. 
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Figure 5.5. Dot-plot relationship between NOx and platelet count 
There was no correlation between NOx and platelet count in CTAD plasma. The 
correlation coefficient (r) is less than 0.50 in all 4 groups of subjects. The r values 
were 0.15 in all subjects together, 0.14 in control group, 0.11 in SS. std. group, 
0.36 in SS. cri. group and 0.12 in SSAU. group respectively. 
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Discussion 
In CTAID plasma samples, VEGF values are essentially independent of the 
platelet count. This means that in such samples, in vitro platelet activation is 
unlikely to account for the variability in VEGF observed. Platelet activation in this 
sample is inhibited in vitro, however. The results also imply that differences in 
VEGF between patient groups are not simply related to VEGF release from 
platelets in vivo as a function of platelet count, since there was no correlation of 
platelet count with VEGF. Therefore variability between patients groups in CTAD 
plasma may result from variability in release of VEGF from other sources, such 
as endothelial cells. Raised VEGF levels in sickle cell patients, are therefore not 
due to the raised platelet count, but may be due to platelet activation or to the 
VEGF release from other cells. 
In order to address whether VEGF levels in vivo reflect platelet activation 
rather than platelet count. CTAD plasma VEGF levels were compared with values 
of two known platelet activation markers (BTG & P174). However before this 
relationship was explored, preliminary examination of the relationship between 
platelet count and BTG and PF4 was examined in section 5.6. 
5.6. RELATIONSHIP OF PLATELET COUNT TO CTAD PLASMA BTG AND PF4 
Study design 
Having shown no relationship between VEGF and NOx with platelet count 
in either controls or any of SS groups, platelet activation markers were compared 
with platelet count in CTAD plasma. This is a control experiment to make sure 
that both BTG and PF4 are released from activated platelets. The same samples 
as the previous section were assayed for BTG and PF4, then compared with the 
results of platelet count obtained from FBC. 
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Results and discussion 
Platelet counts in normal controls, SS. std. SS. cri. and SS. HU. were 
220+10,326+30,263+41 and 342+65 xlO'/gl respectively. Levels of CTAD 
plasma BTG in control, SS. std., SS. cri. and SS. HU. were 26+2.6,146+14.1, 
141+17.9 and 128.4+26.5 IU/ml respectively and levels of PF4 were 10+1.1, 
39+4.1,46+11.3 and 34+6.9 IU/ml respectively (Figure 5.6.1). The dot-plot 
relationship between BTG and platelet count was shown in Figure 5.6.2 between 
PF4 and platelet count in Figure 5.6.3 and between BTG and PF4 in Figure 5.6.4. 
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Figure 5.6.1 Comparison of platelet count and platelet activation markers 
CTAID plasma from 21 normal control subjects, 13 sickle cell patients in steady 
state (SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 sickle cell patients 
undergoing hydroxyurea treatment (SS. HU. ) were assayed for platelet count 
(x103/ý[), BTG (IU/ml) and PF4 (IU/ml). *Indicates significantly higher than the 
control group (p<0.05 for platelet count, <0.001 for the rest). 
In all 3 groups of SS both BTG and PF4 were significantly higher than the 
control group (p<0.001). This shows a clear evidence of platelet activation in vivo 
in all 3 groups of SS. These levels in CTAD anticoagulant are likely to reflect the 
true levels in vivo. No significant difference was observed in either BTG or PF4 
levels between the 3 groups of SS. However the platelet count was significantly 
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higher than control in SS. std. and SS. HU. but not in SS. cri. The fall in platelet 
count in SS. cri. relative to SS. std. in this thesis is in agreement with two previous 
studies (Alkjaersig et al., 1976; Ittyerah et al., 1976), suggesting more platelet 
consumption during the crisis. This could suggest that platelet activation and 
consumption in SS. cri. patients is very high. 
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Figure 5.6. Dot-plot relationship between BTG and platelet count 
The correlation coefficients (r) were 0.56 in all subjects together, 0.25 in control 
group, 0.18 in SS. std. group, 0.97 in SS. cri. group and 0.46 in SS. HU. group 
respectively. 
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Figure 5.6. Dot-plot relationship between PF4 and platelet count 
There was a correlation between PF4 and platelet count in CTAD plasma. The 
correlation coefficients (r) were 0.52 in all subjects together, 0.29 in control 
group, 0.37 in SS. std. group, 0.72 in SS. cri. group and 0.45 in SS. HU. group 
respectively. 
In Figure 5.6.3 and Figure 5.6.4, there is a strong correlation between the 
platelet count and BTG (r=0.970) and PF4 (r=0.716) in SS. cri. Furthermore, these 
markers are significantly raised in SS. cri. (Figure 5.6.1). However, the platelet 
count in this particular group is actually lower, the raised levels of BTG and PF4 
must reflect platelet activation. This finding is in agreement with previous reports 
that the platelets of crisis SS patients are easily activated in vivo and increased 
formation of aggregates and release of BTG and PF4 (Westwick et al., 1983). In 
those reports, both the BTG and PF-4 levels were significantly higher in patients 
than in controls (Adamides et al., 1990). In another study, AIDP release indicated 
platelet activation during acute sickle pain crisis (Beurling-Harbury & Schade, 
1989). Thus, the finding in this thesis confirms platelet activation in SS with high 
levels of platelet activation markers and platelet consumption in crisis patients. 
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5.7. RELATIONSHIP OF CTAD PLASMA VEGF AND NOx TO 
PLATELETACTIVATION MARKERS 
Study design 
The previous sections have established that serum and EDTA plasma 
VEGF levels are affected by platelet activation in vitro and that CTAID samples 
inhibit this activation. Platelet activation in vivo was examined for any relationship 
with CTAID plasma VEGF or NOx. If platelet activation is part of the process of 
vaso-occlusion (as suggested in section 5.6), then markers of platelet activation 
might correlate with VEGF or NOx in sickle cell patients. This could result from 
either secondary increment in VEGF and NO as a result of local hypoxia, or from 
release of VEGF from activated platelets. The same CTAID samples as in the 
previous section were used. VEGF and NOx levels were compared with BTG and 
PF4 levels. 
Results 
CTAD plasma VEGF (pg/ml) levels were 10.7+0.4 in controls (n=21), 
18.0+1.1 in SS. std. (n=13), 23.0+3.3 in SS. cri. (n=7) and was 23.5+3.6 in SS. HU. 
(n=8) respectively. The CTAD plasma NOx (gM) levels were 20±1.5 in controls, 
22+1.7 in SS. std., 23+2.9 in SS. cri. and 24±2.4 in SS. HU. respectively. 
CTAD plasma levels of BTG in controls, SS. std., SS. cri. and SS. HU. were 
26+2.6,146+14.1,141±17.9 and 128.4+26.5 IU/ml respectively and of PF4 were 
10±1.1,39±4.1,46±11 1.3 and 34+6.9 IU/ml respectively. 
The dot-plot relationship between VEGF and BTG is shown in Fiqure 5.7.1, 
between VEGF and PF4 in Figure 5.7.2, between NOx and BTG in Figure 5.7.3, 
between NOx and PF4 in Ficiure 5.7.4 and between BTG and PF4 in Ficiure 5.7.5. 
For all samples, these appear to be a weak correlation between VEGF and 
BTG (r=0.69) and between VEGF and PF4 (r=0.58) respectively. In SSAU. group 
alone, these correlation were also weak (r=0.71 and 0.79 respectively). In the 
another 2 groups, no correlation was observed. These weak correlation may be 
due to a slight contribution of platelet activation in vivo, which is known to release 
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some VEGF. Otherwise it may be a false correlation, because when all samples 
are put together, the lower value in controls and the higher values in patients 
might create an accidental correlation. 
40 
30 
E 
CY) CL 
20 
LL 
C) 
w 
> 10 
0 
0 
0,4q0 0 
- an-- OD 
. CTAD-VEGF 
* Control (21) 
* SS. std. (13) 
SS. cri. (7) 
SS. HU. (8) 
0 100 200 300 
BTG (IU/ml) 
Figure 5.7.1 Dot-plot relationship between VEGF and BTG 
There is a weak correlation between VEGF and BTG in CTAD plasma. The 
correlation coefficients (r) were 0.69 in all subjects together, 0.16 in control 
group, 0.27 in SS-std. group, 0.13 in SS. cri. group and 0.71 in SSAU. group 
respectively. 
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Figure 5.7.2 Dot-plot relationship between VEGF and PF4 
There was a weak correlation between VEGF and PF4 in CTAD plasma. The 
correlation coefficients (r) were 0.58 in all subjects together, 0.10 in control 
group, 0.03 in SS. std. group, 0.03 in SS. cri. group and 0.79 in SS. HU. groups 
respectively. 
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Figure 5.7.3 Dot-plot relationship between NOx and BTG 
There was no correlation between NOx and BTG in CTAD plasma. The 
correlation coefficients (r) were 0.36 in all subjects together, 0.62 in control 
group, 0.37 in SS. std. group, 0.38 in SS. cri. group and 0.51 in SS. HU. group 
respectively. 
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There was no correlation between NOx and PF4 in CTAD plasma. The 
correlation coefficients (r) were 0.43 in all subjects together, 0.69 in control 
group, 0.18 in SS. std. group, 0.67 in SS. cri. group and 0.55 in SS. HU. group 
respectively. 
Although the overall data showed no correlation between NOx and BTG 
and PF4, the control group (r=0.620 and 0.692 for BTG and PF4 respectively) and 
SS. HU. group (r=0.511 and 0.550 for BTG and PF4 respectively) appeared to 
show some weak correlation. However, the SS. cri. group but not the SS. std. 
group, appeared to show a relationship between platelet activation and NOx. This 
could mean that in crisis, there is platelet activation, which is associated with 
microvascular occlusion and hypoxia, leading to NO and VEGF release from 
endothelium. Alternatively, this could be a separate event that occurs 
coincidentally. 
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Figure 5.7. Dot-plot relationship between BTG and PF4 
There was a strong correlation between BTG and PF4 in CTAD plasma. The 
correlation coefficients (r) were 0.87 in all subjects together, 0.93 in control 
group, 0.79 in SS. std. group, 0.65 in SS. cri. group and 0.94 in SS. HU. group 
respectively. 
Discussion 
The weak correlation between VEGF and platelet activation in vivo found in 
this section, is important because it contrasts with the lack of correlation between 
VEGF and platelet counts in the previous section. This suggests that plasma 
VEGF values are not derived totally from platelet activation in SS patients. CTAD 
plasma VEGF appears to be independent of platelet count but platelet activation 
still contributes at least in part to VEGF levels in SS patients. It is likely that VEGIF 
values also reflect activation of other VEGF containing cells. In the next section, 
the relationship of VEGF to markers of endothelium activation is addressed to 
examine whether activation of these cells is important in determining VEGF 
levels. The strong correlation between BTG and PF4 is the consequence of their 
concomitant release from the same alpha-granules after platelet activation. 
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5.8. RELATIONSHIP OF CTAD PLASMA VEGF AND NOx TO ENDOTHELIAL 
ACTIVATION MARKERS 
Study design 
Having shown that plasma VEGF is independent of platelet count with only 
a weak association with platelet activation, how plasma VEGF related to markers 
of endothelial activation was further examined. The same samples as the 
previous sections were assayed for CTAD plasma VEGF, NOx, sE-Selectin and 
sVCAM-1, then the relationships among them were determined. 
Results 
Levels of CTAD plasma sE-Selectin in controls (n=21), SS. std. (n=13), 
SS. cri. (n=7) and SS. HU. (n=8) were 36±2.2,91+14.6,77+18.7 and 52+6.1 ng/ml 
respectively and of sVCAM-1 were 332+10.6,750±76.8,745±67.3 and 684±59.3 
ng/ml respectively. This shows a significant increase of both sE-selectin and 
sVCAM-1 in all 3 SS groups over the control group (p<0.001), but no significant 
difference was observed between SS. std., SS. cri. and SS. HU. (Figure 5.8.1). 
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Figure 5.8.1 Comparison of endotheliall activation markers 
CTAD plasma from 21 normal control subjects, 13 sickle cell patients in steady 
state (SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 sickle cell patients 
undergoing hydroxyurea treatment (SS. HU. ) were assayed for sE-Selectin (ng/ml) 
and sVCAM-1 (x1O ng/ml). *Indicates significantly higher than control group 
(p<0.005). S Indicates x1O of actual values. 
The dot-plot relationship between sE-Selectin and sVCAM-1 is shown in 
Figure 5.8.2, between VEGF and sE-Selectin is shown in Figure 5.8.3, between 
VEGF and sVCAM-1 in Figure 5.8.4, between NOx and sE-Selectin in Figure 5.8.5 
and between NOx and sVCAM-1 in Fiqure 5.8.6 respectively. 
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Figure 5.8. Dot-plot relationship between sE-Selectin and sVCAM-1 
There was a weak correlation between sE-Selectin and sVCAM-1 in CTAD 
plasma. The correlation coefficients (r) were 0.56 in all subjects together, 0.29 in 
control group, 0.56 in SS. std. group, 0.34 in SS. cri. group and 0.13 in SS. HU. 
group respectively. 
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Figure 5.8. Dot-plot relationship between VEGF and sE-Selectin 
There is no correlation between VEGF and sE-Selectin in CTAD plasma. The 
correlation coefficients (r) were 0.27 in all subjects together, 0.18 in control 
group, 0.11 in SS. std. group, 0.02 in SS. cri. group and 0.03 in SS. HU. group 
respectively. 
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Figure 5.8. Dot-plot relationship between VEGF and sVCAM-1 
There was no correlation between VEGF and sVCAM-1 in CTAD plasma. The 
correlation coefficients (r) were 0.42 in all subjects together, 0.11 in control 
group, 0.03 in SS. std. group, 0.47 in SS. cri. group and 0.13 in SS. HU. group 
respectively. 
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Figure 5.8. Dot-plot relationship between NOx and sE-Selectin 
There was no correlation between NOx and sE-Selectin in CTAD plasma, except 
a weak correlation in SS. cri. The correlation coefficients (r) were 0.25 in all 
subjects together, 0.03 in control group, 0.15 in SS. std. group, 0.69 in SS. cri. 
group and 0.18 in SS. HU. group respectively. 
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Fiqure 5.8. Dot-plot relationship between NOx and sVCAM-1 
There was no correlation between NOx and sVCAM-1 in CTAD plasma, except a 
weak correlation in SS. cri. The correlation coefficients (r) were 0.01 in all subjects 
together, 0.12 in control group, 0.14 in SS. std. group, 0.67 in SS. cri. group and 
0.17 in SS. HU. group respectively. 
Discussion 
There is a significant increase in the levels of sE-selectin and VCAM-1 in 
all SS groups compared with the control group (p<0.005). An increase in sVCAM- 
1 in sickle cell disease has been documented previously (Duits et al., 1996; 
Stuart & Setty, 1999). However, this is the first document that sE-Selectin has 
been found significantly increased in SS over the normal subjects. This provides 
a clear evidence of vascular endothelium cell activation in sickle cells patients in 
vivo. 
As expected, there is a correlation between sE-selectin and sVCAM-1. 
Both E-Selectin and VCAM-1 are cellular adhesion molecules (CAMs) found on 
vascular endothelial cells (VECs). CAMs also act as receptors for other adhesion 
molecules on the other cells. When VECs are activated, CAMs are upregulated 
and bound to their ligands on granulocytes, monocytes, lymphocytes and 
platelets. After activation, these CAMs are shed off to become the soluble forms 
(sE-Selectin and sVCAM-1) which neutralise their respective ligands on the other 
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cells. This is a negative feed back loop, which may prevent or delay adhesion. 
Since both sE-Selectin and sVCAM-1 are shed under the same situations, a 
correlation between these two parameters is therefore expected. 
CTAD plasma VEGF levels correlated weakly with sVCAM-1 (r=0.42), while 
no correlation with sE-Selectin were observed. There was a weak correlation 
between VEGF and sVCAM-1 in SS. cri. (r=0.47) but not in SS. std. This finding 
indicates that the increased VEGF levels are associated with endothelial 
damage or activation in SS in crisis. As sVCAM-1 is a marker of VEC activation, 
this correlation, together with the weak correlation of VEGF with platelet activation 
markers (BTG and P174) but not with the platelet count suggests that at least a 
part of plasma VEGF levels is derived from activated VECs. Unfortunately, 
sVCAM-1 is not a specific marker of VEC activation, for example dendritic cells 
may also shed VCAM-1. Another more specific VEC activation marker, sE- 
Selectin, does not correlate with VEGF either in steady state or in crisis. However, 
the mean levels of sE-Selectin in all 3 SS groups were significantly higher than 
the control group, showing evidence of VEC activation in sickle cell disorders. 
NOx did not correlate with endothelial activation markers in SS as a whole. 
However, there were correlation of NOx with both sE-Selectin (r=0.69) and 
sVCAM-1 (r=0.66) in SS. cri. but this correlation is probably dependent on a single 
point, which is high for both values, otherwise there is no correlation. 
Interpretation should be made with caution in this small number of samples. 
There is also no correlation between NOx with either sVCAM-1 or with sE- 
Selectin in control, SS. std. and SS. HU. groups 
Taken together, the findings in this section provide clear evidence of 
vascular endothelial cell activation in sickle cell disorders. In overall there is no 
clear correlation between endothelial activation markers and NOx but weak 
correlation between VEGF and sVCAM-1 both in all subjects together and in 
crisis SS were found. 
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5.9. RELATIONSHIP OF PLASMA VEGF AND NOx TO ANAEMIC MARKERS 
Rationale 
Erythropoietin (Epo), a glycoprotein of 30.4 kDa produced by kidney cells, 
is the principal hormone regulating red cell production (erythropoiesis). 
Production of Epo is regulated by changes in oxygen availability to the kidney 
cells. Epo-producing cells are the fibroblast-like type I interstitial cells (Maxwell et 
al., 1993) or peritubular cells (Lacombe et al., 1988). 
VEGF and Epo are both activated by a similar hypoxic mechanism, Epo 
and Hb were examined to see if there was any relationship with VEGF and NOx. It 
was important to determine whether plasma VEGF levels responded to 
generalised hypoxia, resulting from low Hb, or whether the local ischaernia of 
vaso-occlusion was more important. Haemoglobin (Hb) and erythropoietin (Epo) 
were therefore compared with VEGF and NOx of normal control subjects, 
production defect anaernic patients, and sickle cell disorders. 
5.9.1. Comparison of EDTA plasma VEGF, NOx, Epo and blood Hb levels 
Blood samples 
EDTA plasma samples were taken from 20 control subjects, 8 sickle cell 
patients in steady state (SS. std. ), 8 sickle cell patients in crisis (SS. cri. ), 7 sickle 
cell patients undergoing hydroxyurea treatment and 12 production anaernic 
patients (iron, vitamin B12 or folate deficiency patients, Table 5.9.1). Epo, VEGF 
and NOx levels were determined using commercial ELISA test kits (section 2.5.3) 
and blood Hb levels were obtained from routine FBC data. These parameters 
were performed on EDTA plasma prior to the finding that CTAD was more 
suitable for VEGF measurement. A subsequent study (section 5.9.2) examines 
the relationship between VEGF, NOx and Epo, using CTAD plasma. 
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Table 5.9.1 Diagnosis and clinical data of productional anaernic patients 
No. Age Sex Diagnosis Hb B12 Folate Sl IBC Ferritin 
1. 76 m Fe def. 6.9 816 655 3.2 52 
2. 83 M B12 def. 8.1 112 - - - 
3. 86 F Fe & Fol def. 7.3 285 204 1.7 65 64 
4. 93 F Fol def. 7.3 - 282 11.3 34 270 
5. 88 M Fe def. 10.7 - - 6.1 63 - 
6. 43 F Fe def. 10.4 - - 4.2 66 34 
7. 55 F Fe & Fol def. 6.6 502 31 5.6 26 - 
8. 27 F Fe & Fol def. 5.8 273 405 1.8 72 4 
9. 63 F Fe def. 7.6 - - 2.0 65 6 
10. 82 M Fe def. 9.8 603 784 2.9 62 - 
11. 49 F Fe def. 7.4 - - 2.7 61 5 
12. 30 F Fe def. 10.0 - - 3.8 80 4 
B12 = vitamin B12 (200-1000 pg/ml), Folate = red cell folate (550-2200 nM), Sl 
serum iron (7-45 uM), IBC = iron binding capacity (male 20-50, female 15-50 %), 
Feritin = serum feritin (male 30-284, female 6-186 gg/ml), Age = years, M 
male, F= female, Fe = iron, Fol = folate, def = deficiency, ND = No data 
Results 
Blood Hb levels in normal control subjects (n=20), SS. std. (n=8), SS. cri. 
(n=8), SS. HU. (n=7) and production anaernic patients (n=12) were 14.2±0.3, 
8.4±0.3,7.9+0.6,8.7+0.5 and 8.2+0.5 g/dI, respectively. Levels of EDTA plasma 
Epo in controls, SS. std., SS. cri., SSAU. and anaernic patients were 3±0.5, 
53±8.0,61±8.9,47+6.1 and 46+9.7 mIU/ml, respectively. Levels of EDTA plasma 
VEGF in controls, SS. std., SS. cri., SS. HU. and anaernic patients were 22+2.6, 
115±51.6,73±9.9,170+53.3 and 46+9.7 pg/ml respectively. Levels of EDTA 
plasma NOx in controls, SS. std., SS. cri., SS. HU. and anaernic patients were 
27±3.0,25±2.4,25±2.1,28+4.9 and 32+7.2 ^ respectively. The Epo levels in all 
4 groups of patients were significantly higher than in the control group (p<0.001), 
but no significant difference between SS. std., SS. cri. and SS. HU. groups were 
observed. The Hb level was significantly lower in all 4 patient groups than in the 
control group (p<0.001), but no significant different between SS. std., SS. cri. and 
SS. HU. was observed (Figure 5.9.1.1). The dot-plot relationship between Hb and 
Epo is shown in Figure 5.9.1.2. between VEGF and Hb in Figure 5.9.1.3, between 
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VEGF and Epo in Figure 5.9.1.4, between NOx and Hb in Fiqure 5.9.1.5 and 
between NOx and Epo in Figure 5.9.1.6 respectively. 
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Fiqure 5.9.1.1 Levels of blood Hb, EDTA plasma Epo, VEGF and NOx 
Comparison of blood Hb (g/dl) and EDTA plasma Epo (mlU/ml), VEGF 
(#xlOpg/ml) and NOx (ýM) levels in normal control subjects (Control, n=20), 
sickle cell patients in steady state (SS. std., n=8), sickle cell patients in crisis 
(SS. cri., n=8), sickle cell patients undergoing hydroxyurea treatment (SS. HU., 
n=7) and production anaemic patients (Anaemia, n=12) were shown. *Indicates 
significantly higher than control group (p<0.001). AIndicates significantly lower 
than control group (p<0.05). There was no significant difference among SS. std-, 
SS. cri. and SSAU. groups in any parameter. 
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Figure 5.9.1.2 Dot-plot relationship between blood Hb and EDTA plasma Epo 
There was a strong inverse correlation between Hb and Epo in EDTA plasma. 
The correlation coefficients (r) were 0.77 in all subjects together, 0.50 in control 
group, 0.25 in SS. std. group, 0.60 in SS. cri. group, 0.26 in SS. HU. group and 0.61 
in anaernic group respectively. 
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Figure 5.9.1.3 Dot-plot relationship between EDTA plasma VEGF and blood Hb 
There was no correlation between VEGF and Hb in EDTA plasma, except a weak 
correlation in SS. std. The correlation coefficients (r) were 0.35 in all subjects 
together, 0.39 in control group, 0.60 in SS. std. group, 0.18 in SS. cri. group, 0.48 in 
SS. HU. group and 0.14 in anaernic group respectively. 
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Figure 5.9.1.4 Dot-plot relationship between EDTA plasma VEGF and Epo 
There was no correlation between VEGF and Epo in EDTA plasma, except a 
weak correlation in SS. std. and SS. HU. The correlation coefficients (r) were 0.40 
in all subjects together, 0.20 in control group, 0.52 in SS. std. group, 0.33 in 
SS. cri. group, 0.61 in SS. HU. group and 0.06 in anaernic group respectively. 
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Figure 5.9.1.5 Dot-plot relationship between EDTA plasma NOx and blood Hb 
There was no correlation between NOx and Epo in EDTA plasma. The correlation 
coefficients (r) were 0.06 in all subjects together, 0.13 in control group, 0.46 in 
SS. std. group, 0.34 in SS. cri. group, 0.29 in SS. HU. group and 0.40 in anaernic 
group respectively. 
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Fi_qure 5.9.1.6 Dot-plot relationship between EDTA plasma NOx and Epo 
There was no correlation between NOx and Epo in EDTA plasma. The correlation 
coefficients (r) were 0.10 in all subjects together, 0.13 in control group, 0.16 in 
SS. std. group, 0.28 in SS. cri. group, 0.17 in SS. HU. group and 0.29 in anaernic 
group respectively. 
Discussion 
There are increments of Epo levels and reduction in Hb levels in both 
production amaemias and all 3 sickle groups. However VEGF is not significantly 
increased in the production anaernia group. Thus, generalised anaernia does 
not in itself lead to plasma VEGF upregulation. Therefore the raised in VEGF 
levels in sickle cell groups are most likely to be due to other factors. Dot plot 
analysis shows the expected inverse relationship between Hb and Epo but 
confirms no relationship between VEGF and Hb or Epo in production anaernia or 
in steady state SS. In HU-treated SS, there appears to be a possible relationship 
between VEGF with Hb and with Epo but the numbers are small (n=7). Plasma 
NOx values are unaltered in anaernic or sickle patients and do not correlate with 
either Hb or Epo levels. 
The findings in this section therefore suggest that the raised VEGF values 
seen in SS are independent of generalised hypoxia or anaernia and are likely to 
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result from other causes. The most likely causes are expected to be local hypoxia 
consequence from vaso-occlusion, platelet and endothelial cell activation. 
5.9.2. Relationship of CTAD plasma VEGF and NOx to Epo and blood Hb 
Study design 
In section 5.9.1, EDTA plasma was used for measurements of VEGF, NOx 
and Epo. That study was performed before finding that CTAD anticoagulant could 
inhibit platelet activation in vitro, leading to lower VEGF values, which reflected 
the true values in vivo. A further study was undertaken to examine the 
relationship of CTAD plasma VEGF and NOx to Epo and blood Hb levels in SS. 
Blood samples were obtained from 21 control subjects (Control), 13 sickle cell 
patients in steady state (SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 
sickle cell patients undergoing hydroxyurea treatment (SS. HU. ) and were 
assayed for these parameters using commercial test kits (section 2.5.3). Hb 
levels of these samples were obtained from routine FBC data. 
Results 
Levels of blood Hb (g/dl) in the controls (n=21), SS. std. (n=13), SS. cri. 
(n=7) and SS. HU. (n=8) were 13.8+0.3,8.6±0.5,7.4+0.5 and 8.5±0.4 g/dl 
respectively, with significantly lower levels in all 3 SS groups compared to in 
control group (p<0.001), but no significant difference was observed between 
SS. std., SS. cri. and SS. HU. Levels of CTAD plasma Epo (mlU/ml) in the controls, 
SS. std., SS. cri. and SS. HU. were 4+0.4,62.9+10.7,59+5.5 and 80+14.9 
respectively, with significantly higher values in all 3 SS groups than in the control 
group (p<0.0001), but no significant difference was observed between SS. std., 
SS. cri. and SS. HU. groups (Figure 5.9.2.1). The dot-plot relationship between Hb 
and Epo is shown in Figure 5.9.2.2, between VEGF and Hb is shown in Figur 
5.9.2.3, between VEGF and Epo in Figure 5.9.2.4, between NOx and Hb in Figure 
5.9.2.5 and between NOx and Epo in Figure 5.9.2.6 respectively. 
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Figure 5.9.2.1 Comparison of levels of blood Hb and CTAD plasma Epo 
CTAD plasma from 21 normal control subjects, 13 sickle cell patients in steady 
state (SS. std. ), 7 sickle cell patients in crisis (SS. cri. ) and 8 sickle cell patients 
undergoing hydroxyurea treatment (SS. HU. ) was assayed for Epo (mIU/mI) and 
Hb concentrations were obtained from FBC data. *Indicates significantly higher 
than control group (p<0.001). 'Indicates significantly lower than control group 
(p<0.05). 
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Figure 5.9.2.2 Dot-plot relationship between blood Hb and CTAD plasma Epo 
There was a strong inverse correlation between Hb and CTAD plasma Epo in 
overall and in SS. std. group. The correlation coefficients (r) were 0.75 in all 
subjects together, 0.20 in control group, 0.60 in SS. std. group, 0.32 in SS. cri- 
group and 0.08 in SS. HU. group respectively. 
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Figure 5.9.2.3 Dot-plot relationship between blood Hb and CTAD plasma VEGF 
There was a weak correlation between Hb and CTAD plasma VEGF in over all 
group. The correlation coefficients (r) were 0.58 in all subjects together, 0.14 in 
control group, 0.19 in SS. std. group, 0.06 in SS. cri. group and 0.37 in SS. HU. 
group respectively. 
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Figure 5.9.2.4 Dot-plot relationship between CTAD plasma VEGF and Epo 
There was a weak correlation between Hb and CTAD plasma Epo in over all 
group. The correlation coefficients (r) were 0.55 in all subjects together, 0.17 in 
control group, 0.00 in SS. std. group, 0.49 in SS. cri. group and 0.03 in SSAU. 
group respectively. 
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Ficlure 5.9.2.5 Dot-plot relationship between blood Hb and CTAD plasma NOx 
There was no correlation between Hb and CTAD plasma NOx. The correlation 
coefficients (r) were 0.18 in all subjects together, 0.37 in control group, 0.46 in 
SS. std. group, 0.17 in SS. cri. group and 0.12 in SS. HU. group respectively. 
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Figure 5.9.2.6 Dot-plot relationship between CTAD plasma NOx and Epo 
There was no correlation between CTAD plasma NOx and Epo. The correlation 
coefficients (r) were 0.16 in all subjects together, 0.35 in control group, 0.06 in 
SS. std. group, 0.47 in SS. cn. group and 0.33 in SS. HU. group respectively. 
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Discussion 
These findings confirm those in section 5.9.1 that levels of VEGF appear 
essentially independent of Hb and Epo levels. Thus the raised VEGF in sickle 
disorders is unlikely to be a consequence of generalised hypoxia. The values of 
EDTA plasma VEGF (section 5.9.2) are generally higher than the values in CTAD 
plasma (this section). The finding of higher values in EDTA plasma appeared to 
be secondary to platelet activation in vitro during blood collection and storage. 
The difference between EDTA and CTAD VEGF levels is much more marked in 
SS patients than in the controls, suggesting that there might be some factors in 
SS samples which accelerate platelet activation in vitro or more cell numbers or 
cell types that contain and are able to release VEGF after blood collection. With 
respect to the relationship between Hb and Epo with VEGF, the conclusions from 
the findings in EDTA and CTAD plasma studies are essentially the same. The 
firm evidence found is that generalised hypoxia does not account for increased 
plasma VEGF levels. 
The correlation was determined in a total of 49 CTAD blood samples 
regardless of diagnosis. As expected, Epo levels were negatively correlated with 
Hb levels (r=0.75), consistent with anaernia-associated renal hypoxia inducing 
Epo release. Importantly, VEGF levels were significantly negatively correlated with 
Hb levels (r=0.58), and positively correlated with Epo levels (r--0.55). This is 
consistent with the original hypothesis that tissue hypoxia could induce VEGF 
production and release. The anaernic patients studied here were all SS. It is 
possible therefore that the relationship between VEGF and Hb is only found in SS 
patients. However, it should be noted that, in preliminary studies (performed in 
EDTA plasma samples before knowing that CTAID was preferable) showed a 
weak negative correlation between VEGF and Hb and a weaker positive 
correlation between VEGF and Epo (r=0.35 and 0.40 respectively). 
The levels of Epo in all 3 groups of SS were higher but the Hb levels were 
lower than in the control group. The high Epo levels result from the anaernic 
status in these patients. In addition, the CTAID plasma VEGF level was 
significantly correlated with Epo and with Hb, with the stronger correlation than in 
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EDTA plasma. This indicates that VEGF shares the same anaernic or low 02 
responsive process with Epo and Hb. The relationship appeared stronger in 
CTAD than in EDTA plasma because the interference of VEGF release from 
platelet activation in vitro was prevented. There was no correlation between NOX 
levels in CTAD plasma with either Epo or Hb. 
5.10. CONCLUSIONS 
The principle finding in this chapter is that plasma VEGF is raised in sickle 
cell disorders, a finding not previously reported when this work was started. This 
finding has since been confirmed by others (Solovey et a/., 1999). 
The original hypothesis which triggered the work in this chapter was that 
as VEGF synthesis was controlled by a hypoxia sensitive element in vascular 
endothelial cells (VECs), microvascular occlusion and consequent tissue 
hypoxia in sickle cell disorders would lead to increased VEGF synthesis in VECs. 
The initial finding in this thesis that VEGF was raised in serum samples of SS 
patients could have been interpreted as consistent with this hypothesis. 
However, it soon became apparent that in vitro platelet activation was 
responsible for the majority of serum VEGF. This was not reported at the 
commencement of this work but has subsequently been confirmed by a variety of 
investigators in non-sickle patients. Interestingly, it appears that VEGF release in 
vitro is greater in SS patients than in control subjects, suggesting a greater 
tendency to platelet activation in vitro in sickle cell disorders. The reason for this 
has not been investigated in this thesis, but at, platelet activation is a recognised 
feature of SS and sickle red cells or red cell spicules are known to interact with 
platelets, it is likely that this process occurs in vitro during collection of the serum 
samples. It is clear that CTAD, which inhibits in vitro platelet activation also 
inhibits VEGF release in vitro, but that even in CTAD plasma, VEGF is 
significantly greater in SS patients than in control subjects. 
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The question therefore arises as to the mechanism of raised VEGF levels 
and whether this results from hypoxia-mediated vaso-occlusion or from platelet 
or endothelial activation. The evidence presented in this thesis is inconclusive in 
this regard but offers some clues. It is clear that generalised hypoxia, such as 
occurs with anaemia, is not the cause of the raised VEGF. This is because VEGF 
is not raised in production anaernia, a new finding, and secondly because VEGF 
does not correlate with Epo or Hb in production anaernic or in SS patients. There 
is no obvious relationship between VEGF and markers of endothelial activation, 
sE-Selectin and sVCAM-1, although both are raised in SS patients relative to 
healthy control subjects. Raised sVCAM-1 has been reported previously in SS 
patients but not in sE-selectin. A lack of correlation between VEGF and these 
endothelial markers does not exclude an endothelial origin of VEGF but 
suggests that the factors determining plasma levels of VEGF and endothelial 
makers are not regulated in the same way. 
The evidence with respect to platelet activation requires careful scrutiny. In 
CTAD plasma, VEGF levels in SS patients are approximately 2 fold higher than in 
the control group, whereas BTG and PF4, markers of platelet activation, are 
raised by approximately 6 and 4 fold in SS patients over the control subjects. 
Thus VEGF is raised in SS patients proportionally less than markers of platelet 
activation. However, production of VEGF is not restricted to platelets. There are 
many sources of VEGF, which may associated with raised plasma VEGF such as 
vascular endothelial cells, vascular muscle cells, leukocytes and platelets. 
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CHAPTER 6 
GENERAL CONCLUSION AND FUTURE TRENDS 
6.1. KEY THEMES OF THE THESIS 
Although the basic pathophysiology of sickle cell anaemia (SS) is well 
known, the sources of variability in disease severity are incompletely understood. 
In this thesis a number of factors which have the potential to modify the severity of 
SS have been examined. The importance of foetal haernoglobin (HbF) on 
modifying SS has been increasingly recognised but it is clear that HbF levels are 
not the sole determinants of disease severity. For example adhesion of blood cells 
to endothelium also appears to be important. The factors examined in this thesis 
include the role of HbF in red cells, surface adhesion molecule (AM) expression on 
red cells and the effect of a number of endothelial factors. 
Key goals in this thesis were to examine how HbF in red cells and the 
presence of AMs on red cells could interact as determinants of disease severity. In 
order to examine this interaction, it was first necessary to develop a technique to 
measure co-expression of AMs, HbF and RNA in the red cells. The first part of the 
thesis was therefore concerned with development of suitable methodology. A 
method of staining for surface red cell adhesion molecules and for internal HbF 
and RNA contents was successfully developed which has not been described 
previously. The relative effects of HbF expression and AM expression on survival 
of red cells beyond the reticulocyte stage were then examined in SS patients in 
steady state, in crisis and on HU treatment. The shedding of AMs by reticulocyte in 
culture was also examined in order to gain insight into the relative expression of 
AMs in mature red cell and reticulocyte populations. 
270 
Chapter 6 
6.2. KEY METHODOLOGICAL DEVELOPMENTS 
Single-colour staining flow cytometty 
The first new development in this thesis was to simplify the flow cytometric 
method for F'cell assay obtained from Davis et a/. 1998. The simplified procedure 
contains no washing step and gives comparable results with more convenience 
than previously. Either FITC or TC conjugated to monoclonal antibody against 
human HbF (MoAb-HbF-FITC or MoAb-HbF-TC) can be used without any 
difference in procedure nor results obtained. Three conventional (EDTA, citrate, 
heparin) and 1 special (CTAD) anticoagulants are all suitable for the procedure. 
The samples can be kept at 40C for 2 weeks prior to test without any change in 
results obtained. Reproducibility indicated by intra- and inter-assay %CVs are 
acceptable (not exceed 10 and 20% respectively). The simplified procedure for 
F'cells assay developed in this thesis is now available to be applied in any flow 
cytometric laboratory. 
Double-colour staining flow cytometry 
The second achievement in this thesis was the development of a double- 
colour staining flow cytometry for simultaneous assay of F+cells, reticulocytes and 
F+reticulocytes. The original procedure was taken from Dr. Bruch H. Davis 
(personal communication). However, the procedure was then simplified to contain 
no washing step and no volume calculation. This simplification needs less than one 
and a half hours to be ready for flow cytometry. All 4 anticoagulants mentioned 
before are suitable for the procedure. The reproducibility is acceptable, indicated 
by intra- and inter-assay %CVs less than 10 and 20% respectively. Samples can 
be kept at 4"C for 5 days prior to test. This is relatively convenient for the sample 
obtained on Friday afternoon to be kept in a refrigerator over the weekend to be 
performed on the next working day even on the longer holiday for up to 4 days. 
The results obtained from this procedure are relatively the same as the results 
obtained from single-colour staining. Furthermore, %reticulocytes obtained from 
this procedure are comparable to the results obtained from a reticulocyte analyser 
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(Sysmex SE-9500). This procedure is also ready to be installed in any flow 
cytometry laboratory. 
Triple-colour staining flow cytometfy 
The third and probably the most important achievement in this thesis is the 
development of simultaneous triple-colour staining flow cytometry for measurement 
of the co-distribution of AMs (CD36, CD41 and CD49d). HbF (F*cells) and RNA 
(reticulocytes). The 3 colours (green, red and deep-red) are used to stain RNA, 
AMs and HbF in the same assay. AMs, which are surface molecules, are stained 
first, follow by HbF and RNA, which are cytoplasmic molecules. Colour 
compensation has to be used in order to reduce the interference of one colour to 
another. This was done on a special program named "fast comp" in the computer, 
which controls all functions of flow cytometer. The results obtained from this 
procedure are consistent with the results obtained from the separated single-colour 
staining procedures. All 4 anticoagulants mentioned before are suitable for the 
procedure. The reproducibility is acceptable, indicated by intra- and inter-assay 
%CVs less than 10 and 20% respectively. Samples can be kept at 4"C for 3 days 
prior to test. This procedure can in principle be applied in any flow cytometry 
laboratory. 
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6.3. KEY FINDINGS 
Contribution of foetal haemoglobin to sickle red cell survival 
The findings in this thesis confirm that HbF and F+cells are increased in SS 
patients and even more marked increase in HU-treated SS patients. Using the ratio 
of %F+mature red cells to F+reticulocytes recognised as the enrichment ratio (ER), 
it is clear that F+cells survive longer than F-cells, indicating an older age distribution 
of F+cells than F-cells. This is consistent with the finding that the patients who have 
higher %HbF or %F+cells, normally have less clinical complications. 
Contribution of adhesion molecules to survival of sickle red cells 
The proportion of reticulocytes expressing AMs are much higher than the 
proportion of mature red cell expressing the same AMs. This finding is consistent 
with the knowledge that younger cells carry more AMs, since AMs are required for 
homing and maintaining cells within the bone marrow. Freshly released red cells 
(reticulocytes) still express surface AMs, and the in vitro culture of sickle 
reticulocyte shows that AMs are shed within 5 days of culture. However, this 
finding cannot rule out that AM expressing reticulocytes are preferentially 
sequestrated and removed from the circulation. Cells containing HbS polymers, 
become less flexible with slower transit through the microcirculation, and those 
which also express AMs, may be particularly likely to have shorter survival. 
Previous findings by other investigators that the proportions of reticulocytes and 
mature red cell expressing AMs in sickle cell patients are higher than in controls 
are consistent with the findings in this thesis. 
In HU-treated patients, the proportion of mature red cell but not reticulocytes 
expressing AMs is reduced. This finding disagrees with the previous claim by 
Styles et a/. 1997 that the reduction in AM expression is not caused by a decrease 
in reticulocytes in HU-treated patients. The findings in this thesis suggest that 
reduction in AM expression is secondary to the reduction of reticulocytes, since the 
% of reticulocytes expressing AMs is not significantly reduced after HU treatment. 
These findings are confirmed both in unpaired and paired studies. 
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Interactions of AMs and HbF on sickle red cell survival 
In healthy control subjects, the proportion of F+cells expressing AMs 
appears to be higher than for F-cells. This applies for both reticulocytes and mature 
red cells. This finding suggests that F+cells are possibly more primitive than F-cells, 
because they carry more AMs, which could be an indirect indicator for a less 
differentiated population. This is also consistent with a lack of survival advantage 
for F+cells over F-cells in the control subjects. This is the first documented finding 
that F+cells show any differentiating feature from F-cells other than HbF content. 
Unlike control subjects however, in sickle cell patients the proportions of 
cells expressing AMs is roughly equal in F+ve and F-ve populations. This indicates 
that HbF produces a benefit of prolonging red cell survival in SS patients. Because 
F+cells have a survival advantage, and therefore an older age distribution, they 
have more time to shed AMs. Thus the higher AM expression which is seen in 
F+cells of control subjects relative to F-cells is counterbalanced in SS patients by 
the longer survival of F+cells than F-cells leading to a lowering of AM expression in 
F+ve relative to F-ve populations. 
In HU-treated sickle cell patients, the proportion of F"cells expressing AMs 
appears to be even lower than in SS patients without HU treatment. Examination of 
HbF content in red cells post-HU treatment shows more HbF per F"cell, which 
would produce an additional survival benefit for such cells. Thus the effect of 
survival advantage leading to reduced AM expression is more pronounced than SS 
patients without HU treatment. 
Endothelial, platelet and anaemic factors in sickle cell disorders 
The original hypothesis which triggered the work in Chapter 5 was that as 
VEGF synthesis by endothelium is controlled by a hypoxia-sensitive element in 
vascular endothelial cells (VECs), microvascular occlusion and consequent tissue 
hypoxia in sickle cell disorders could lead to increased VEGF synthesis in VECs. 
Furthermore, as nitric oxide synthase (NOS) is also responsive to hypoxia, plasma 
levels of NOx (NO metabolites), might be predicted to be influenced by vaso- 
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occlusion. Thus in principle, plasma VEGF and NOx levels could be indicators of 
the degree of ongoing microvascular occlusion. 
NOx levels in sickle cell patients and control subjects 
In practice, NOx levels in plasma are likely to reflect a complex series of 
events. Factors affecting synthesis include local hypoxaemia in blood vessels, 
release of NO from platelets, endothelium and macrophages, hepatocytes and 
many other cells. NO synthesis is also affected by diet so that patients and control 
subjects having diversities in dietary intake could produce wide differences in 
plasma NOx levels. Blood NOx levels will also be affected by the rate of 
metabolism and interaction with other molecules such as haemoglobin. NO is 
known to be associated with Hb as nitrosyl-Hb and travel around the body within 
the red cells. NO may be stored intracellularly as nitrosothiol and dinitrosyl-iron- 
cysteine. Thus NOx levels in the plasma may not directly reflect the amount of NO 
produced at any moment. 
The findings in this thesis of a lack of raised NOx in SS patients either in 
crisis or in steady state disagree with previous reports of either raised (Rees et al. 
1995) or decreased (Lopez et al. 1996) levels of NOx. This is partly explained by 
the sample collection procedure. Serum and plasma NOx levels are unlikely to be 
secondary to platelet activation because control experiments in which platelets 
were activated in vitro did not increase NOx significantly. This suggests that other 
cells such as macrophages or circulating endothelial cells (Sowemimo-Coker et al, 
1989) may be involved. However, this is speculative at present and the main 
conclusion of the work in this thesis is that serum and plasma NOx levels are not 
significantly modulated in SS patients. 
VEGF levels in sickle cell patients and control subjects 
Our initial finding that VEGF was raised in serum samples of SS patients 
could have been interpreted as consistent with the hypothesis that hypoxia 
upregulates VEGF production and release. However, it soon became apparent that 
in vitro activation of platelets was responsible for most of the measured serum and 
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plasma VEGF levels. This was not reported at the commencement of this work but 
has subsequently been confirmed by a variety of investigators in non-sickle 
patients. Interestingly, it appears that VEGF release in vitro is greater in SS 
patients than controls especially in serum samples, suggesting a greater tendency 
to platelet activation in vitro in sickle cell disorders. The reason for this has not 
been investigated in this thesis, but as platelet activation is a recognised feature of 
SS and sickle red cells or red cell spicules are known to interact with platelets. It is 
likely that this process occurs in vitro during collecting the serum samples. 
When samples were collected into CTAD in order to inhibit platelet 
activation in vitro, VEGF remained high in SS patients compared with control 
subjects, although the difference was less marked. Causes of this raised VEGF in 
SS patients could in principle be due to generalised hypoxia, localised hypoxia with 
vaso-occlusion or to in vivo platelet activation. In order to address which of these 
was most responsible for raised VEGF levels, correlations were sought between 
VEGF and markers of hypoxia, in vivo platelet activation and endothelial activation. 
The results show no correlation of VEGF levels with plasma Epo, suggesting that 
generalised hypoxia secondary to anaernia was not responsible for the raised 
VEGF levels in SS patients. There was also no correlation of VEGF with markers 
of platelet activation (PF4 and BTG) or endothelial activation (sE-selecetin and 
sVCAM-1) despite there being good evidence for increased platelet and endothelial 
activation in SS patients compared to control subjects. The results in this thesis 
show that there are clearly increased VEGF levels in plasma, although the exact 
cellular origin remains obscure. It is also clear that there is an extensive endothelial 
and platelet activation in SS patients compared to control subjects. The lack of 
clear correlation with any particular factors suggests a complex interplay of both 
vascular endothelial cells and platelets. 
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6.4. FUTURE TRENDS 
Application of flow cytometty in studies of sickle red cells 
Phosphatidylserine (PS) exposure in sickle red cells has become an area of 
recent interest. PS exposure is known to activate coagulation in sickle cell patients 
(Wood et al., 1996). Single-colour staining flow cytometry for PS exposure is now 
well established (Wood et al., 1996). It would be valuable to know whether F+cells 
show more or less PS exposure than F-cells and whether this is associated with 
differences in activation of platelets and coagulation. The first question can in 
principle be answered by developing a double-colour staining flow cytometry for 
co-distribution of PS exposure (using annexin-V-conjugated FITC) and HbF 
content (using MoAb-HbF-TC). The preliminary result of this development is quite 
promising. However, the reproducibility of the procedure is yet to be improved. 
Another area, which could be clarified using the flow cytometric staining 
developed in this thesis, is that of the relationship of HbF content to red cell 
density. Some ion-transporting channels, especially the Ca+-dependent K+ 
channel, which is responsible for ionic balance and cell density, do not function 
properly in sickle red cells (Franco et al, 1997). This malfunction leads to failure to 
maintain intracellular ionic balance that makes sickle red cells more dense. Some 
sickle red cells are dense at the time of release from the bone marrow (at 
reticulocyte stage) but some become more dense later (at mature red cell stage). 
The method developed in this thesis could allow examination of HbF content, RNA 
content and AM expression in subpopulations of cells previously separated by 
using centrifugation with density gradient media. This could show the effect of HbF 
content on red cell density both in reticulocyte and beyond reticulocyte stages. It 
would also be of interest to examine whether AM expression was similarly 
distributed between dense and less dense cells. 
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Markers of endothelial and platelet activation in sickle cells disorders 
The findings in this thesis show clear evidences of endothelial and platelet 
activation in SS patients. These may be secondary to local vaso-occlusion but 
could also reflect a more generalised process. Any treatment that reduced vaso- 
occlusion, such as HU treatment, blood transfusion or bone marrow transplantation 
could reduce these effects and it would be of interest to study these systematically. 
A relatively less known area is the effect of anti-platelet drugs on severity of SS. 
Although there have been clinical studies undertaken on the role of aspirin in 
preventing vaso-occlusive crises (Greenberg et al., 1983), there has been little 
systematic study of the effects of drug intervention on platelet and endothelial 
activation markers in SS patients. In addition to studying the effects of anti-platelet 
drugs on markers of endothelial and platelet activation, it would be of interest to 
compare these markers before and after HU therapy. The extent to which the rates 
of change in these markers with HU therapy parallel changes in AM expression 
and increments in F"cells, could help elucidate the extent to which the benefits of 
HU result from changes in HbF or from changes in AM expression. Such studies 
would bring together the themes explored in chapter 4 and chapter 5. 
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